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There is a dearth of recent surveillance data on the prevalence of cardiovascular disease 
(CVD) risk factors, which are highly prevalent and significant contributors to morbidity 
and mortality, in the South African population. Previous studies in Cape Town were 
conducted approximately two decades ago.  
Aims 
To determine the prevalence of CVD risk factors in 2008/09, changes in these risk factors 
between 1990 and 2008/09 and the association between psychosocial stress and other 
CVD risk factors in a random sample of the 25-74-year-old urban black population of 
Cape Town.  
Methodology  
A randomly selected representative cross-sectional study, stratified for age and gender, 
was conducted in the same communities sampled in 1990. Data were collected by 
administered questionnaires, clinical measurements and biochemical assessments. The 
prevalence of CVD risk factors and psychosocial measures, including sense of 
coherence (SOC), locus of control and adverse life events, was determined.  
Results 
There were 1099 participants, 392 men and 707 women (response rate 86%). Age-
standardised (SEGI) prevalence (95% confidence interval) was: diabetes: 11.3% (8.0-
14.6) and 14.7% (12.1-17.3), hypertension: 39.3% (33.4-45.2) and 39.4% (35.5-43.4), 
and raised low-density lipoprotein cholesterol (LDL-C): 37.9% (32.6-43.4) and 48.3% 
(44.5-52.2) in men and women, respectively. These rates were higher than in 1990 and 
management was poor with suboptimal rates of awareness, treatment and control. 
Overweight/obesity in women (82.9%) was higher than in men (28.9%) but daily smoking 
(49.4%) and problem drinking (49.7%) were higher than in women (7.9% and 18.1%, 
respectively). Between 1990 and 2008/09, overweight/obesity increased in women and 
decreased in men, smoking in men, but not women, decreased, and alcohol consumption 
increased in both sexes. In the multiple logistic regression models, age, body mass index 
(BMI) and waist circumference were significantly associated with diabetes in both men 
and women, but psychosocial stress (SOC) was only relevant in women. Age, BMI, 
positive family history, physical inactivity and urbanisation were independently related to 
hypertension, and age, BMI and high fat intake were independently associated with 
raised LDL-C. 
Conclusions 
The prevalence of many CVD risk factors was high in 2008/09 and substantially higher 
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CHAPTER ONE: LITERATURE REVIEW 
The literature review focuses on the global cardiovascular disease (CVD) epidemic 
including type II diabetes (henceforth referred to as diabetes), and highlights their 
trends as well as those of the individual risk factors in developed and developing 
regions. The literature relating specifically to the CVD risk factor burden in Sub-
Saharan Africa (SSA) and South Africa is summarised towards the end of this 
chapter while the details are presented in Chapter Four so as to avoid repetition.  
1.1. GLOBAL OVERVIEW OF CARDIOVASCULAR DISEASE  
1.1.1. INTRODUCTION  
The dawn of the third millennium has seen chronic non-communicable diseases 
(NCDs) sweeping the entire globe following the major health transitions observed in 
the second half of the 20th century (1, 2). Reddy emphasised that the most pervasive 
change among these health transitions has been the rising burden of NCDs, and in 
particular CVD (2). CVD has grown from a relatively minor condition over the last 
century to a leading cause of morbidity and mortality worldwide (3). This is the 
foremost cause of death in all regions except SSA, responsible for over one in four 
deaths in developed nations, and over one in five deaths in developing nations (4). 
Here it causes nearly twice as many deaths as tuberculosis (TB), human 
immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and 
malaria combined. 
1.1.2. DRIVERS OF THE CARDIOVASCULAR DISEASE EPIDEMIC 
The rapid rise in CVD over a fairly short period is attributable mainly to the following 
factors: 1) the projected 60% rise in population between 1990 and 2020, 2) the 
increasing average life expectancy on account of improvements in public health and 
medical care, and 3) the economic, technological, social and cultural changes, and 
the subsequent profound changes in diet and lifestyles that enable CVD risk factors 
to flourish (1-3, 5-8).  
1.1.3. PREVALENCE AND MORTALITY TRENDS  
At the beginning of the 20th century CVD accounted for less than 10% of all global 
deaths. A century later it has shifted from being a minor cause of death and disability 
to a major contributor to the global burden of disease, responsible for ≥30% of 
mortality worldwide (3, 9-16). CVD accounted for approximately 17 million deaths 
















disease were from ischaemic heart disease (IHD) and cerebrovascular accidents 
(stroke) (18). By 2030, the number of CVD deaths is predicted to increase to 25 
million annually (17).  
The global CVD epidemic has evolved with the burden shifting to developing 
countries because of the large populations residing in these regions. This is now 
endemic worldwide and no longer confined primarily to developed nations as once 
believed (14, 19-21). About 80% of the global CVD burden currently occurs in 
developing nations and CVD mortality is already twice as high as in developed 
countries (9, 13, 22, 23). As the phenomenon of the epidemiological transition 
gathers momentum, the CVD epidemic will continue to accelerate worldwide and 
involve all social classes (2, 24). 
Furthermore, according to Yusuf and colleagues, IHD mortality was predicted to 
increase by 137% for men and 120% for women in developing countries compared 
with 48% and 29%, respectively, in developed countries between 1990 and 2020. 
The predicted increase in mortality attributable to stroke among men and women was 
similarly higher in developing (124% and 107%, respectively) compared to developed 
nations (78% and 56%, respectively) (6).  
Not only are the absolute numbers greater in developing countries but so too are the 
age-specific morbidity and mortality associated with CVD compared to developed 
regions. Whereas almost 80% of CVD mortality in developed countries occurred in 
those older than 60 years old; in developing countries, only 42% of CVD deaths 
occurred in this age group (5). CVD morbidity and mortality disproportionately affects 
the working-age population in developing countries in their prime and at younger 
ages rather than the older retired members of society commonly found in developed 
nations (16, 18, 25-27).  
In addition to the suffering and loss of life, there are far-reaching social and financial 
repercussions as breadwinners succumb to CVD and other NCDs thereby 
perpetuating the vicious cycle of poverty (5, 7, 22, 24). In low-resource settings, 
healthcare costs for these conditions, including often prolonged and expensive 
treatment, together with the loss of breadwinners rapidly drain household incomes 
and force 100 million people into poverty each year (28, 29). 
CVD mortality accounted for the largest proportion of NCD deaths (48%) in 2008; the 
other main causes were cancers (21%), chronic respiratory disease (12%) and 
diabetes (3.5%) (17). The World Health Organization (WHO) reported that 36 million 
















with about 80% of the NCD mortality occurring in developing regions. Further, 48% of 
these deaths occurred in those <70 years in developing countries compared to 26% 
in developed nations. Mortality attributable to NCDs in 30-70-year-olds was highest in 
SSA, Eastern Europe and parts of Asia, highlighting the greater adverse impact in 
poorer regions (17). 
1.1.4. MANAGEMENT  
Since the risk factors for CVD and other NCDs are known, and many have the 
potential for control and modification, means that about 80% of premature heart 
disease and stroke, 80% of diabetes and 40% of cancers are preventable (1, 12). 
Measures directed at high-risk individuals cover those with acknowledged risk factors 
for the disease (1, 5) and have been shown to substantially reduce the absolute risk 
for CVD and to avoid unnecessary costs (30).  
In developed countries, CVD prevention programmes have probably averted much 
premature disease over the past few decades (31) such that the age-standardised 
morbidity and mortality rates are lowest in high-income compared with middle- and 
low-income countries (32). Concerted measures to prevent, diagnose and treat IHD 
and stroke have succeeded in delaying these CVDs to more advanced ages and 
deferring death (5, 6, 33). Therefore, despite the overall increase in burden, the age- 
standardised CVD mortality has been halved (5, 34) with only 10% of cardiac 
mortality occurring in populations younger than 65 years in North America, New 
Zealand, Australia and parts of Europe (35). According to the WHO, CVD and other 
NCDs occur among both the wealthy and the poor; however, wealthier individuals are 
able to access services and products to protect them from the greatest risks, while 
the poor often cannot afford this (28).   
Most low-income countries are not geared to respond to the growing problem of CVD 
and other NCDs (24, 36); they lack national policies for the control of these 
conditions and primary healthcare (PHC) systems have not adapted to cope with the 
new additional challenges (37). In keeping with these findings, Alwan and colleagues 
found that 23 low- and middle-income countries with a high burden of NCDs lacked 
the capacity to effectively deal with the existing and projected burden of these 
conditions (38). With prevention not a priority and effective treatments not widely 
available (39), it is not surprising that NCD mortality occurs at earlier ages in 
developing countries with  the increased incidence of these conditions compounding 
















Nevertheless, countries in resource-poor settings with already burdened healthcare 
budgets cannot afford to ignore the opportunity to address this major problem (7) by 
implementing cost-effective primary and secondary prevention programmes, as has 
been shown in developed nations (24). Although a challenge, prevention and control 
of CVD and other NCDs need to be a priority even in resource-limited settings (41) 
since existing healthcare systems do not have the capacity to cope with this burden 
(1). PHC systems in developing regions are currently oriented towards management 
of acute problems and need to evolve rapidly to deliver care, which is fundamentally 
different, for common chronic diseases both infectious and non-communicable (42). 
Innovative solutions are required to overcome the enormous difficulties of deficient 
health systems in these settings (37).  
Vitally important is to use the limited resources that are available as efficiently as 
possible by prioritising cost-effective strategies and by targeting those most likely to 
benefit from evidence-based interventions (43). High impact essential interventions to 
strengthen early detection and timely treatment need to be delivered through a PHC 
approach (28) with cost-effective measures implemented to achieve these goals (37). 
Mendis and colleagues have shown the total cardiovascular risk approach to be more 
cost-effective, enabling more accurate targeting of high-risk individuals, than using 
the single risk factor approach (44). Even in resource-scarce setting such as SSA, 
Gaziano recommends the total cardiovascular risk assessment approach as a cost-
effective strategy for the effective prevention, treatment, and management of CVDs 
(45). 
The emphasis on treating and preventing CVD and other NCDs are excellent 
economic investments because, if applied early, can reduce the need for more 
expensive treatment with significant cost savings (28, 46). Simple, inexpensive and 
cost-effective measures with high impact have been proven to produce rapid health 
gains (13, 47, 48). Individual-based strategies with the greatest cost-effectiveness 
include BP-lowering drugs, lipid-lowering agents and aspirin. According to Lim and 
colleagues, an opportunistic screening-based multidrug regimen for CVD prevention 
in high-risk individuals could potentially avert many deaths. Over ten years, this 
would amount to almost 18 million deaths, equivalent to almost a fifth of CVD 
mortality, in 23 low- and middle-income countries, including the SSA region (49). 
Investing in such intervention measures, particularly those related to primary 
prevention, will have the maximum impact health wise and economically (48). 
















system is required as part of an integrated health system to respond to the burdens 
of communicable and cardiovascular and other NCDs (13). 
For the successful prevention and control of the CVD epidemic, in combination with 
the individual high-risk approach, the equally important population-based strategies 
are essential to shift the current distribution of cardiovascular risk in a population to a 
more optimum distribution in the long term (16, 43, 50-53). Small improvements in 
the overall distribution of risk in a population have the potential to yield greater gains 
in disease reduction when the underlying conditions that confer risk are pervasive in 
the population (53). Such interventions, which encompass low-cost solutions to 
reduce the common modifiable risk factors of tobacco and harmful alcohol use, 
unhealthy diets and physical inactivity (28), if implemented, could more than half the 
burden of CVD (5). The population-based approach includes prevention of the 
emergence of risk factors from the outset by targeting the social, economic and 
cultural determinants that contribute to the development of CVD risk factors (30, 48, 
54). These interventions require actions outside the health system to realise the 
maximum impact (47). For example, Asaria and colleagues found that salt reduction 
and tobacco control initiatives could avert 13.8 million deaths in 23 developing 
countries over ten years with most of the deaths averted (75.6%) being from CVDs 
(55). 
To lessen the impact of these diseases on individuals and society, a comprehensive 
population-based approach attempts to modify the prevalence of risk factors across 
an entire population by national economic and environmental policies (1, 5, 18, 48, 
52, 56, 57). A holistic government approach that includes not only health but all 
sectors such as health, finance, foreign affairs, education, agriculture, trade, food 
security, planning, need to cooperate to reduce the risks associated with CVDs and 
to promote interventions for the prevention and control of these conditions (28, 29, 
58). Alwan and MacLean state that comprehensive strategies will encompass laws 
and regulations, tax and price interventions, improving the built environment, 
advocacy, mass media, community-based interventions, school- and workplace-
based interventions, screening and clinical prevention (48).  
Such strategies create an enabling environment that facilitates healthy behaviour and 
thereby avert the development of CVD risk factors in the population as a whole (54, 
58). Healthy individual choices are easier to practice if supported by enabling 
environments such as tobacco-free public and work spaces, easy access to healthy 
foods, and opportunities for physical activity (59). Without such government 
















changes at the individual level, particularly for the disadvantaged in all societies (60). 
Therefore, governments have a pivotal role in the fight against rising CVD and other 
NCDs by developing appropriate policies and implementing strategies that influence 
the uptake of healthy lifestyles (27, 48, 56).  
The success in materialising such policies depends on factors such as political 
commitment and the involvement of political leaders and the mass media (54, 61). 
Sustained national leadership is, however, missing and governments, predominantly 
in developing regions, have up to now largely abdicated the responsibility for tackling 
the CVD and other NCDs epidemic (48, 61). Although health policymakers are now 
increasingly recognising these conditions as a major health priority, unfortunately, 
this has generally not been translated into serious policies or plans (48).  
1.1.5. INTERNATIONAL STAKEHOLDERS AND GLOBAL INITIATIVES 
In addition to government action within countries, Beaglehole and colleagues 
emphasise that international leadership is essential because of the part played by 
multinational companies and trade agreements in exacerbating the CVD epidemic 
(47). For nations to successfully address the transnational factors influencing 
smoking rates, and dietary, nutrition, and physical activity patterns through effective 
national and international regulation of products, activities, and conditions that 
adversely affect health or lead to health inequities, collective action at a global level 
is necessary (4, 62). 
The key international stakeholders 
Among the first to accentuate the need to ensure that NCDs are urgently accorded 
greater priority in the health and development policies of poor nations and on global 
aid agendas has been the WHO (56). In 2000, WHO introduced the Global Strategy 
for the Prevention and Control of NCDs (63) and is recognised as the principal 
organisation with the capacity to shape global health policies. This has been possible 
through its strong knowledge base, convening powers and ability to identify and 
disseminate best practices (4). 
The World Bank is another important stakeholder in NCD prevention and control, with 
extensive resources and experience in developing regions, which have the greatest 
need for development assistance in this area. The World Bank has also 
acknowledged the ‘formidable challenge’ of NCDs caused by tobacco and obesity, 
and stressed their comparative advantages in the health sector in their recent health, 
nutrition and population (HNP) strategy. Strengthening healthcare systems remains 
















disease prevention within their health and development strategies, through a multiple 
sectorial approach (4). 
Other agencies that have embraced the NCD challenge include action oriented 
groups such as the Oxford Health Alliance, which is a network of institutional and 
individual collaborators aimed at preventing and controlling NCDs; and collaborative 
global priority-setting groups such as the Global Alliance for Chronic Diseases which 
is a consortium of six influential health agencies (27). Similarly, the NCD Alliance is a 
partnership of four international non-governmental organisations (NGOs), the World 
Heart Federation (WHF), International Diabetes Federation (IDF), Union for 
International Cancer Control, and International Union Against TB and Lung Disease, 
which aims to stimulate and support action for NCD intervention (47). Other 
professional societies including the European Society of Hypertension (ESH), the 
International Society of Hypertension (ISH) and the American Heart Association 
(AHA) also contribute to setting the NCD agenda. In addition, the world’s largest 
philanthropic organisations have recognised the need for developing nations to 
implement interventions to reduce tobacco use and the associated mortality (48).  
The Institutes of Medicine (IOM) in the USA advocated action on the prevention and 
control of NCDs as a global health priority, particularly in developing regions (27, 48, 
64). The IOM highlighted intensifying existing interventions, generating and sharing 
knowledge, investing in institutional and human capacity, increasing financial 
commitments, and engaging in respectful partnerships (27).  
WHO Framework Convention on Tobacco Control and Global Strategy for Diet, 
Physical Activity and Health 
As recently as 2005, the lack of global control efforts resulted in NCDs being 
regarded as ‘the neglected development goal’ in a series on chronic diseases 
published in The Lancet (65). The global framework for action on chronic diseases 
had, until recently, been mainly exemplified in two WHO initiatives (4). These 
included the WHO Framework Convention on Tobacco Control (FCTC) and the 
Global Strategy for Diet, Physical Activity and Health. 
In recognition of the threat that tobacco use posed to global public health and the 
need for comprehensive tobacco-control policies, the FCTC was adopted in May 
2003 (66, 67), marking a critical achievement in the efforts to stem the global tobacco 
epidemic (66, 68, 69). The FCTC was the first-ever international treaty devoted to 
health and remains the only example of the WHO using its treaty making right (70). 
















promotion and sponsorship, illicit trade of tobacco products, tobacco taxes and 
agricultural diversification (8). The FCTC is an important mechanism to tackle 
tobacco-control and provides a basis for multi-lateral commitment, cooperation and 
action (71, 72). Furthermore, it offers governments, health professionals and many 
others with suggested policies and programmes for reducing tobacco use. 
The 2004 WHO’s Global Strategy for Diet, Physical Activity and Health emphasised 
that comprehensive and coordinated public health efforts were required by all 
stakeholders, particularly governments (58, 73). This would address the problem of 
CVD and other NCDs in developing regions, a consequence of changing lifestyles 
related to diet and physical activity. Detailed guidelines were provided on strategies 
to improve diets and encourage physical activity. However, few governments have 
made progress in the implementation of these strategies (74). Moreover, products 
such as processed foods and alcohol urgently require stronger global, regional, and 
national regulatory controls (62).  
Millennium Development Goals 
The WHO’s support for the NCD agenda was the impetus for the new global goal for 
the prevention and control of NCDs proposed to supplement the Millennium 
Development Goals (MDG) (4, 56, 65). The most ambitious example of a global 
health partnership (4), these are a set of development outcomes that government 
leaders have committed to achieve, collectively, over the period 2000–2015 (4, 75). 
The WHO’s new free-standing goal is a reduction in mortality attributable to the main 
NCDs (heart disease, stroke, cancer, diabetes, and chronic respiratory diseases) by 
an additional 2% per annum between 2005 and 2015 (39). Achieving this global 
target would prevent 36 million deaths between 2005 and 2015, of which half would 
be attributable to CVD (4, 13, 56, 61, 76). Most of these averted deaths will be in 
developing countries (28 million), and approximately half will be in people younger 
than 70 years old (13, 39, 61, 76).  
WHO Non-communicable Disease Action Plan 
According to Strong and colleagues, there has been a major shift in the emphasis 
from a few years ago where the gap between the reality of the chronic disease 
burden worldwide and the response of national governments, civil society, and 
international agencies remained wide (39). This occurred despite increasing 
awareness of the rising global burden of NCDs. The new global initiative by the WHO 
for NCDs is based on the 2000 Global Strategy for the Prevention and Control of 
















States and international partners with steps on how to address NCDs (28, 48). This 
action plan advocates a comprehensive approach for the prevention and control of 
CVD and other NCDs that can be achieved through a combination of complementary 
and synergistic strategies, targeting the whole population and those with disease or 
at high risk of developing disease (18, 48). These encompass the development of 
national policy frameworks, establishment of programmes, capacity building for 
effective national responses, monitoring and evaluation at different levels, and 
research promotion (10, 56, 77).  
These efforts, across almost 20 years, have led to very limited, if any, policy change 
at the country level. Mamudu and colleagues suggest that this may essentially be on 
account of the complexity and cross-cutting nature of CVD and other NCDs, but may 
also be because of inadequate political leadership at the global level. Despite 
providing technical leadership for NCDs, the WHO lacks the political authority and 
governance to mobilise intensive action by the wide range of global stakeholders 
(63).  
United Nations High-Level Meeting  
International political support can be garnered through the United Nations (UN) which 
is uniquely placed to assume a strong political leadership role to complement the 
WHO’s technical lead in the fight against NCDs. The UN, by convening the recent 
High-level meeting on NCDs in New York in September 2011, elevated the NCD 
issue on the domestic policy agendas of Member States (63, 78) securing recognition 
of NCD prevention and control as a global priority. This represents a major 
breakthrough in the global struggle to garner recognition, support and action for the 
threat posed by NCDs (17). This was only the second occasion in its history that the 
UN has met on a health issue, the previous one a decade earlier related to the 
HIV/AIDS epidemic (79-81). 
The UN raised international awareness on the magnitude, and socioeconomic and 
developmental impacts of CVD and other NCDs (82).  The need for governments to 
recognise their primary role and responsibility to respond to the challenges of NCDs 
was also stressed (81, 83). A Political Declaration on the threats posed by the 
growing burdens of NCDs and calls for national plans by 2013 were adopted at the 
meeting (78, 81, 84). Also emphasised was the responsibility of the international 
community in assisting developing countries to generate effective responses (83) 
















However, the inclusion of time-bound goals and targets as originally called for by the 
Secretary General would have been ideal (81, 84). 
Notwithstanding, this marks a major turning point in the attitude and attention 
allocated to CVD and other NCDs globally. Hopefully, the focus and momentum 
garnered at the UN High-level meeting will translate into concrete action in the form 
of strategies, policies and programmes in member states, especially in developing 
regions and particularly in SSA.   
1.1.6. SUMMARY 
The worldwide spread of CVD and other NCDs presents an opportunity for all 
countries, developed and developing, to jointly confront the major global challenge 
that threatens health and economies alike (27). There needs to be a sustained 
response and political commitment to the prevention and control of these epidemics. 
If the battle against NCDs is to succeed these conditions need to be a global public 
health priority (10, 56). Population-based strategies to address tobacco and 
excessive alcohol use, unhealthy diets, physical inactivity and overweight/obesity are 
imperative. Simultaneously, high-risk individuals must be identified and targeted 
through PHC systems using cost-effective and integrated approaches (43, 44). A 
concerted effort is required to change the course of the CVD and other NCD 
epidemics; the price of inaction will otherwise be potentially devastating (7).  
The general consensus, as stated by Labarthe and Dunbar, is that there is now 
reason for cautious optimism as the pandemics of CVD and other NCDs have moved 
from initial neglect in the MDGs to prominence at the highest levels of the UN in a 
decade. The momentum garnered should allow for meaningful progress globally in 
cardiovascular health promotion and CVD prevention (79).  
1.2. CARDIOVASCULAR DISEASE RISK FACTORS 
1.2.1. INTRODUCTION  
The WHO reported that eight preventable risk factors, tobacco use, physical 
inactivity, raised blood pressure (BP), raised blood glucose, raised blood cholesterol, 
alcohol use, high body mass index (BMI), and low fruit and vegetable intake 
accounted for 61% of total CVD deaths (10, 85). Of note, is that over 84% of the total 
global burden of disease caused by these risk factors occurs in developing regions 
(85). Global life expectancy would increase by almost five years if exposure to these 
















The INTERHEART and INTERSTROKE studies, large international multi-centre 
standardised case-control studies of acute myocardial infarction (MI) and acute 
stroke, respectively, showed that approximately 90% or more of the risk were 
attributable to most following risk factors. These include smoking, hypertension, 
abnormal lipids, diabetes, abdominal obesity, unhealthy diets, alcohol consumption, 
physical inactivity and psychosocial factors such as stress (86, 87). 
Furthermore, Lopez and colleagues determined that high BP, smoking and high 
cholesterol were the three leading risk factors responsible for global mortality in 
2001. Overweight/obesity, physical inactivity and alcohol use were also among the 
ten leading causes of global mortality. Apart from physical inactivity, these risk 
factors were also among the ten major causes of the global burden of disease (88). 
The CVD risk factors may be described as those that are related to behaviour and 
the environment and which are modifiable, and those that are physiological. 
1.2.2. ENVIRONMENTAL AND BEHAVIOURAL RISK FACTORS 
1.2.2.1. Psychosocial Stress 
Introduction  
Stress is defined as the process whereby environmental demands strain an 
individual’s adaptive capacity causing both psychological burdens and biological 
changes that could place the individual at risk for illness (89). The concept of 
psychosocial stress incorporates several factors, from external stressors such as 
work stress, adverse life events and financial problems, to possible reactions to 
stress such as depression, anxiety, psychological distress and sleeping difficulties 
(90, 91). However, compared with many other biological and lifestyle risk factors, 
there is no universally accepted definition or measurement of psychosocial stress. 
Psychosocial stress and cardiovascular disease  
Nonetheless, multiple studies, using different study designs and approaches, have 
examined the relationship between psychosocial stress and CVD and its risk factors 
(90, 92, 93). During the past few decades, evidence has emerged on the association 
of markers of psychosocial stress with: 1) CVD, such as acute MI and stroke (87, 90, 
94), 2) the increased likelihood of developing hypertension (93, 95-102), 3) adiposity, 
including general obesity (103, 104), raised waist circumference (WC) (103, 104) and 
raised waist-to-hip ratio (WHR) (105-107), and 4) the metabolic syndrome (MS) (103, 
















Psychosocial stress and diabetes 
Regarding psychosocial stress and diabetes, which shares many of the risk factors 
for IHD and stroke and is simulaneously a risk factor for CVD, many studies have 
found an association between depression and diabetes (115, 116). There is also 
growing evidence that other forms of psychosocial stress contribute to the 
development of diabetes (115). A cross-sectional study found an association 
between adverse life events and chronic stress with reported diabetes in two 
American Indian communities (117). The Copenhagen City Heart Study, defining 
stress as ‘tension, nervousness, impatience, anxiety or sleeplessness’, demonstrated 
that stressed men, but not women, were more than twice as likely to develop 
diabetes during follow-up (118). In the Whitehall II study psychosocial work stress 
was an independent predictor of diabetes in middle-aged women, but not in middle-
aged men, after 15-years of follow-up (119). Job strain was also found to be 
associated with an increased likelihood for diabetes in women in two case-control 
studies in Sweden and one cross-sectional study in Belgium (120-122).  
In contrast, in the Nurses’ Health Study II, work strain was unrelated to newly 
diagnosed diabetes (123). Furthermore, in a meta-analysis of longitudinal studies no 
association between stressful life events, stress-prone personality or coping style and 
poor social support, and incident diabetes was found. However, the authors stated 
that the findings should be interpreted with caution on account of the limited number 
of studies that were included (116). These studies underscore the lack of conclusive 
evidence on the association of psychosocial stress with diabetes. 
Psychosocial stress and hypertension 
Numerous studies have evaluated psychosocial stress as a possible risk factor for 
hypertension with the intensity and duration of the exposure reputed to be important 
determinants of risk. In a meta-analysis of cohort studies, Gasperin and colleagues 
found that individuals who had stronger responses to stressors (reactivity) and high 
BP in the recovery period were more likely to develop BP increases or hypertension 
(124). Nonetheless, although acute stressors have been shown to affect BP, on-
going exposure to stress may more likely be related to sustained BP elevations and 
hypertension incidence. Chronic psychosocial stress related to various spheres such 
as occupation, finance, relationships, personality traits, low socioeconomic status 
and, recently, race discrimination have been examined and linked to BP outcomes 
(125-127).  
In a cohort of young adults in the Coronary Artery Risk Development in Young Adults 
















was associated with incident hypertension after eight years (128). Also in the 
CARDIA study, the psychosocial factors of time urgency/impatience behaviour and 
hostility were associated with an increased risk of developing hypertension at the 15-
year follow-up; however, achievement striving/competitiveness, depression and 
anxiety were not related (129). On the other hand, in the Healthy Women Study 
(HWS), the likelihood of hypertension increased in women who experienced 
consistently high anxiety levels, increasing feelings of anger, and decreasing social 
support over nine years. However, baseline levels of these variables were not 
predictive of subsequent hypertension (97). Psychosocial stress associated with high 
levels of anger traits, compared with low/moderate levels, were significantly related to 
progression from prehypertension to hypertension in the Atherosclerosis Risk in 
Communities (ARIC) cohort study (130). Changes in financial strain, another 
measure of chronic psychosocial stress, were associated with ambulatory BP in a 3-
year follow-up in a sub-study of the Whitehall II participants; however, there were no 
cross-sectional associations between financial strain and ambulatory BP (131).  
The variability in evidence of the association between psychosocial stress and BP is 
suggested to be, among others, related to the limitations of clinical BP 
measurements, such as using office-based rather than ambulatory BP, and 
consequently the failure to exclude individuals with isolated hypertension (126). Also, 
the different indicators used to define psychosocial stress invariably result in varied 
outcomes (127).  
Pathogenesis 
There are several pathways postulated by which psychosocial stress can lead to 
CVD and its risk factors. These include behavioural mechanisms because of the 
association between emotional stress and unhealthy lifestyle behaviours, such as 
poor diet, decreased physical activity, smoking and excessive alcohol consumption. 
These, in turn, would lead to BP increases, obesity and predispose to diabetes and 
CVD (115, 116, 118, 124). Physiological mechanisms have also been postulated 
whereby chronic stress activates the hypothalamic-pituitary-adrenal axis and the 
sympathetic nervous system resulting in increased cortisol levels and sympathetic 
predominance, respectively (91, 110, 111, 115, 132-134). Chronic stress adversely 
affects BP, blood glucose and lipid levels; additionally, it increases atherosclerotic 
progression and inflammation, and promotes endothelial dysfunction and central 
obesity (110, 115, 124, 134). Pouwer and colleagues postulated that another 
pathway for the association of stress with diabetes is that of stress-induced 
















cytokines (115). Interestingly, low sense of coherence (SOC), an indicator of stress, 
has been shown to be associated with higher cortisol levels in normal controls (135). 
Nonetheless, an individual’s unique combination of genetics, personality and coping 
mechanisms determine the perception of an event and its attached meaning (91).  
Psychosocial measures  
There is a dearth of standardised tools to measure psychosocial stress. Three of 
those available included the SOC, locus of control (LOC) and the Brugha life events 
questionnaires. 
Antonovsky’s SOC or orientation to life questionnaire is a theoretical construct to 
study stress and health (136, 137). The SOC questionnaire assesses a personality 
and related ‘stress-resistance resource’ that comprises the belief that life is 
comprehensible, manageable and meaningful, and has been suggested to be 
important in coping with stressors and for maintenance of health (120). For example, 
individuals with the same adverse life experience but dissimilar SOC will perceive the 
event differently, with the higher SOC individual coping more successfully with the 
stressor than the low SOC individual (136, 137). 
Low SOC, i.e., a low ability to cope with stressors, was associated with diabetes in 
middle-aged Swedish women (120). In a Finnish cohort study of male employees it 
was demonstrated that low SOC was associated with a higher risk of diabetes in 
participants who had been younger than 50 years old on entry into the study (136). In 
the EPIC-Norfolk study in the United Kingdom, no association was found between a 
three-item SOC questionnaire and systolic BP. However, high SOC was associated 
with a reduced rate of stroke incidence, a frequent complication of high BP (138) and 
also with a reduction of all-cause, cardiovascular and cancer mortality (139).The 
SOC questionnaire has been validated cross culturally, including in South Africa 
where it has previously been used in Tswana and Afrikaans (140). 
The concept of LOC, developed by Rotter, refers to the belief that individuals have in 
the amount of control they exert over their lives (141, 142). LOC, therefore, 
determines an individual’s perceived sense of control over his/her environment and 
life (90). Individuals with high scores or internal LOC are more likely than those with 
low scores or external LOC to exert efforts to control their environment and to take 
responsibility for their actions (141, 142). High LOC individuals believe in their ability 
to cope with anything that might happen to them (143) and subsequently experience 
















Low LOC was associated with IHD in the INTERHEART study (90) and in Swedish 
men (144), as well as with total mortality in Norwegian men (145). The LOC scale 
has been used widely in studies in Eastern Europe and was reported to predict 
cardiovascular events in longitudinal studies (90). A British cohort study 
demonstrated an association between poor LOC at age 10 years and the 
development of hypertension in 30-year-old women (146). In a French study, using a 
single LOC question, hypertension was found to be associated with low LOC in 
hypercholesterolaemic participants (147).  
The Brugha Life Events questionnaire assesses the perceived impact of different life 
stressors (148). In addition to ascertaining the number of adverse life events, it is 
relevant to assess the intensity of the stress experience. Stressful life events may 
pose different experiences in various individuals, thus examining the perceived 
severity of adverse events is important (104). Previous studies have demonstrated 
the association of various stressors, both work and non-work related, with diabetes 
(107, 120, 149). In a Dutch study, researchers reported the association of stressful 
life events, for example, death of a partner, with diabetes. The prevalence of 
previously undetected diabetes increased significantly with the number of stressful 
life events experienced (107). Chronic stress as a result of work-related problems, 
financial difficulties or marital conflict was associated with hypertension in reviews by 
Spruill  (125) and Sparrenberger and colleagues (127).  
1.2.2.2. Tobacco Use 
Introduction 
Mass-manufactured cigarettes first appeared in the 19th century and since then 
cigarette smoking has spread worldwide on a massive scale (150). Industrialisation, 
urbanisation and other processes of modernisation including globalisation have 
enabled the rapid uptake of cigarette smoking (150, 151), with the tobacco industry 
driving the development of the tobacco pandemic in the 20th century (151, 152). The 
tobacco conglomerates have expanded and are now targeting new markets. Initially 
men were targeted, then women and youth in the developed world, and now the 
developing world (152, 153). The globalisation of tobacco use has imposed a huge 
and growing public health burden worldwide with the threat to global health greater 
today than ever before (153-155). 
Current smokers are estimated to consume approximately six trillion cigarettes every 
year (156). In addition to cigarettes, other forms of tobacco are smoked, particularly 
















in Europe and the Americas (156, 157). Also, smokeless tobacco through chewing or 
sniffing is used worldwide.  
Prevalence and trends  
The worldwide number of smokers is staggering despite the risks of tobacco smoking 
being known for decades (71, 151, 158, 159). Approximately 20% of the global 
population smoked tobacco in 2010, comprising 800 million men and 200 million 
women (160). The overall prevalence of tobacco smoking was highest in the WHO 
European Region (almost 29%) and lowest in SSA (8%) (156). There was a male 
preponderance for smoking globally with the highest rate of male smokers in the 
WHO Western Pacific Region (46%). Smoking in women was much lower than in 
men with the highest prevalence in the European Region (20%).  
Worldwide, men smoke more than women with a smaller gender difference in 
developed regions (154, 157). Nonetheless, rates are increasing in women, 
particularly young women (160). Disturbingly, the age of smoking initiation in women 
appear to be approaching the young ages at which men begin (157). Marketing 
efforts of tobacco companies that especially target young women (153, 157, 161), in 
conjunction with increased social and economic independence and changes in 
women’s roles particularly in developing regions, have contributed to the rise in their 
smoking uptake (151, 161).  
While cigarette consumption has historically been highest in developed regions, 
according to the Tobacco Atlas, targeted marketing, increased social acceptability, 
continued economic development and population increases have seen consumption 
rise in developing nations (160). About 80% of current smokers resides in developing 
countries; the enormous expansion in tobacco use in these regions is the 
predominant contributor to the global rise in smoking (71, 150, 154, 155, 159, 162-
164). The number of smokers are predicted to reach 1.5 billion by 2025 (153). The 
increased consumption of manufactured cigarettes in developing countries seems to 
follow the patterns found in developed regions. Initially occurring among men then 
among women, first in older people and then passing to younger individuals, among 
the more affluent at the outset and then spreading and concentrating in the less 
affluent (164).  
Among developed nations, by contrast, while smoking continues to increase in some 
groups, there has been a decline in the overall smoking prevalence for decades, 
particularly in men (150, 154). For example, cigarette consumption in Western 
















use have occurred in developed countries as individuals increasingly understand the 
dangers of smoking and governments continue to implement tobacco-control policy 
and legislation. In contrast, in developing regions tobacco marketing relates male 
smoking with masculinity, happiness, wealth, virility and power. In reality, however, 
smoking kills nearly four million men every year and leads to infertility, health 
disparities, illness and premature mortality (160). 
Consequences  
The health consequences of smoking are well documented, with tobacco use known 
to cause or probably contribute to more than 25 diseases (71, 150, 165). The 
predominant tobacco-related morbidity and mortality is on account of lung and other 
cancers, CVDs including IHD, stroke and peripheral vascular disease (PVD), and 
respiratory diseases such as chronic obstructive airway disease and TB (71, 150, 
156, 163, 166, 167). The use of smokeless tobacco is also hazardous and has been 
related to oral cancer, hypertension, heart disease and other conditions (156).  
Tobacco smoking was found to be second only to dyslipidaemia in importance for 
determining the attributable risk of acute MI in the INTERHEART study, underscoring 
the strong adverse influence of this risky behaviour (90). Furthermore, over and 
above its independent effect on CVD, smoking interacts synergistically with the other 
major CVD risk factors such as hypercholesterolaemia, hypertension and diabetes to 
substantially increase the risk of CVD (71, 167).  
Morbidity and mortality  
Tobacco use was the second leading cause of mortality, after elevated BP, 
responsible for almost six million deaths in 2011, and accounting for 12% and 6% of 
global mortality in all men and women, respectively. Of note is that of the global 
mortality just over 600 000 deaths were attributable to second-hand smoke exposure 
among non-smokers (156). 
Smoking causes about 71% of lung cancer, 42% of chronic respiratory disease and 
nearly 10% of CVD (156). The risk of death from smoking is extremely high with 
about one-half to two-thirds of long-term smokers killed by their addiction (154). 
Compared with other risky behaviours, tobacco smoking is associated with an 
extremely high risk of premature death (150). Mortality in 50% of long-term smokers 
is attributable to tobacco use, and of these deaths, half will be during the productive 
middle age, thereby losing 20-25 years of life compared with the life expectancy of 
non-smokers (150, 154). Tobacco use is mounting in importance as a leading 
















mortality is apparent earliest in life: below the age of 45, IHD is the main cause of 
increased mortality owing to cigarette smoking (167).  
Nearly 80% of mortality occurred in low- and middle-income countries, indicating the 
high burden in poorer regions. As consumption rates in developing regions continue 
to increase, these countries will experience a disproportionately greater burden of 
tobacco-related morbidity and mortality (160). Mortality related to tobacco 
consumption is projected to soar in coming decades, particularly in developing 
regions, as the adverse effects accrue among those who began smoking over the 
past few decades, along with population growth and ageing (71, 165). This will 
exacerbate the health disparities between developed and developing regions (153). 
By 2020, the number of deaths attributable to tobacco use is predicted to increase to 
7.5 million, accounting for 10% of all mortality (156).  
Developed nations have begun to hold tobacco companies responsible for the high 
burden of disease inflicted by cigarette smoking and have introduced measures to 
deter smoking. This has led to declines in the use of cigarette and other tobacco 
products in developed regions. Consequently, tobacco multinationals have turned 
their focus to expanding smoking uptake in developing regions (153). Unfortunately, 
their marketing efforts have been remarkably successful because of limited 
awareness of the hazards of tobacco use and minimal tobacco-control policies in 
many developing countries (151). The implementation of effective interventions and 
policies are urgently required to halt the outreach of the tobacco industry to reduce 
smoking among men and prevent increases among women in developing countries 
(165).  
Tobacco control 
Seeing that smoking is a powerful CVD risk factor and smoking cessation is probably 
the single most effective lifestyle measure to prevent CVD (168), reducing tobacco 
use and deterring uptake is of paramount importance. A window of opportunity 
currently exists, particularly in developing regions, to reverse these trends and 
decrease the epidemic of tobacco-related morbidity and mortality given the long 
delay between smoking uptake and the development of disease (71, 154). 
Substantial evidence shows that smoking cessation reduces mortality from tobacco-
related diseases and improves health (154). Within 12-18 months of smoking 
cessation, most of the increased cardiovascular risk disappears and by 3-5 years the 
















Governments have the main responsibility to control tobacco consumption with 
effective and strong action; adopting and implementing comprehensive tobacco 
control policies have the greatest potential to stem the tobacco epidemic (72). The 
FCTC provides a template for developing and sustaining comprehensive tobacco 
control programmes at the national level (72, 159). Measures proven to be effective 
in reducing tobacco use include increased tobacco tax, dissemination of information 
about health risks from smoking, restrictions on smoking in public and work places, 
comprehensive legislation prohibiting tobacco advertising and promotion, and 
increased access to smoking cessation therapies (7, 71, 154, 169).  
By investing in such tobacco control strategies, governments have a unique 
opportunity to improve the health of their citizens (71). Tobacco-control legislation is 
essential as this influences the social acceptability of smoking by shifting attitudes 
and changing individual rights. Previously, the right to smoke-free air was contested 
but legislation unambiguously prioritises the right of non-smokers to smoke-free air 
(170). 
While extensive knowledge about effective tobacco control measures exist, 
dissemination of best practices and the adoption and implementation of 
recommended policies are fragmentary (154, 159). By 2008, 1.1 billion individuals 
were covered by the adoption of the most effective tobacco-control policies (157). 
These include advertising bans (9%), health warnings and access to cessation 
programmes (8%), optimal tobacco taxation levels (6%) and smoke-free 
environments (5%) (70). However, 83% of the global population are not covered by 
two or more of these policies (157).  
That many nations, particularly in developing regions, have not implemented tobacco 
control measures as advocated in the FCTC is disquieting. The economic power and 
financial clout of the tobacco conglomerates, as well as to the social acceptability of 
smoking contribute to the low implementation of tobacco-control initiatives (164).The 
limited implementation of effective tobacco-control initiatives in developing countries 
is because of political constraints along with a lack of awareness of the 
unprecedented effectiveness and cost-effectiveness of these interventions (154). 
Additionally, the lack of financial resources and capacity to develop and sustain 
tobacco-control programmes may be a key barrier to the implementation of the FCTC 
in developing countries (68, 72).  
In 2011, tobacco control was identified as the ‘most urgent and immediate priority’ 
















NCDs. To reduce the global smoking prevalence by 30% by 2025, countries were 
urged to fully implement the FCTC (157).  
Conclusion  
Despite its central role in morbidity and mortality, it is of grave concern that smoking 
prevalence has been shown to be increasing globally (171). Cigarette smoking 
represents the most important cause of preventable morbidity and premature 
mortality globally and concerted measures for prevention are essential (160, 172). 
While aggressive tobacco-control policies can and will diminish the toll of tobacco, 
the prospects for the foreseeable future seem bleak (69). Unless there is a rigorous 
attempt to reduce tobacco use by effective interventions and policies, the number of 
deaths attributable to this health hazard will increase dramatically (71, 165). 
1.2.2.3. Alcohol Use  
Introduction 
Alcohol has been a part of human culture since the beginning of recorded history and 
today approximately two billion people globally consume alcohol (173, 174). There 
was a high level of variation in alcohol consumption around the world with global 
adult per capita intake estimated, on average, at 6.0 litres of pure alcohol per year in 
2008. This was highest in Europe (12.2 litres) and lowest in the Eastern 
Mediterranean (0.6 litres) (156). Almost all societies that use alcohol demonstrate 
related health and social problems to the extent that there are about 76.3 million 
individuals worldwide diagnosed with alcohol use disorders (173, 174). 
Consequences of alcohol misuse  
Problematic alcohol consumption constitutes a serious public health problem; 
nonetheless, it is generally an underappreciated risk factor for many conditions (175, 
176). Alcohol use is strongly related to many CVDs, including hypertensive disease, 
haemorrhagic stroke and atrial fibrillation (83, 174, 177). Regarding other NCDs, 
alcohol has been linked to eight different cancers, various liver diseases and 
pancreatitis (83, 174, 177, 178). Consumption of alcohol, together with smoking, diet 
and physical inactivity, are among the four most important risk factors for NCDs (83, 
178).  
The relationship between alcohol consumption and IHD and strokes is complex 
depending on the amount and the pattern of alcohol consumption (156). While 
alcohol has been reported to have beneficial effects on IHD, by increasing the high-
density lipoprotein cholesterol (HDL-C) in the blood, these beneficial effects are 
















closely dose-dependent (176, 179, 180). The protective effects tend to disappear if 
the pattern of drinking is characterised by heavy episodic drinking (156). On the 
whole, the literature suggests that the detrimental effects of alcohol far exceed the 
health benefits and arguments must not be undermined by considerations of 
cardiovascular benefit (175, 178, 181, 182). For public health purposes, it is essential 
that the harmful alcohol-related health effects are emphasised (173, 180).  
The average volume of alcohol consumed and the pattern of use, especially heavy 
drinking occasions, contribute to disease burden (174). The impact of average 
volume of consumption on morbidity and mortality is partially moderated by the 
pattern of alcohol consumption, which in turn is influenced by the cultural context 
(183). 
Determining alcohol misuse 
The two dimensions of alcohol consumption include the average volume of alcohol 
consumed and pattern of drinking (184). Patterns of drinking extend from light regular 
drinking to drinking to intoxication, heavy drinking occasions and other more 
detrimental drinking patterns. Questions identifying adverse drinking patterns include 
the number of heavy drinking occasions (often termed binge drinking), high usual 
quantity of alcohol per occasion, drinking daily or almost daily and proportion of 
drinking occasions when drinkers got drunk. 
Considering the disapproval associated with heavy drinking in many societies, direct 
questioning may not always result in truthful answers. This has led to the 
development of various tools for detecting alcohol misuse and dependence such as 
the CAGE (cut down, annoyed, guilty, eye-opener), MAST (Michigan Alcoholism 
Screening Test) and AUDIT (Alcohol Use Disorders Identification Test) 
questionnaires (185). The initial approach was pioneered by Ewing with the 
development of the CAGE set of four questions (186, 187), a brief and commonly 
used screening instrument that is a valid and reliable tool for detecting lifetime 
alcohol abuse and/or dependence (185, 188). In contrast to the CAGE, the MAST 
and AUDIT questionnaires preclude their use in setting where brevity is essential 
(185).  
Burden of disease  
The global burden related to alcohol consumption in terms of morbidity and mortality 
is considerable (174). Alcohol consumption was responsible for 3.8% of mortality 
worldwide in 2008, which is about half the number attributable to tobacco use (156, 
174, 176). NCDs, including CVD, cancers and liver cirrhosis account for over 50% of 
















(1.1%), a reflection of the difference in consumption, with respect to overall volume 
and pattern of heavy drinking  (174). Nevertheless, the increase in mortality rate from 
3.2% in 2000 (173) to 3.8% in 2008 was mainly on account of increases in the 
number of women consuming alcohol. 
An estimated 4.5% of the global burden of disease, in terms of morbidity, was 
attributable to the harmful use of alcohol (156). This was approximately the same as 
that caused by tobacco (174, 176). CVD, cancers and liver cirrhosis were responsible 
for a quarter of the alcohol-related disease burden (156). Poor populations and 
developing countries have a higher relative burden compared to high-income 
populations and developed countries (174, 176). In addition to high healthcare costs, 
the mostly unmeasured social costs of alcohol misuse are also substantial (176). 
Rising pattern of alcohol use  
Without measures to curb alcohol abuse, traditionally low alcohol-consuming cultures 
may be transformed into high alcohol-consuming countries, for example, as has 
transpired in Thailand (181, 189). The transition occurred because of permissive, 
industry-friendly, governmental policies on production, marketing, and availability of 
alcohol (181). Global, regional, and national policies are supporting the expansion of 
alcohol corporations in developing regions (189). A strong connection between 
purchasing power and per-capita alcohol intake prevails. With aggressive and 
sophisticated marketing techniques by the alcohol industry, consumption and 
associated harm are, therefore, likely to increase in most societies in the future (176, 
189). Alcohol use and alcohol-related harm is expected to rise particularly in 
developing regions and in young individuals in developed nations (189). 
Despite the evidence of rising alcohol consumption, the high global burden of 
disease and the substantial economic costs attributable to alcohol misuse, the focus 
on alcohol control is disconcertingly inadequate in most countries (189). The fact that 
the alcohol-attributable burden is increasing at a time when available strategies can 
efficiently and cost-effectively control alcohol-related harm, is unacceptable (174). 
This is occurring because the alcohol industry is well organised and effectively lobby 
for industry-friendly policies both internationally and nationally (178, 189). There is an 
imbalance of power between the alcohol industry and health groups which results in 
the continuing neglect of alcohol as a global health issue (176). 
Strategies to reduce alcohol use 
Cost-effective and efficient evidence-based measures to address the harmful use of 
















drink-driving legislation (83, 156, 189). Ideally these would encompass implementing 
a full ban on alcohol advertising, augmented with other policy interventions. These 
would include raised alcohol excise taxes, addressing alcohol availability through 
tighter control on the hours of sale and strengthening measures to counter driving 
while under the influence of alcohol (175-177, 189, 190).  
Strategies that make alcohol more expensive, less available and less acceptable can 
curb the problematic use of alcohol consumption (176) and reduce the alcohol-
related burden by up to 25% (175). Decreasing the alcohol-related health burden has 
the potential to be one of the most cost-effective population-based health 
programmes in developing countries (175). 
Implementation of alcohol control strategies 
Seeing that effective regulatory control, including cost-effective and affordable 
interventions to restrict alcohol harm, exist (189), the need now is to move beyond 
strategy development and encourage nations to approve and implement alcohol 
policies (191). As demonstrated in North America, Europe and Australia, this is a 
considerably more difficult process (191). Factors hampering progress include a lack 
of political will, obstruction by the alcohol industry in the policy process, and 
globalisation with its free-trade environments that prevents an adequate response at 
a national level (189). Therefore, taking action on alcohol requires strong political will, 
both internationally and nationally, with governmental action being essential (176, 
189).  
Alcohol control needs to be given political priority as a global health issue with calls 
for international, national and local sustained efforts to prevent and control alcohol-
related harm (176, 189). Until 2009, in contrast to tobacco and illicit drugs, alcohol 
lacked a coherent framework for global control within the UN system, despite the 
clear need and importance relative to these substances (189). Unfortunately, in the 
past, neither the WHO, the policy holder for alcohol within the UN system, nor other 
UN agencies with potential interests, had paid much attention to alcohol. 
Recently however, alcohol has been receiving increasing recognition, particularly 
within the WHO which approved the Global Strategy to Reduce the Harmful Use of 
Alcohol in 2010 (83, 156, 178). Alcohol, together with tobacco, diet and lack of 
exercise, was named as one of the four major common risk factors for NCDs in the 
recent status report of the WHO, in addition to the Lancet NCD action group (83). 
Other international agencies such as the World Bank, which once facilitated the 
















to strengthen their alcohol policies, particularly for tax, availability control and 
advertising bans (189). Regional and international NGO networks have also been 
established in the past decade in response to the perceived need for a global 
response to the aggressive promotion of alcohol. 
Framework Convention on Alcohol Control  
Furthermore, in light of the strong parallels between tobacco and alcohol, and the 
precedent established by the WHO FCTC, there have been calls for a Framework 
Convention on Alcohol Control (FCAC). The utilisation of international law, in the 
form of the FCAC, to achieve a medium for cooperation and negotiation is essential. 
While the initial steps have been undertaken to this end, these need to be urgently 
accelerated (189). However, despite the success of the FCTC, and the need for 
measures to counterbalance the pressures from globalised industries, and free trade 
treaties and settlements, there seems to be little immediate chance of the WHO or 
member states supporting the complex process of developing a FCAC (176, 178, 
189). 
1.2.2.4. Insufficient Physical Activity 
Introduction  
The physical, economic and social environments in which individuals reside today 
have been changing rapidly and more so since the middle of the last century (192). 
The changes include revolutions in transportation, communication, workplace and 
domestic-entertainment technologies, which are occurring predominantly in urban 
settings. The consequences of urban living and employment, coupled with easier 
access to public transport and a lack of basic infrastructure for exercising, have been 
associated with significantly reduced physical activity (26, 192-194).  
Of note is that even rural locations far from cities are increasingly becoming 
urbanised and mechanised (195). Even in developing regions, the physical activity 
patterns over the past few decades have shifted from labour-intensive lifestyles to 
more sedentary and less physically demanding activities (196). Technology and 
economic incentives tend to discourage activity; technology by decreasing the energy 
requirements for routine daily activities, and economics by greater reimbursements 
for sedentary than active work (197). 
Prevalence  
Adults aged 18–64 years are recommended to participate in at least 150 minutes of 
moderate-intensity aerobic physical activity or 75 minutes of vigorous-intensity 
















vigorous-intensity activity (198). However, 31% of adults (men: 28%, women: 34%), 
age ≥15 years globally, were insufficiently active and did not meet these minimum 
requirements in 2008. Inactivity was higher in women compared to men in all WHO 
regions with the highest rates in the Americas and the Eastern Mediterranean 
regions. Almost 50% of women were insufficiently active in both regions, while 40% 
and 36% of men, respectively, were inactive. The least inactive men (15%) and 
women (19%) were in the South-East Asia region. Insufficient activity rose in 
accordance with increasing country income level, with the prevalence in high-income 
countries more than double that of low-income countries. Increased work and 
transport-related physical activities in developing compared to developed regions 
may explain the differences in activity levels (156).   
Consequences 
The declining environmental needs for physical activity are associated with shifts in 
health-related behaviours and a rise in the risk of related conditions (192). Strong 
evidence demonstrates that insufficient physical activity increases the risk of many 
adverse health conditions including CVD, thromboembolic stroke, hypertension, 
diabetes, obesity, dyslipidaemia, osteoporosis, colon and breast cancers, anxiety and 
depression, and shortens life expectancy (73, 197, 199-204). Insufficient physical 
activity increases the risk of all-cause mortality by 20-30% compared to individuals 
meeting the minimum requirement of participating in at least 30 minutes of moderate 
intensity physical activity on most da s of the week (156).  
Therefore, it is not surprising that physical inactivity has been identified as the fourth 
leading risk factor for global mortality responsible for 6% (3.2 million) of deaths 
globally in 2008; only high BP, tobacco use and high blood glucose contributed to 
more deaths (156, 198). The Lancet Physical Activity Series Working Group 
attributed 9% of premature mortality and 6-10% of the NCD burden in 2008 to 
physical inactivity. Insufficient activity caused 6% of the disease burden from IHD and 
7% from diabetes globally demonstrating the major impact of this unhealthy 
behaviour (203). 
Physical activity is beneficial for physical, mental and social health as well as being 
fundamental to maintaining energy balance and weight control (73, 205). The 
cardiovascular benefits of physical activity are mediated through several mechanisms 
including improved glucose metabolism, reduced body fat and lowered BP, resulting 
in a reduced risk of CVD and diabetes (73, 168, 200). Engaging in 150 minutes of 
moderate physical activity each week (or equivalent) is estimated to reduce the risk 
















the risk of stroke and hypertension (156), and is associated with improved low-
density lipoprotein cholesterol (LDL-C) particle size, lower triglycerides and higher 
HDL-C levels (73, 204, 206).  
Measuring physical activity 
Physical activity is a complex multi-dimensional behaviour, including different 
dimensions (type, intensity, duration, frequency) and domains where activity takes 
place (196). This makes it difficult to quantify physical activity and various 
methodologies, instruments and analyses have been used (200). Nonetheless, 
subjective self-reported questionnaires are routinely used to measure physical 
activity levels. Some self-reported tools developed to measure physical activity in the 
past decade include the International Physical Activity Questionnaire (IPAQ) and the 
Global Physical Activity Questionnaire (GPAQ) (200, 207). The accuracy of 
questionnaires, however, is limited by recall bias and the difficulty in assessing all 
dimensions and domains of physical activity when using self-reported instruments 
(196). 
The gold standard method for measuring free-living total energy expenditure is 
doubly labelled water but this is not appropriate for large population studies. 
Objective methods such as accelerometry, heart rate monitoring, and combined 
movement and heart rate monitoring are considered to be more accurate than self-
report methods (196). The development of these sophisticated device-based 
instruments to measure physical activity has enabled the accurate accounting of an 
entire range of activity, from sedentary through to highly vigorous activities in free-
living participants over a number of days. The most frequently used device-based 
tool in population-based studies thus far has been the accelerometer (199). Although 
device-based measures are being used more frequently for measuring physical 
activity in epidemiological studies in developed regions, their uptake in developing 
nations has been limited (196) and is likely to be delayed by high cost factors.  
Sedentary behaviour  
In addition to insufficient physical activity, an added concern is that of sedentary 
behaviour in the form of excessive sitting. In contemporary society this is a common 
occurrence that extends across many settings including transportation, the workplace 
and the home. Of note, is that even if the recommended levels of activity are 
achieved, sitting for prolonged periods can compromise cardio-metabolic health as 

















Strategies to increase physical activity  
Physical inactivity remains an urgent public health issue globally (197) and seeing 
that it has major health consequences, decreasing or removing this unhealthy 
behaviour would greatly improve health. Therefore, all avenues and all efforts should 
be explored to reduce physical inactivity worldwide (203). Complex variables, 
including personal, programmatic, social, environmental and related factors, facilitate 
a physically active lifestyle and need to be maximised (29, 197). The WHO 
recommendations for promoting physical activity target policy-makers at the national 
level and support population-based strategies (198). These have been incorporated 
in its Global Strategy on Diet and Physical Activity with suggested strategies 
highlighting the need for national physical activity plans and their integration with diet 
and obesity control programmes (207). 
Environmental influences on physical activity patterns  
Information and awareness have increased on the role that the environment plays in 
influencing physical activity, and efforts to promote physical activity need to consider 
the manner in which individuals interact with the environment (29, 197). 
Environments that facilitate physical activity need to be encouraged with easier 
access to such facilities (29, 73). The creation of these environments requires 
government involvement to implement policies that promote population-based 
approaches for enhanced physical activity. For example, there needs to be dedicated 
safe and accessible spaces to encourage walking, cycling and other forms of 
physical activity (29, 73, 208). Public policies and legislation that can potentially 
impact on opportunities for physical activity are multi-sectoral and include those 
relating to transport, urban planning, education, labour, social inclusion, sport and 
recreation, and healthcare funding connected to physical activity (73, 195). 
Additionally, constraints to physical activity such as crime and air pollution also need 
to be addressed (208).  
Socio-cultural influences on physical activity patterns 
Equally important, it must be noted that societal, cultural and personal influences 
affect the uptake or continuation of physical activity patterns, and need to be 
identified and incorporated into strategies of exercise promotion (209). Strategies 
need to overcome social norms that prevent activity and improve community 
understanding and acceptance of integrating physical activity into everyday life (73). 
National strategies must therefore be culturally appropriate and capable of 
















In summary, efforts to improve physical activity need to take cognisance of 
increasing urbanisation and various aspects of city planning, transportation, safety 
and access to physical activity during leisure, and socio-cultural attitudes to 
exercising (73). The implementation of such a strategy requires sustained political 
commitment and the collaboration of numerous stakeholders. The benefits of 
promoting a population-based physical activity strategy will contribute to the effective 
prevention of CVDs and other NCDs. 
1.2.2.5. Unhealthy Diets  
High fat intake 
Introduction 
Over the past century, with rising industrialisation, urbanisation and mechanisation 
evident in most countries worldwide, diet and nutritional status have undergone major 
changes (8, 210). The changing dietary patterns are a product of the modern trade 
systems and the effect of the global food industry on food-supply chains (211). 
Consequently, there has been a shift away from traditional diets toward the higher fat 
and higher refined carbohydrate western diet (212), with dietary fat intake increasing 
steadily over the last four decades (156). 
Patterns of fat intake 
There are large variations globally in the amounts of total fats consumed. The highest 
proportions of energy derived from total fat intake are in parts of North America and 
Europe (>30%), while the lowest quantities consumed are in Africa and South-East 
Asia (<20%) (8, 156). The proportion of energy from dietary fats is over 30% in 
developed regions and in most other regions this share is increasing (8). The pace of 
dietary change is occurring at varying degrees in different regions of the world (210). 
While the proportion of fat intake has increased with growing country level income, 
unhealthy diets have been rising quickly in lower-resource settings with particularly 
rapid increases in fat intake in lower-middle-income countries since the 1980s (156). 
Growing incomes in developing regions have led to increases in the accessibility and 
intake of energy-dense high-fat diets, especially among the poor (8).  
Consequences  
The WHO recommendation is that fat intake should not exceed 30% of daily energy 
intake (94), as an unrestricted fat intake is associated with potential excess energy 
consumption and unhealthy weight gain (213). Intake of unhealthy diets that are 
















imbalances, and the rapidly rising global levels of obesity and subsequent CVDs 
(208).  
In addition to affecting body weight, dietary fat intake, specifically the qualitative 
composition of dietary fats of high saturated and trans-fatty acid intake, influences 
the risk of CVDs such as IHD and stroke. This occurs through effects on blood lipids, 
thrombosis, BP, arterial (endothelial) function, arrhythmogenesis and inflammation 
(8, 205, 213-215). However, not all fats are categorised as unhealthy; while saturated 
and industrially produced trans-fats contribute to CVDs, polyunsaturated and 
monounsaturated fats are cardio-protective (94). High total fat intake has also been 
associated with a higher risk of impaired glucose intolerance (IGT) and higher fasting 
glucose and insulin levels (8).  
Other dietary influences on cardiovascular health 
In addition to high fat intake, other diet and nutrition factors also play a key role in the 
causation of CVDs by influencing the biological variables that mediate the risk for 
these conditions. The quantities of fruit and vegetables, and salt consumed daily are 
likewise key influences on cardiovascular health. Although other food items also 
contribute to greater or reduced CVD risk, these are the main determinants of diet-
related risk for CVD (213).  
Adequate quantities of fruit and vegetable intake (400–500 grams/day) are 
recommended by the WHO to lower the risk of IHD, stroke and high BP, as well as 
stomach and colorectal cancers (94, 156, 213). These contribute to cardiovascular 
health through numerous phyto-nutrients, potassium and fibre (213). Salt or sodium 
intake has been directly correlated with BP and the prevalence of hypertension (55, 
156, 213). Likewise, high intakes have a direct effect on stroke, left ventricular 
hypertrophy, progression of renal disease, and proteinuria, independent of but 
additive to the impact of salt on BP (55, 216). Consequently, a daily intake of less 
than 5 grams/day has been recommended to reduce the risk of IHD and stroke (217).  
Strategies to improve diets 
Considering that dietary changes can substantially alter the risk of CVD, 
opportunities exist to modify the direction and dimensions of the global CVD 
epidemic through policy interventions at the local, national and global levels. As 
stated by Reddy, policies and intervention strategies that promote the availability, 
affordability and acceptability of health enhancing diets, and restrain the marketing 
















agricultural policies ought to be consistent with the protection and promotion of public 
health (73).  
Globalisation presents a major challenge to implementing nutritional policies at 
national levels because of the ubiquitous presence of the fast-food industry. This 
global industry, with its rapid penetration of high-salt, high-fat, high-energy processed 
foods into developing country markets, promotes the consumption of foods 
detrimental to cardiovascular health (213). Therefore, global and national agriculture 
and trade policies need to urgently address these concerns and find sustainable 
solutions.  
Effective interventions include the development of food-based dietary guidelines 
deduced from the recommendations of specific amounts of nutrient intakes and the 
appropriate dissemination of these to consumers. However, these has not been 
introduced yet at a national level in most countries (156). Equally important is to 
ensure effective product labelling practices, whereby adequate nutritional information 
with respect to fat and sodium content is provided (156, 195, 213). To promote 
cardiovascular health, dietary intake of trans-fats should be <1%. This is particularly 
important in developing regions where this low-cost fat is frequently consumed (218). 
Industrially produced trans-fatty acids (hydrogenated fats) are harmful and need to 
be reduced through mandatory regulation o  food standards; the most effective action 
is a total ban (156). Another important strategy is to lower the sodium content of 
manufactured foods and meals (156), particularly of regularly consumed foods like 
breads and cereals (213). Also, subsidising or lowering prices of more healthful foods 
was associated with greater intake of these foods. For example, in observational 
studies in the United States (US), fruit and vegetable intake increased and BMI 
dropped with lower prices of these foods (51).  
1.2.3. PHYSIOLOGICAL RISK FACTORS 
1.2.3.1. Overweight and Obesity 
Drivers of the obesity epidemic 
Before 1980, global obesity levels were generally much lower than 10% (219). 
However, there has been a rapid rise in the prevalence of overweight and obesity 
with the emergence of an ‘obesogenic’ environment (220, 221). Globalisation and 
urbanisation have over the past few decades contributed to environmental and 
societal changes with subsequent alterations in dietary and physical activity patterns. 
These processes have resulted in an abundant supply of processed, energy-dense 
















marketed (74, 77, 219, 220, 222). Reduced physical activity promoted by the built 
environment, particularly in urban settings, is attributable to increasing sedentary 
occupations and changing modes of transportation (77, 220-222). In addition, the 
complex interplay between biological factors operating during foetal development and 
infancy, and the related energy imbalances aggravate many health problems (222). 
The overconsumption of food, decreased physical activity, or both have contributed 
to the energy imbalance between calories consumed and calories expended. The 
energy imbalance, with greater calories consumed than expended, leads to the 
accumulation of abnormal or excessive fat that presents a risk to health and is the 
hallmark of overweight/obesity (77, 220, 223). The obesity epidemic seems to be 
related to increased energy consumption in developed regions and to increased 
consumption and decreased energy expenditure in some developing countries (223). 
The obesogenic environment is exacerbated by the absence of supportive policies in 
sectors such as health, agriculture, transport, urban planning, environment, food 
processing, distribution, marketing and education (77). As a result, 
overweight/obesity has become a major and serious, yet neglected, public health 
problem that threatens to overwhelm developed and developing regions (205, 220, 
224). Overweight/obesity has reached epidemic proportions (224), overtaking 
tobacco as the largest preventable cause o  disease burden in some regions (74).  
Prevalence and trends 
In 2008, 34% men and 35% of women ≥20 years old, comprising 1.46 billion adults 
globally, were overweight/obese suggesting that one in three adults were affected 
(50, 156, 225). The prevalence of overweight/obesity was highest in the WHO 
Region of the Americas (overweight: 62%, obesity: 26%) and lowest in South-East 
Asia (overweight: 14%, obesity: 3%) (17, 156) .  
Worldwide, women were more likely to be obese than men, with the rates in women 
in Africa, South-East Asia and the Eastern Mediterranean approximately twice those 
of men in 2008 (156). Women, for biological reasons, usually have a higher mean 
BMI and thus higher rates of obesity at all ages worldwide, compared to men (205). 
The obesity prevalence almost doubled between 1980 and 2008 from 5% to 10% for 
men and from 8% to 14% for women (17, 156, 225). During this period, the mean 
global BMI increased by 0.4 kg/m² for men and 0.5 kg/m² for women per decade 
(225). 
The prevalence of overweight/obesity by country income level, was higher in high-
















income countries (156). Nonetheless, overweight/obesity cannot be considered a 
problem only of developed regions as it is becoming more prevalent in low- and 
middle-income countries, particularly in urban settings (77, 224). Furthermore, 
although more prevalent in developed regions, substantially larger absolute number 
of individuals are affected by overweight/obesity in developing regions because of 
the considerably larger population in the latter (226). Also, in several developing 
countries in Asia and SSA the prevalence of obesity is comparable to that found in 
the US and other high-income nations (224). Developing regions are now facing a 
double burden of disease, with infectious disease and under-nutrition continuing to 
be a problem. They are experiencing a rapid rise in CVD risk factors such as 
overweight/obesity, and as mentioned earlier, particularly in urban areas (77, 224). 
The prevalence of overweight/obesity worldwide differs by socio-economic status. An 
inverse relationship exists between socioeconomic status and obesity in women in 
developed nations, yet in developing nations the relationship is positive in women 
and men (156). However, trends indicate that while overweight/obesity initially affects 
wealthier individuals in urban areas in developing regions, this is followed by a 
reversal of the socioeconomic gradient as overweight/obesity becomes a disease of 
the poor (221). This is particularly true when a country’s gross domestic product 
(GDP) exceeds about US$5000 per year (205). 
Of added concern is that not only have the global overweight/obesity rates risen 
steadily over the past few decades in developed and developing regions but there is 
little indication of this trend slowing down (220, 227). The prevalence of 
overweight/obesity is predicted to rise to about 58% (overweight: 38%, obesity: 20%) 
by 2030, with 3.3 billion adults either overweight or obese if recent secular trends of 
obesity continue. The proportional increase in the number of overweight/obese 
individuals will be larger in developing regions because of factors including growth in 
population size, population ageing, urbanisation and changes in lifestyle related to 
higher total calorie intake and decreased physical activity (226). 
Consequences  
The risk attributable to excess body weight is exceedingly high with no other 
modifiable effect having such an impact on health (228). Consequently, obesity has 
also been identified by the International Statistical Classification of Diseases as a 
chronic disease in its own right (224, 229). Excess body weight is associated with an 
increased risk of many diseases, notably diabetes, hypertension, dyslipidaemia, IHD, 
stroke, musculoskeletal diseases, several cancers including endometrial, breast and 
















WHO Comparative Risk Assessment Study (Global CRA) estimated that in ≥30-year-
old adults, BMI >21 kg/m2 was associated with approximately 58% of diabetes, 39% 
of hypertensive disease, 21% of IHD and 23% of ischaemic stroke, among other 
conditions (234). In addition to reduced life expectancy and the health-related risks 
and costs, excess adiposity has other substantial implications for the individual and 
society in terms of lost productivity and economic liabilities (205, 220). 
Mortality 
Overweight/obesity is the fifth leading risk for global mortality, responsible for about 
4.8% of global mortality or at least 2.8 million deaths annually (77, 85). The excess 
mortality is mainly attributable to CVD. Using BMI as the measure of adiposity, each 
five units above the overweight category is associated with about 30% higher overall 
mortality and 40% higher cardiovascular mortality (220).  
Depending on the severity of obesity, the life expectancy of overweight/obese adults 
may be shortened by 4-10 years (205, 220). On account of the high obesity 
prevalence in young individuals, it has been projected that for the first time in this 
century their expected lifespan will decrease in the near future. This is because of the 
earlier onset of diabetes and its complications, mainly CVD and end-stage renal 
disease, compared to previous generations (228).  
Strategies to reduce overweight/obesity  
The obesity epidemic requires urgent action, particularly by policy makers and 
international stakeholders, such as the UN, so as to provide global leadership to 
dismantle the obesogenic environment (74, 220).  
The WHO responded to the global obesity pandemic by adopting the Global Strategy 
on Diet, Physical Activity and Health in 2004. This document, as discussed 
previously in Section 1.1.5., describes the actions needed to support healthy diets 
and regular physical activity and advocates stakeholders at global, regional and local 
levels to act to improve diets and physical activity patterns at the population level 
(77).  
Nonetheless, public health interventions have been limited, especially in developing 
regions. In these regions, where healthcare resources are scarce, primary prevention 
of overweight/obesity through population-based initiatives is particularly important, 
and more feasible and cost-effective than the challenge of weight reduction. A 
reduction in the global burden of overweight/obesity will translate into declines in 

















In order to create such supportive environments the key determinants of the 
obesogenic environment need to be targeted (220, 235). Governments at all levels 
need to enact policies that facilitate greater physical activity and healthy food 
consumption in a manner which makes these the easy choices (220). Structural, 
regulatory, and economic interventions have the potential to bring about these 
changes (225). Seeing that supportive environments and communities are key to 
shaping individual choices, by making a healthier dietary choice and regular physical 
activity the easiest one, overweight/obesity can be prevented (77, 220, 228, 231). 
At individual level, it is vital to encourage weight loss in those who are overweight or 
obese. Modest weight loss of, for example, 5% to 10% is associated with 
improvements in cardio-metabolic risk factors (236), with significant improvements in 
BP in those with and without hypertension, in lipid profiles by lowering triglycerides 
and raising HDL-C, and in glucose tolerance or insulin resistance with a reduction in 
the progression to diabetes (232, 236).  
Nonetheless, it must be emphasised that although health behaviour modification 
remains the cornerstone for the treatment of overweight/obesity (220), simple advice 
and exercise alone have not been found to be effective (225), with a lack of 
motivation a massive barrier to change (205). Weight-management is a long-term 
process and the proportion of people who are adequately motivated to accept 
treatment is estimated to be less than 20% (205). Therefore, obesity is virtually 
impossible to treat by conventional methods (235), particularly as the range of 
options within which individuals make their choices is skewed in favour of weight gain 
rather than weight loss (237). Changing the environment within which these 
decisions are made to help support behaviour change is likely to be far more 
effective than merely encouraging individuals to make better choices (235, 237) since 
overweight/obesity cannot be managed solely at the individual level (238).  
1.2.3.2. Diabetes Mellitus 
Introduction 
Diabetes mellitus, a metabolic disorder characterised by chronic hyperglycaemia that 
occurs because of defects in insulin secretion, insulin action, or both (239), is 
escalating and poses a threat to health and socioeconomic development in the 21st 
century (240). The number of individuals with diabetes worldwide has more than 
doubled over the last three decades; a remarkable increase that is occurring in all 
corners of the globe (241, 242). Diabetes today poses a global public health crisis 
that threatens the economies of all countries, particularly those of developing nations 

















The predominant form of diabetes is type II diabetes, which accounts for 
approximately 90% of cases, and is the type of diabetes investigated in this thesis. 
Another important class of diabetes is type I diabetes, which is attributable to an 
autoimmune process or beta–cell destruction for which neither an aetiology nor a 
pathogenesis is known (idiopathic) (239). Diabetes may also occur during pregnancy 
and is classified as gestational diabetes. Less common secondary causes of 
diabetes include diseases of the exocrine pancreas, such as tumours or pancreatitis, 
endocrinopathies like Cushing’s syndrome or phaeochromocytomas, drug-induced 
diabetes and infections. 
There are intermediate metabolic states between normal glucose homeostasis and 
diabetes that are too high to be considered normal. These consist of IGT and  
impaired fasting glycaemia (IFG) (244). These forms of impaired glucose regulation, 
while not clinical entities in their own right, are transitional stages in the development 
of diabetes (244, 245); almost half of those with these pre-diabetes states progress 
to diabetes. Individuals with pre-diabetes are also at increased risk for CVD: IGT 
increases the risk of CVD by approximately 60% and IFG by about 30% (246). 
Predisposing factors 
Driven by rapid globalisation and urbanisation, with subsequent changes in diet and 
increasingly sedentary lifestyles, the diabetes epidemic has expanded in line with the 
worldwide rise in overweight/obesity. The rapid rise of obesity is the single most 
important predictor of diabetes that has contributed to the worldwide spread of this 
condition (242, 247). In addition, diabetes is rising on a global level on account of 
population ageing and rapid urbanisation (242, 243, 248-253).  
A complex gene-environment interaction of non-modifiable (genetics, age, sex, 
ethnicity and family history) and modifiable risk factors predisposes to the 
development of diabetes (194, 247, 254). The significant modifiable risk factors 
include overweight, abdominal obesity, physical inactivity and sedentary behaviour, 
and increased total dietary fat and carbohydrate intake (249, 254, 255). In addition, 
intra-uterine and early childhood influences as well as stress may also play a role 
(194, 242, 254, 255).  
Although genes that predispose to diabetes are considered an essential factor in the 
development of the disease, the activation of a genetic predisposition necessitates 
the presence of environmental and behavioural factors that are usually associated 
















may be prevented by only avoiding being overweight/obese (228). 
Overweight/obesity has the most potent effect on diabetes with every unit increase in 
BMI producing a 12-% rise in the risk of diabetes (249, 254). 
Prevalence and trends   
The rise of obesity, driven by rapid globalisation and urbanisation with subsequent 
changes in diet and increasingly sedentary lifestyles, has been central to the 
expansion of the diabetic epidemic (194, 242, 247, 254). Diabetes has escalated to 
become a global epidemic that is expected to worsen in the coming decades (256).  
In accordance with rising levels of dysglycaemia, mean fasting glucose levels have 
been increasing globally between 1980 and 2008 (241). According to the fifth edition 
of the IDF Atlas, the global diabetes prevalence was 8.3% among 20-79-year-old 
adults, equating to approximately 366 million individuals (253). This is estimated to 
reach pandemic levels by affecting 552 million individuals or 9.9% of the adult 
population by 2030 (228, 253). In addition, the global prevalence of IGT in adults in 
2011 was 6.4% (280 million individuals) and is predicted to rise to 7.1% (398 million 
individuals) by 2030.  
The dynamics of the diabetes epidemic are shifting rapidly; once a disease of 
developed regions and the affluent, diabetes has now spread to every country in the 
world and is becoming increasingly common among the poor (194). The major 
burden of diabetes today occurs in developing, compared to developed, regions with 
approximately 80% of diabetic individuals residing here. According to the IDF 
Diabetes Atlas, China and India had the greatest numbers of affected individuals but 
diabetes was most preval nt in the Middle East and North Africa Region in 2011  
(11.0%) (253). Furthermore, the proportion of young to middle-aged individuals with 
diabetes was higher in developing than in developed countries (242, 252). In 
developed regions, most diabetic individuals were above 60 years old (252).  
Consequences 
Hyperglycaemia and diabetes contribute significantly to morbidity and premature 
mortality worldwide (241, 253). Chronic hyperglycaemia leads to micro- and macro-
vascular complications. The micro-vascular complications include retinopathy with 
the potential for blindness, nephropathy which may lead to renal failure, and/or 
neuropathy with risk of foot ulcers and subsequent amputation (239). The macro-
vascular complications make diabetes a significant contributor to CVD: it affects the 
heart (IHD), the central nervous system (cerebrovascular disease) and the lower 


















Among 20-79-year-old adults, 8.2% of the global all-cause mortality (4.6 million) was 
attributable to diabetes in 2011 (253). CVD is usually the leading cause of mortality 
among diabetic individuals accounting for over 50% of deaths in some populations 
(249, 253). Globally, 22% of IHD and 16% of stroke mortality was attributable to 
raised blood glucose (85).  
Mortality attributable to diabetes was highest in the Western Pacific Region (>15%) 
and lowest in SSA (6.1%). However, the Western Pacific Region and developed 
countries had the lowest age-specific risk of mortality from high blood glucose (85). In 
SSA, the majority (72.8%) of diabetes mortality occurred in people younger than 60 
years old compared to the global proportion of 48% (253).  
Management  
Diabetes is associated with a heavy health burden and to slow the progression to 
micro-vascular and macro-vascular complications, it is vital for healthcare systems to 
develop programmes that improve the detection and management of diabetes (241). 
This is particularly true for developing regions like SSA where early detection of 
established diabetes will improve outcomes and decrease costs (247). Equally 
important for successful management, is the need for health education and increased 
public awareness of diabetes (245, 256).  
The rising number of individuals with diabetes has important implications for 
healthcare provision aimed at diabetes control (245). Feasible and cost-effective 
interventions in diabetic individuals that improve health include tight glucose and BP 
control, and foot care for individuals with a high risk of ulcers. BP control in diabetic 
individuals is very effective in reducing the risk of cardiovascular complications as 
well as retinopathy and nephropathy. In resource-poor regions, BP control is 
estimated to be one of the most feasible and cost-effective interventions in 
individuals with diabetes (156). 
Nonetheless, diabetes management remains suboptimal, even in developed 
countries, with a major gap between recommended care and that actually received. 
Reports from Asia found that 32-50% of diabetic individuals had poor glycaemic 
control, defined as >2% above the upper limit of the normal range of HbA1C (258). 
Among diabetic adults aged 60 years or older in an urban slum in Delhi, awareness, 
treatment and control among were 36.0%, 22.5% and 16.9%, respectively (259). 
















proportion of diabetic adults with HbA1C <7.0% improved from 44.3% in 1999-2002 to 
52.2% in 2007-2010 (260). 
Prevention strategies 
In addition to optimal detection and management of diabetes, prevention is of 
paramount importance. Seeing that approximately 90% of individuals who developed 
diabetes had BMI higher than 23.0 kg/m2 (205), intensive lifestyle interventions in 
high-risk individuals specifically aimed at weight loss and increased physical activity 
can prevent or at least delay the progression to overt diabetes by 50%(261).  
However, sustained shifts in diet and lifestyle require not only individual behavioural 
changes, but also fundamental shifts in public policies. Public health strategies that 
alter the obesogenic environment by promoting healthy diets and lifestyles are 
paramount to curtail the diabetes epidemic (194). Despite the difficulties in 
implementing such population-based interventions, these strategies are vital since 
diabetes has become one of the most important public health challenges following 
the dramatic rise in the global prevalence (241, 242, 256).  
1.2.3.3. Dyslipidaemia 
Introduction 
The value of abnormal blood lipid levels to predict IHD has been studied for decades 
(262), with the importance of total cholesterol (TC) as a risk factor for the 
development of IHD originally demonstrated in the Framingham Heart Study (263). 
However, the initial focus has shifted from examining the relationship with TC to that 
of the individual components associated with TC. TC is a composite measure of the 
cholesterol content of lipoprotein particles including LDL-C and HDL-C (262).  
Consequences  
Dyslipidaemia is defined as the clinically significant alteration in circulating lipids and 
lipoproteins that predisposes to IHD and related disorders, with the key lipid 
abnormalities including those related to TC, HDL-C, LDL-C and triglyceride levels 
(264, 265). Furthermore, it is a determinant for the development of atherosclerosis 
and a major independent risk factor for heart disease, stroke and other vascular 
diseases (85, 156, 264, 266).  
In the INTERHEART study, dyslipidaemia was found to be the single most powerful 
cardiovascular risk factor for IHD (86). A 10-% reduction in TC in 40-year-old men 
can reportedly reduce heart disease by 50% within five years (156). Worldwide, a 
















middle-income European countries, and lowest in low- and middle-income Asian 
countries (85).  
The most common and clinically significant lipid abnormality is 
hypercholesterolaemia, i.e. elevated serum TC (265). LDL-C is the most atherogenic 
of the lipoprotein particles, with raised levels required for the initiation and 
progression of atherosclerosis (267). Hypertriglyceridaemia is also an independent 
predictor of IHD (268) with this association more robust in those with than without 
diabetes (269). In addition to excess lipids or hyperlipidaemia, such as raised TC, 
LDL-C and triglyceride levels which lead to adverse consequences (265), a low HDL-
C is independently atherogenic (270). This is recognised as a major risk factor for 
IHD, with high levels usually protective against atherosclerosis and subsequent CVD 
(265). Compared to Caucasians, HDL-C levels are usually much higher in individuals 
of African descent (271, 272). Consequently, TC may not be as important a proxy 
measure for CVD risk in the latter compared to other populations where it may be an 
accurate substitute for high LDL-C levels. However, emerging data on HDL-C-raising 
agents and Mendelian randomisation studies have lately questioned the causal 
relationship between HDL-C and atherosclerosis. Further research is required to 
clarify the role of HDL-C in the development of CVD risk (273). 
Predisposing factors 
TC levels are affected by diet and physical activity patterns as well as genetics, with 
dietary saturated fat the main determinant of TC and LDL-C levels (85, 233, 274). 
Conditions such as hypothyroidism, nephrotic syndrome and pregnancy, and the use 
of some drugs may also predispose to dyslipidaemia (265).    
Prevalence and trends  
While the dyslipidaemic patterns of high levels of LDL-C and/or low HDL-C have 
been found to impart high risk for developing IHD, globally, there is more information 
available on TC levels in populations than on LDL-C and HDL-C levels (85, 262). The 
global prevalence of TC ≥5.0 mmol/l among ≥25-year-old adults in 2008 was 39% 
(men: 37%, women: 40%). The highest prevalence was in Europe (54%) and the 
Americas region (48%), while the lowest was in SSA (23%). The prevalence of raised 
TC increased according to the income level of the country from about a quarter of 
adults in low-income countries to a third in lower-middle income countries and over 
50% in high-income countries (156).  
Although mean TC levels were highest in developed nations, these were decreasing; 
















rise (275). The likely drivers of these polarised global trends are dietary fats and 
adiposity, and probably statin use in high-income countries. Globally, mean TC has 
remained reasonably stable between 1980 and 2008, falling by <0.1 mmol/l per 
decade in men and women worldwide (156). The modest decline in TC predates the 
widespread use of statins in most parts of the world with their use remaining 
extremely low, even for secondary prevention in most countries (50).  
Mortality  
Approximately 4.5% of global mortality (2.6 million deaths) was attributable to TC 
≥5.0 mmol/l in 2008, making it the sixth leading cause of death (85, 156). The 
proportion of mortality attributable to raised TC was higher in high-income (5.8%) 
compared to low-income countries (3.4%); however, the numbers were higher in low- 
compared to high-income countries (0.9 million vs. 0.5 million) (85), emphasising the 
problem in poor regions.  
Management  
Population-based interventions that promote healthier lifestyles, including dietary 
modification, weight loss, smoking cessation and increased exercise, are important to 
prevent or improve lipid abnormalities (276, 277). TC levels are influenced favourably 
by improved dietary changes as well as increases in physical activity (233), while low 
HDL-C levels may be raised predominantly by smoking cessation, weight loss and 
aerobic exercise (270). Physical activity is associated with lower levels of LDL-C and 
triglycerides, and higher levels of HDL-C (204). Replacing 60% of saturated fat intake 
with other fats and reducing dietary cholesterol intake could reduce TC levels by 
about 0.8 mmol/l, that is, 10 to 15%. About 80% of this reduction will be in LDL-C 
(274).  
The treatment of dyslipidaemia is central to cardiovascular prevention (278), with 
high LDL-C levels being the primary target for cholesterol-lowering therapy (270). 
Lipid-lowering agents, statins in particular, have been shown to greatly improve 
cardiovascular morbidity and mortality (204, 266). Studies have demonstrated that 
each 1-% reduction in TC level was associated with approximately 1-% reduction in 
the risk of cardiovascular events (279).   
Although the use of lipid-lowering drugs, such as statins, is increasingly common in 
high-income countries, there is lower coverage of screening and treatment in low- 
and middle-income regions (275). The WHO MONICA study, conducted in 19 
countries, also showed better management in wealthier compared to poorer 
















cholesterol testing in the previous year (men: 37%, women: 30%). Awareness of 
hypercholesterolaemia was 19% in men and 17% in women. Among men and 
women, 45% and 44%, respectively, with raised TC were receiving treatment while 
61% and 65%, respectively, of those on treatment had desired levels <6.5 mmol/l. 
Other studies have reported suboptimal control of hypercholesterolaemia even in 
high-risk individuals. In Asia, TC >5.2 mmol/l among diabetic individuals was high in 
Singapore (67%), India (46%) and Taiwan (47%) (258). Notably, a multidisciplinary 
approach is required for the management of dyslipidaemia; in addition to lifestyle and 
diet interventions and pharmacological treatment of dyslipidaemia, treatment of 
concomitant CVD risk factors such as hypertension and diabetes is needed (266).  
1.2.3.4. Hypertension 
Prevalence and trends  
The high prevalence of hypertension has gained global importance and is recognised 
as a key contributor to the present pandemic of CVD (11, 281). Worldwide, the 
hypertension prevalence in ≥25-year-old adults was about 40% in 2008 amounting to 
almost one billion individuals, with most residing in developing countries (156). 
Hypertension was higher in low-income (40%) compared to high-income countries 
(35%), demonstrating the greater burden in poorer regions.  
Hypertension has been on the rise over the last few decades, with the numbers 
increasing from 600 million in 1980 to nearly one billion in 2008 (282), and by 2025 
the total number is estimated to increase to 1.56 billion (11, 283). The major rise is 
expected to occur in developing countries with an 80% increase in the number of 
hypertensive individuals as compared to a 24-% increase in developed nations (11). 
Predisposing factors  
The development of hypertension is a complex combination of genetic and 
environmental influences and cannot easily be simplified. In any given individual, 
although one factor may be more important than others, hypertension is often 
multifactorial (284). The key risk factors for essential hypertension, also referred to as 
primary or idiopathic hypertension are excess body fat, a salt-rich diet with processed 
and fatty foods, a low consumption of fruit and vegetables (that is, low potassium 
intake), physical inactivity, excessive alcohol consumption and psychosocial stress 
(37, 85, 168, 216, 285-288). These changing lifestyles associated with globalisation 
and urbanisation (233) as well as population growth and ageing, seeing that these 

















A specific cause of BP elevation can be identified in a small proportion of individuals 
with hypertension. Secondary causes of hypertension include polycystic kidney 
disease, renovascular hypertension, phaeochromocytoma, primary aldosteronism, 
Cushing’s syndrome, coarctation of the aorta and drug-induced hypertension (168).  
Consequences  
Raised BP has serious and life-threatening consequences; it is a major risk factor for 
IHD, stroke, heart failure and chronic renal failure, and a predominant contributor to 
CVD morbidity and mortality (11, 53, 94, 156, 281, 289, 290). Other common target 
organ damage includes left ventricular hypertrophy, arrhythmias, sudden death, 
retinopathy and PVD (156, 291, 292). Hypertension also contributes to diabetic 
nephropathy, with the coexistence of overt diabetes and hypertension doubling the 
risk for CVD, as well as for nephropathy (267).  
Cardiovascular morbidity and mortality demonstrate a continuous relationship with 
BP levels which is positively and progressively related to the risk (156, 168). Of note 
is that cardiovascular risk occurs even at systolic and diastolic levels of 110–115 
mmHg and 70–75 mmHg, respectively. The relationship has been reported to be less 
steep for coronary events than for stroke; stroke is recognised as the most important 
hypertension-related complication (168). Globally, approximately two-thirds of strokes 
and almost half of all IHD cases were attributable to systolic BP ≥115 mmHg (293). 
About 4-6% of global disease burden was attributable to high BP (19, 85, 293). 
High BP was the foremost cause of death worldwide responsible for 13-14% of global 
mortality or about 7.5 million deaths (19, 85). This is not surprising bearing in mind 
the high global prevalence of hypertension and that high BP is a powerful 
independent risk factor for deaths attributable to stroke and IHD (281). Worldwide, 
51% of stroke and 45% of IHD deaths were attributable to high systolic BP (85), 
making raised BP the leading risk factor for CVD mortality (282).  
The hypertension burden is already imparting a profound effect on populations in 
low- to middle-income countries (36). Approximately 80% of the hypertensive disease 
burden occurs in developing regions and over half in those aged 45–69 years (19).  
The number of deaths was higher in low- (2.0 million) and middle-income (4.2 million) 
compared to high-income countries (1.4 million) (85), reinforcing the higher burden in 
poorer regions. Furthermore, a greater proportion of the burden occurred in younger 
individuals in developing regions (19) because, at any given age, the risk of dying 
from high BP was more than double in low- and middle-income countries compared 

















Despite the gravity of complications, significant numbers of hypertensive individuals 
are unaware of their condition and diagnosed hypertensive treatment is often 
inadequate (294). If the march of hypertension-related morbidity and mortality is to be 
contained, prevention, detection, treatment, and control of hypertension should 
receive high priority (11), particularly in developing regions. 
In developed regions, levels of hypertension awareness and treatment were relatively 
high with approximately one-half to two-thirds of hypertensive individuals aware of 
their diagnosis and one-third to one-half receiving treatment. The rates of 
hypertension control among treated individuals were 30-50% (294). The lower 
mortality burden attributable to high BP in high-income countries is likely related to 
their better hypertension management compared to poorer regions. Although 
hypertension prevalence increased in high-income countries (295), there was a 
marked decline in mean BP in this region (50, 282), likely because of the active 
management of hypertensive individuals through the widespread use of drug 
treatment (295). 
In contrast, while mean BP in high-income countries dropped between 1980 and 
2008, in low-income countries, the mean BP increased during the same period (50, 
282). The rising BP levels in developing regions are suggestive of a lack of effective 
measures to optimise hypertension management, despite the availability of effective 
treatment. The levels of hypertension awareness, treatment and control in most 
developing countries tended to be lower than those reported in economically 
developed countries, with approximately one-quarter to one-half of hypertensive 
individuals aware of their diagnosis, 10-50% receiving treatment, and 20-50% of 
treated individuals being controlled (294).  
A systematic review by Pereira and colleagues (2009), however, found no significant 
differences between developed and developing regions (281). Among men, the 
highest prevalence of hypertension awareness, treatment and control was reported in 
North America (66.1%, 46.3% and 24.9%, respectively). The lowest rates among 
men were in Southern Asia (awareness: 35.3%), Southern Europe (treatment: 
23.6%) and Northern and Central Asia (control: 5.7%). Among women, the highest 
prevalence of hypertension awareness, treatment and control was observed in South 
and Central America (73.6, 62.5 and 33.2%, respectively). The lowest rates among 
women were in Southern Asia (awareness: 46.4%) and Northern Europe (treatment: 
















Although the overall prevalence of controlled hypertension was higher in more 
affluent countries, hypertension control among treated individuals was not so 
different in developing compared to developed regions (37). This suggests that the 
large difference in hypertension control between these regions is likely attributable to 
the extent that hypertension was diagnosed, which is much lower in low-income 
regions. The difference in levels of awareness may be related to a lack of resources 
characteristic of less affluent settings (37).  
Considering that hypertension accounts for more deaths globally than any other CVD 
risk factor, including cholesterol, tobacco, BMI, and physical activity (296), 
antihypertensive therapy, when optimally prescribed, is among the most efficient 
means for disease prevention (297). Lowering BP is associated with a reduction in 
cardiovascular morbidity and mortality associated with stroke, IHD and heart failure, 
as well as chronic kidney disease (156, 281, 282, 289). Effective treatment could 
prevent 250 000 deaths per annum (298), with antihypertensive therapy reducing the 
incidence of stroke by 35-40% and of MI by 20-25% (297, 299). 
Therefore, the early detection, treatment and control of hypertension are central to 
the integrated management of cardiovascular risk (300). Even in developing regions 
a substantial commitment of scarce resources must be considered for the 
management of hypertension using the total CVD risk assessment approach (289, 
297).  
Although hypertension management may be better in developed than in developing 
regions, there still remains a large ‘care gap’ worldwide among those who would 
benefit from treatment but are not detected, treated or adequately controlled (43). 
Hypertension care and control remains difficult, even in developed countries, for 
several reasons (283). Barriers to optimal hypertension management include the 
healthcare service, the healthcare provider and the patient indicating that a multilevel 
approach is required to improve outcome (168, 301). The WHO has identified poor 
adherence as the most important cause of uncontrolled hypertension worldwide, with 
an estimated 50–70% of patients not taking their antihypertensive drugs as 
prescribed (289).  
Considering the asymptomatic and chronic nature of the condition, hypertension 
poses the challenge of daily vigilance and continuing commitment to treatment (302, 


















Lifestyle modification strategies  
Along with pharmacological interventions, and irrespective of the level of 
hypertension, BP reduction by non-pharmacological means is equally important and 
always preferable (289). Interventions that have proven effective include weight loss, 
modification of eating habits with increased fruit and vegetable and decreased 
saturated and total fat intake, reductions in salt and alcohol consumption, and 
increases in physical activity (11, 168, 281, 289, 294, 304, 305). However, adherence 
to such lifestyle interventions is known to be extremely poor (289).  
Lifestyle modifications are likely to be more sustainable when instituted in supportive 
environments (306). Therefore, population-based approaches targeting diet and 
lifestyle, for example, a reduction in salt intake, a key contributor to raised BP, can 
achieve a downward shift in the distribution of BP in the whole population (307). 
Currently, unfavourably high salt consumption is prevalent, with the average daily salt 
intake of 9-12 gram/day approximately twice the recommended level of <5-6 grams 
daily (216, 285, 308-310). Beaglehole and colleagues recommend reducing salt 
consumption as one of five immediate priority interventions that are considered highly 
cost-effective in low-resourced settings (80). Indeed, the available data suggest that 
reducing salt consumption is more or at least just as cost-effective as tobacco control 
in terms of reducing CVD per se (55, 285).  
Numerous salt-reducing initiatives at the population level have proven to be effective 
and to potentially reduce BP and CVD risk (37, 94, 216, 307-309, 311). The evidence 
suggests that modest, long-term reductions in population salt intake would 
immediately reduce mortality from stroke and IHD by approximately 14% and 9%, 
respectively, in hypertensive individuals, and by about 6% and 4% in those with 
normal BP (94). Nonetheless, public health efforts to reduce salt intake remain 
limited to a few countries (19, 308, 309).  
Policymakers need to introduce legislative measures that create a congenial 
environment and facilitate the adoption of healthy lifestyles (305, 306). Such 
population-based strategies that promote healthier lifestyle choices will contribute to 
lower BP levels in the whole population as well as reduce the hypertension 
prevalence (305). In economically developing regions where healthcare resources 
are particularly scarce, investment in prevention strategies are likely to yield the 
greatest benefit (11) and should be a public health priority in these countries (36). 
Moreover, many lifestyle modifications also have a positive effect on other 

















Hypertension is thus a major public health challenge and an acknowledgement of the 
global nature of the problem is needed to effect optimal management via 
pharmacological and non-pharmacological interventions (281, 294). Currently, this 
silent epidemic is not matched with comparable levels of awareness among policy 
makers or the general population or with optimal interventions by healthcare 
systems. 
1.3. METABOLIC SYNDROME 
1.3.1. INTRODUCTION 
The associations among diabetes, hypertension and dyslipidaemia have been known 
for many decades but the seminal paper by Reaven in 1988 that ascribed much of 
the aetiology of these risk factors to insulin resistance ushered in a new era of 
awareness and research focus with a better appreciation of the impact of obesity on 
CVD (232, 312). The concept that these metabolic abnormalities cluster commonly 
resulted in the emergence of the term ‘metabolic syndrome’ (232) and refers to a 
cluster of risk factors for CVD and diabetes, which occur together more often than by 
chance alone (313-315). The MS is characterised by variable combination of central 
obesity and alterations in BP, glucose and lipid metabolisms (168, 313).  
1.3.2. PATHOGENESIS  
The pathogenesis of the MS and each of its components is complex and not well 
understood; nonetheless central obesity and insulin resistance are considered the 
primary underlying risk factors (315-318). Genetics, physical inactivity, ageing, a 
proinflammatory state and hormonal changes are also proposed to have a causal 
effect, but the role of these may vary depending on ethnic group (315, 316). 
1.3.3. CONSEQUENCES  
The MS is associated with an increased added risk of diabetes, CVD morbidity and 
mortality, and total mortality compared to those without the syndrome (168, 249, 304, 
314-321). The risk of CVD is approximately doubled (315, 322) while the risk of 
developing diabetes in those without diabetes is about 3-6-fold higher (168, 315, 316, 
319, 323, 324) and the risk of new onset hypertension is also greater in those with 
the MS (168). Individuals with both diabetes and the MS are at an even greater risk 
for CVD with the risk greater than the sum of the measured risk factors (314-316, 
318, 325). The MS is frequently associated with subclinical organ damage such as 
















ventricular hypertrophy, diastolic dysfunction and atrial enlargement (168). The risk 
for CVD and diabetes is greater in the presence of more components of the MS (315, 
317, 319) and worsened by concomitant elevations in LDL-C (319).  
1.3.4. RELEVANCE 
While accepted by many, the clinical utility of the MS has been questioned by some 
(232, 324). The claim made is that aggregating the metabolic risk factors adds little to 
clinical management. Even so, most experts agree that the clustering of metabolic 
risk factors is a real and relatively common phenomenon (324). Of relevance is that a 
combination of even modest elevations in BP, plasma lipids, and blood glucose 
confer substantial excess risk for diabetes, CVD and death, and a diagnosis of MS 
warns of extremely adverse metabolic states (326, 327). Diagnosing the MS extends 
the concept of cardiovascular risk; the importance of the syndrome is the 
identification of individuals at high risk of developing diabetes, hypertension and 
premature CVD (289, 319, 321).  
The increased risk associated with the presence of the MS makes it a valuable tool to 
alert healthcare providers that early diagnosis is essential and that comprehensive 
care with optimal control of multiple CVD risk f ctors is required (304, 328). The 
presence of the MS also underpins the need to emphasise earlier intervention with 
lifestyle therapies to reduce risk factors and disease incidence (289, 321, 324, 328). 
Although the MS is not a robust risk assessment tool for estimating absolute 10-year 
risk, its presence indicates the need for more extensive short-term risk assessment 
(316) and warrants aggressive intervention to reduce levels of individual risk factors 
(326, 327). The MS represents that part of global risk which is attributable to 
underlying metabolic causes such as obesity and abnormal body fat distribution (324) 
and may be useful in predicting risk among individuals classified as low or 
intermediate risk by the Framingham or other risk scores (329).  
1.3.5. DEFINITION  
Over the past few decades there have been several definitions of the MS using 
various diagnostic criteria; the most commonly cited include those proposed initially 
by the WHO (1998, 1999), European Group for the Study of Insulin Resistance 
(1999) and the American Association of Clinical Endocrinologists (AACE) (2000), 
then by the National Cholesterol Education Program Third Adult Treatment Panel 
(ATPIII) (2001,2004) and more recently, the International Diabetes Federation (IDF) 
(2005) (304, 323, 330). Notwithstanding the various definitions, central obesity, 
















317, 320).The main difference between the two major sets of criteria that were 
commonly used, i.e. the ATPIII and IDF criteria, was that central obesity, as 
measured by WC, was a prerequisite in the IDF definition with WC cut-points being 
ethnic specific and lower than in the ATPIII definition (313, 315, 316, 318, 331, 332). 
In 2009, in an attempt to unify the criteria, an additional definition was proposed as a 
joint interim statement (JIS) by several organisations (313). For a diagnosis of MS, 
three out of five abnormal findings were required with WC not an obligatory 
component. Notably, the WC criteria for Africans is the same as Caucasians but 
likely require modification as shown by Motala and colleagues (331).  
1.3.6. PREVALENCE  
The numerous definitions of the MS have resulted in widely differing prevalence 
estimates depending on the definition used (304, 331). Nonetheless, the MS is highly 
prevalent worldwide and presents a serious public health challenge (312, 324, 333). 
In most countries, approximately 20-30% of adults can be characterised as having 
the MS (324). Current lifestyle trends and increasing obesity are contributing to the 
global rise in the MS (324, 331, 333). The likelihood of a further increase in the MS 
can be expected on account of the predicted higher obesity prevalence in the future 
(324, 326).  
1.3.7. MANAGEMENT 
The objective of treatment in the MS is to reduce the high risk of a cardiovascular 
event and to prevent the much greater likelihood of developing diabetes or 
hypertension (334). Concurrent with pharmacological management of the individual, 
MS components of hyperglycaemia, raised BP and dyslipidaemia, therapeutic 
lifestyle changes, especially weight reduction, increased physical activity and an anti-
atherogenic diet are the cornerstone of management in the MS to improve the 
metabolic profile (168, 249, 304, 313, 316, 317, 319, 322, 326, 333, 335). 
Additionally, smoking cessation is mandatory (316, 319). 
Important to note is a wide spectrum of total cardiovascular risk that is present in 
individuals with the MS, which compels careful assessment (304), and the use of 
drug therapy guided by the level of risk (249).  After an initial risk assessment with 
the Framingham or other risk algorithms, utilising novel risk markers and screening 
for subclinical atherosclerosis may improve the risk stratification and identify those at 
















1.4. TOTAL CARDIOVASCULAR DISEASE RISK ASSESSMENT 
1.4.1. INTRODUCTION  
Treatment of CVD risk factors have traditionally been based on the presence or 
absence of a single cardiovascular risk factor, such as hypertension, hyperlipidaemia 
or diabetes without considering the continuous relationship between BP, blood 
glucose, blood cholesterol and cardiovascular risk (5, 43, 336). While this approach 
appears straightforward, it may result in committing some individuals with only a 
small cardiovascular risk to years of unnecessary treatment or, conversely, 
neglecting to treat individuals with an overall higher risk (10, 43, 336). This is 
because a combination of several slightly elevated risk factors may result in a much 
higher total risk than a single, more strikingly raised factor (30, 34, 168).  
The goal of primary prevention is the avoidance of all atherosclerotic CVD, which 
encompasses IHD, stroke and PVD (30, 337). Since all atherosclerotic diseases of 
the vascular tree share the same risk factors, the most appropriate outcome for risk-
estimation systems is considered to be total CVD where combined risk factor effects 
are evaluated (30). Consequently, clinical guideline recommendations on assessing 
risk and preventing CVD have undergone a substantial change over the past two 
decades with the recent focus on total cardiovascular risk a cost-effective strategy to 
assess individual risk (9, 34). Risk prediction has now assumed a key role in the field 
of CVD prevention (338), with primary preventive treatment targeted at asymptomatic 
individuals with an elevated absolute 10-year CVD risk (339). CVD management has 
shifted from an era of single risk factor intervention to multiple risk factor approach in 
high-risk individuals (182). 
1.4.2. RELEVANCE  
Moreover, single risk factor approaches are neither cost-effective nor affordable for 
poorer individuals and in developing regions with limited resources (10, 43). Given 
the enormous burden of CVD and the high costs of management, it is therefore 
essential to prioritise cost-effective approaches that target high-risk individuals (43). 
The use of the multifactorial cardiovascular risk-assessment approach to identify 
high-risk individuals who need interventions is being widely advocated with the 
initiation of therapy based on the predicted absolute cardiovascular risk of the 
individual (336). Total cardiovascular risk assessment is the most cost-effective 
approach with targeting treatments at high-risk individuals leading to the greatest 
absolute reduction in disease (5, 36). The total CVD risk assessment approach is 
















scarce resources. A higher cut-point of >30% risk of having a CVD event in the next 
10 years may be used as the guideline for treatment compared with the standard 
>20% risk for a cardiovascular event that is recommended for less resource 
constrained settings (44).  
1.4.3. RISK-ESTIMATION SYSTEMS  
That CVD risk factors cluster and interact multiplicatively to promote vascular risk led 
to the development of multivariable risk prediction algorithms (337). Several 
computerised methods for estimating total cardiovascular risk have been developed 
(168). The first risk-estimation system was developed by the Framingham Heart 
Study researchers in the US and is the best known internationally and the most 
frequently used (30, 34). This is also the score that has been best validated across 
different populations, modified for use in several countries and recommended by 
numerous international guideline committees for CVD prevention. European 
investigators, in addition, have developed various risk prediction scores and these 
numerous risk-estimation systems have been the foundation for guidelines and 
prevention strategies in developed countries (34).  
Most scoring systems require expensive laboratory tests; however, recent advances 
include the development of models that used simple office-based predictors easily 
obtained in primary care and did not require laboratory testing. BMI replaced TC and 
HDL-C in these models. The unchanged variables included age, systolic BP, 
antihypertensive medication use, current smoking and diabetes status (337). This is 
highly relevant in the developing world with its increasing burden of CVD and the 
need for cost-effective use of limited resources. The use of non-laboratory-based 
total CVD risk assessment has the potential to improve worldwide utility of the risk 
scores and enhance targeted CVD prevention efforts, particularly in low-resource 
settings where widespread laboratory availability is problematic (30, 34). 
1.4.4. LIMITATIONS 
Despite the utility of the risk assessment tools, all total cardiovascular risk models 
have limitations and these need to be noted (168, 329). These models do not 
incorporate all CVD risk factors, particularly physical activity and stress. They also do 
not consider the duration of exposure to a risk factor nor do they include relevant 
family history (168, 340).  
One of the most relevant criticisms is that the risk estimation models strongly favour 
treatment of elderly versus young individuals on account of age being a powerful 
















younger individuals treatment decisions would be better guided by quantification of 
the relative risk, i.e. the increase in risk in relation to average risk in the population 
(168). The absence of adequate treatment in younger individuals may lead to the 
earlier development of organ damage or to partly irreversible high risk conditions in 
later years.  
In women, while high scores identify those at high risk, lower scores do not 
sufficiently ensure that individual women are at low risk. It is difficult for women <75 
years, even with several markedly elevated risk factors, to be classified as high risk. 
For cardiovascular risk management in women, factors beyond the risk scores 
including medical and lifestyle history, family history of CVD, markers of preclinical 
disease, and other conditions need to be considered when determining the intensity 
of preventive therapy. Recommendations also include a lower cut-point for defining 
high risk in women as ≥10% 10-year risk for all CVD compared to the traditionally 
≥20% 10-year risk estimate utilised (340).  
The international applicability of these guidelines is a critical issue, because these 
risk assessment tools are applicable primarily to populations of European origin in 
developed regions. Additionally, important differences prevail in the incidence of 
coronary and stroke events between developed and developing regions. Therefore, 
further assessments are necessary to determine the optimal methods for identifying 
high-risk individuals in developing regions, where 80% of the global CVD burden 
occurs (34). The development of accurate ethnic- and region-specific risk tools for 
developing regions thus need to be prioritised (36). 
1.4.5. CONCLUSION 
The strategy for CVD prevention now advocates multivariable assessment rather 
than management of individual risk factors with the adoption of a total cardiovascular 
risk approach as the strategy to inform decisions for initiating drug treatment (37). 
Appropriate action according to the level of risk must guide treatment (337, 341). The 
weaknesses of the CVD risk prediction models should not defer the control of the 
major risk factors through this cost-effective approach (10, 339). Total CVD risk 
assessment is likely to remain an important therapeutic component for individuals 

















1.5. OVERVIEW OF CARDIOVASCULAR DISEASE IN SUB-SAHARAN 
AFRICA 
Countries in Africa are among the poorest in the world with per capita GDP as low as 
US$200 (343). Expenditure by governments on health is low with most spending 
<2% on healthcare services (343) or about US$10 per person annually (54). The 
limited resources available are allocated to combat communicable diseases such as 
HIV/AIDS, TB and malaria which have an impact on economic development that are 
much more noticeable than NCDs (343). Consequently, PHC services often lack the 
most basic equipment to manage NCDs, such as a calibrated and functioning 
sphygmomanometer or a glucometer (37). 
Although SSA is the only world region where infectious diseases (798 per 100 000) 
outnumber NCDs (779 000 per 100 000) as the predominant cause of mortality in 
2008 according to the WHO (17), it is a misperception that they are not important 
contributors to the burden of disease in the region (344). The proportion of deaths 
attributable to NCDs is below that of developed nations because of the very high 
mortality from infectious diseases (17, 345). SSA has the unenviable challenge of 
dealing with a double burden of disease: rapidly rising CVDs and other NCDs which 
occur alongside continuing high rates of infectious diseases in SSA (7, 344, 346, 
347). In 2008, the age-standardised mortality among 30-70-year-old adults for CVD 
and diabetes was 382 per 100 000 in Africa, the highest in the world and more than 
double that of the lowest WHO region (Region of the Americas: 169 per 100 000) 
(17). Even though HIV/AIDS is the main overall cause of death in this region, CVD is 
the second-leading contributor and the major cause in those >30 years old (14). 
Furthermore, CVD is anticipated to soon overtake communicable and poverty-related 
diseases as the predominant cause of morbidity and mortality in the region (348) and 
the greatest proportionate increase in NCDs over the next 10 years globally is 
predicted to occur in Africa (81).  
Along with the poor nations of Asia and Latin America, Africa bears a significant 
proportion of the global burden of CVD and other NCDs (344). The WHO has 
projected that the largest increase in mortality rates (27%) from CVD and other NCDs 
will be in Africa with 28 million deaths over the next 10 years. Most markedly, 
mortality from diabetes is projected to increase by 42% (32). Although these figures 
highlight the impending dire consequences of NCDs, these are highly avoidable. The 
WHO emphasises that if measures were introduced to curb the CVD and other NCD 
epidemic with the aim of a 2% reduction in NCD mortality over and above the current 
















million of these averted in individuals younger than 70 years old (32). However, 
without concerted measures this is unlikely to happen; the high burden of disease in 
SSA is compounded by the weakest health systems and workforces as well as the 
lowest per capita income globally (7, 58, 349, 350). 
Similar to other developing regions of the world, SSA’s NCD burden is attributable to 
numerous factors including increasing life expectancy, changing lifestyle behaviours, 
poverty, urbanisation and globalisation (7, 32, 348, 351). SSA, in particular, is 
currently experiencing one of the most rapid increases in urbanisation and changes 
in lifestyle behaviours (348). With the urban population in SSA currently growing at 
an average annual rate of 4.5% (346, 352), CVD and its risk factors have the 
potential to rise exponentially. Exacerbating the CVD and other NCD burden is a lack 
of comprehensive government programmes for the prevention of these conditions (7, 
344, 348).  
Regarding the prevalence of the individual CVD risk factors in SSA countries, these 
will be discussed in detail in Chapter Four. Suffice to say, the rates of these risk 
factors are on the rise as reported in several SSA countries including Tanzania 
(diabetes, hypertension, obesity and hypercholesterolaemia) (345, 351, 353, 354), 
Cameroon (diabetes, hypertension, obesity and physical inactivity) (351, 355), 
Nigeria (diabetes and hypertension) (356), and South Africa (diabetes and 
hypertension) (345). Furthermore, many CVD risk factors are highly prevalent in SSA 
(351) as demonstrated in recent reports from Kenya (357), Tanzania (358), Nigeria 
(356, 359) and South Africa (351, 360, 361).  
There is considerable variance in the prevalence of the CVD risk factors among 
countries in SSA as well as by urban-rural location and sub-populations which is 
likely a reflection of the varying rapidity at which communities are undergoing 
transition. For example, population-based studies demonstrate a wide range in the 
prevalence of obesity in SSA from 0.4% reported in rural Tanzania to 34% in black 
South African women (351). The evidence indicates that overweight/obesity is rising 
in Africa especially among women with increases in the intake of fat and sugar as 
well as sedentary lifestyles linked to the development of the epidemic (7, 240). 
Processed foods have become easily available in SSA as a result of foreign direct 
investment from transnational food companies. In addition to weight gain, the 
adoption of physically inactive lifestyles in SSA is high (362) and increasing, and can 
be ascribed to rapid urbanisation and socio-economic transitions (240, 363). The 
estimated doubling of the urban population in SSA to 487 million by 2020 (352) is 
















Besides the impact of an obesogenic environment, a complex set of cultural, 
psychosocial and biological factors influence the maintenance of a healthy weight 
(197, 210, 364). Particularly in SSA, where access to food remains a daily challenge, 
overweight/obesity is perceived as a sign of affluence and good living, and is a 
deeply rooted status symbol conferring respect and influence (221, 243, 248). 
Another important influence on the positive attitude to overweight/obesity is the 
association of thinness with HIV/AIDS, with overweight/obesity perceived as an 
absence of the disease and with being healthy (205, 221) 
Although tobacco use is lower in SSA compared to other world regions (153, 156) 
with a prevalence in men of ≤10% in countries like Ethiopia, Nigeria and DRC (38), 
tobacco-related conditions are emerging as an increasingly important public health 
problem in the region (7). Among developing nations, the greatest rise in the rate of 
tobacco use is occurring in Africa (7); the prevalence has increased by over 40% 
over the last few decades (365). However, the prevalence of smoking varies across 
countries; population-based studies in SSA reported rates in the last decade ranging 
from 3% and 6% in urban Ghanaian men and women, respectively, to 57% in South 
Africa (351). The rising tobacco use can be attributed to urbanisation, acculturation 
and globalisation together with aggressive marketing by tobacco conglomerates (7, 
153, 365). 
These influences are also likely to have a similar impact on the lower rates of alcohol 
consumption in SSA. Currently, the prevalence of non-drinkers is higher in SSA 
compared to Europe (men: 32% vs. 8%, women: 45% vs. 14%, respectively). 
Nevertheless, 19% of SSA men could be classified as binge drinkers (366). Some 
CVD risk factors display gender disparities in SSA with smoking (344, 351, 354, 367) 
and alcohol consumption (351, 354, 367) much more common in men than women 
while the opposite holds true for overweight/obesity (344, 347-349, 351, 354, 356, 
362, 367, 368), and lower activity levels (354, 362). 
Diabetes, once rare in SSA, is now responsible for a considerable amount of 
morbidity, mainly attributable to micro-vascular complications, and mortality, primarily 
due to infection and acute metabolic complications, in the region (240, 243, 248, 250, 
352, 369, 370). Even in this region with the lowest diabetes prevalence (253), and 
one of the lowest mean fasting glucose levels in 2008 (241), diabetes was not only 
no longer rare but had risen markedly over the last few decades. The IDF Diabetes 
Atlas reported that in 2011, the diabetes and IGT rates in SSA were 4.5% and 9.7%, 
respectively, and expected to rise to 4.9% and 10.7%, respectively, by 2030 (253). Of 
















years old and over a quarter were between 20 and 39 years old. Considering that 
diabetes affects mainly the economically active population in SSA, it is disconcerting 
that the region has the highest proportion of undiagnosed diabetes worldwide; 78% 
compared to the global prevalence of 50% (253), which is nonetheless also 
unacceptably high. The number of individuals with diabetes in SSA is projected to 
increase by 90% from 14.7 million in 2011 to 28.0 million in 2030; markedly higher 
than the 51% rise predicted globally. This highlights the rapid epidemiologic transition 
occurring in SSA with diabetes emerging as a significant NCD in the region (243, 
371). Factors underwriting the rise in diabetes here include a change in demography 
with an ageing population, urbanisation, and the increasing prevalence of obesity and 
physical inactivity (249-251, 369, 372). 
Although historically, African populations have tended to have relatively favourable 
lipid profiles, with lower TC, higher HDL-C and lower triglyceride levels (54, 344, 365, 
366), the data available indicate that dyslipidaemia is no longer rare and is emerging 
as an important CVD risk factor in SSA (347, 348, 356). Recently, for example MI, 
the main consequence of dyslipidaemia, was found to be the leading cause of CVD 
mortality in Kenya, contributing nearly 20% of the 134 autopsy cases of 
cardiovascular related deaths examined (373). These findings were in contrast to 
previous reports from SSA, including Kenya, where IHD was once considered to be 
rare (365, 373, 374).  
Despite the high burden imposed by HIV/AIDS, TB and malaria (375), hypertension 
has emerged as a significant medical and public health problem in SSA (348, 366). In 
contrast to the other CVD risk factors, the highest prevalence of hypertension 
globally was in SSA (46%) (156); a far cry from the early 20th century when 
hypertension was rare in the region (54, 365). Furthermore, unlike high-income 
countries where mean BP has decreased over the last three decades, in Africa this 
has remained stable or increased in most countries (17) with hypertension emerging 
as the most prevalent CVD risk factor in the latter half of the 20th century (365). 
Hypertension constitutes the foundation for the CVD epidemic in the region (298, 
306, 376) and is regarded as one of the continent’s greatest health challenges after 
HIV/AIDS (377). Remains the primary cause of significant financial burden, which 
includes the cost of caring for stroke, IHD and congestive cardiac failure related to 
hypertensive heart disease and systolic dysfunction (45). Notably, mortality 
attributable to hypertension in under 60-year-old individuals was 25% in SSA 
compared to only 7% in high-income countries (85). Notwithstanding, the high and 
















mortality, hypertension awareness, treatment, and control are unacceptably low in 
the region (300, 378).  
Worryingly, two of the most common infectious diseases seen in Africa, TB and 
HIV/AIDS, not only co-exist but interact with CVDs, with the one exacerbating the 
other (344, 346, 352, 375). Diabetes increases the risk of developing TB three-fold 
(352, 375) and it seems that TB may predispose to diabetes (352). The co-morbid 
presentation of diabetes and TB is associated with poorer outcomes (344, 352). 
Antiretroviral therapy (ART) for HIV/AIDS is associated with an increased risk of 
diabetes and the MS (350, 375) as well as worsening lipid profiles (344, 346, 352, 
375). HIV has also been linked with an increased risk of developing CVD (352).  
The progress made in combating infectious disease is being undermined by CVD 
and other NCDs (379). Therefore, despite the challenges faced by healthcare 
systems in SSA it is imperative that NCDs be prioritised with greater attention given 
to primary prevention of these conditions. If left unattended, CVDs and their risk 
factors will impose an increasingly significant socio-economic burden including a 
decreased quality and length of life across the continent; the price of inaction will be 
devastating (7).  
1.6. OVERVIEW OF CARDIOVASCULAR DISEASE IN SOUTH AFRICA  
According to Census 2011, the Republic of South Africa, a country occupying the 
southernmost tip of Africa, has a population of almost 52 million, most of whom are 
black Africans (79%) (380). This country is in the midst of a health transition 
characterised by a high burden communicable diseases, in particular HIV/AIDS and 
TB, rising NCDs including CVDs, a heavy burden of perinatal and maternal disorders, 
and injury and violence (381, 382). Consequently, until recently, inadequate attention 
had been paid to the rising burden of NCDs despite the high mortality attributable to 
these conditions: 40% in women and 36% in men (381). CVD and the related risk 
factors are highly prevalent and significant contributors to morbidity and mortality in 
the general South African population. At 16.6%, CVD was the second leading cause 
of death after HIV/AIDS with ischaemic heart disease, stroke, hypertensive heart 
disease and diabetes among the principal ten causes of death in 2000 (381). In 
addition, the years of life lost for CVD and other NCDs (25%) approached that for 
infectious diseases (28%) (25). 
The high prevalence of many CVD risk factors in the country were reported in the 
South African Demographic and Health Surveys (SADHS) conducted in 1998 and 
















consumption (men: 21%, women: 7%), physical inactivity (men: 48%, women: 63%), 
overweight/obesity (men: 29-30%, women: 55-56%) and hypertension (men: 23%, 
women: 25%) in ≥15-year-old South Africans (360, 361).  
Diabetes and dyslipidaemia were not ascertained in these national studies, but 
smaller regional epidemiological studies conducted approximately 15-20 years ago 
reported moderate prevalence of diabetes (383-385) and favourable lipid profiles in 
black populations (385-387). The most recent diabetes prevalence data for the black 
population in Cape Town, obtained in 1990 using the 1985 WHO criteria, reported a 
crude prevalence of 6.3% (age-standardised prevalence 8.0%) in >30-year-old men 
and women (383); higher than that found in other SSA countries and in black 
populations from other urban (5.3-6.0%) and rural (3.9-4.8%) centres in South Africa 
(384, 385, 388). The national prevalence of hypercholesterolaemia (TC >5 mmol/l) in 
≥30-year-old black African men and women, estimated from a few regional studies, 
was 19.7% and 29.2%, respectively (389). Further details on the prevalence of CVD 
risk factors, as pertaining to this thesis, will be discussed in detail in Chapter Four. 
The patterns and trends described above strongly suggest that the CVD risk profile 
may be deteriorating in South Africa and that the black population, in particular, 
because of rapid urbanisation, might be experiencing these trends most forcefully. 
This highlights the need for current CVD risk factor studies in the black South African 
population to identify the trends and patterns that need to be addressed in effective 






































CHAPTER TWO: STUDY RATIONALE, AIMS, HYPOTHESES 
AND OBJECTIVES 
2.1. STUDY RATIONALE 
In order to appropriately allocate resources and develop cost-effective therapeutic 
strategies and programmes, the prevalence, distribution and trends of CVD risk 
factors need to be established. However, in South Africa, there is a dearth of recent 
national and regional surveillance data; for example, the prevalence of diabetes, 
dyslipidaemia, hypertension and other CVD risk factors have not been ascertained in 
approximately 1-2 decades in the urban black population of Cape Town. Using these 
historical prevalence data for current and future health service planning can result in 
inappropriate resource allocation for CVD management and a lack of understanding 
of the size of the problem in South Africa if the risk factor prevalence has changed. 
The suggestions that the prevalence of CVD risk factors are rising in SSA as 
described in Chapter One, the high rates of obesity, physical inactivity and 
urbanisation, and the changes in demography with ageing populations in South 
Africa (250, 390), provide reasonable evidence that the prevalence of CVD risk 
factors have also increased in the local urban black population.  
Data on the potential increased prevalence of CVD risk factors would have important 
implications for the provision of healthcare and for strategies to control the rising risk 
factors levels (245). Such data would be fundamental to highlight the problem and 
advocate for action (382); more resources may be allocated for CVD management as 
well as efforts to promote screening and prevention may be stimulated. This 
information, unique to the population being targeted, would assist in appropriate 
health service planning and be invaluable for the implementation of effective, 
population-specific, and gender- and age-orientated CVD risk prevention and 
management programmes. 
Additionally, to target all potentially modifiable determinants of CVD risk factors, it is 
important to identify all these factors. One of the potentially modifiable risk factors 
includes psychosocial stress, which has been shown to be related to CVD and some 
of its risk factors (90, 92, 93). Notably, however, there is variance in the association 
of psychosocial stress with diabetes (115, 116, 118, 119) and hypertension (126, 
127). There is thus a need to clearly identify whether a relationship exists between 
psychosocial stress and either diabetes or hypertension. Equally important, is to 
determine screening tools that can identify individuals with psychosocial stress who 

















To determine the prevalence of CVD risk factors in 2008/09, the changes in these 
between 1990 and 2008/09, and the association between psychosocial stress and 
the other CVD risk factors in a random sample of the 25-74-year-old urban black 
population of Cape Town.   
2.3. HYPOTHESES 
1. The prevalence of diabetes, hypertension and other CVD risk factors has 
increased in the urban black population of Cape Town between 1990 and 
2008/09.  
2. There is an association between the presence of psychosocial stress and having 
diabetes and/or hypertension. 
2.4. OBJECTIVES 
The objectives of the study were to determine: 
1. The prevalence of diabetes by means of a standardised oral glucose tolerance 
test (OGTT) and to assess the association with potential predisposing factors.  
2. The prevalence of dyslipidaemia by means of standard biochemical procedures 
measuring TC, HDL-C and triglycerides, and calculating LDL-C levels in fasting 
serum samples, and to assess the association with potential predisposing factors. 
3. The prevalence of hypertension by measuring the BP electronically using 
standardised methodology and to assess the association with potential 
predisposing factors.  
4. The anthropometric profile by measuring height, weight, waist and hip 
circumference and calculation of the BMI, raised WC and raised WHR and to 
assess the associations with potential predisposing and socio-demographic 
factors.  
5. The prevalence of smoking, problematic alcohol use, degree of urbanisation, 
physical inactivity and high fat intake using standardised questionnaires. 
6. The association between the presence of psychosocial stress and diabetes and 
hypertension using three validated measurements: SOC, LOC and life events 
questionnaires. 
















8. The prevalence of the MS by the harmonised JIS criteria and to assess the 
association with the socio-demographic factors. 
9. The total cardiovascular risk by the Framingham risk equations using laboratory 
based lipid measurements of TC and HDL-C, as well as non-laboratory based 
measures of BMI replacing TC and HDL-C and to assess the associations with the 
socio-demographic factors.  
10. And compare the CVD risk factor patterns found in 2008/09 with those found in 





































CHAPTER THREE: METHODOLOGY 
3.1. STUDY DESIGN AND SAMPLING PROCEDURE  
The city of Cape Town, located on the southwest tip of South Africa, has a population 
of about 3.3 million inhabitants. During apartheid, people were forced to reside in 
racially segregated areas with black Africans earmarked to live in townships on the 
outer limits of the city. These include, among other places, Langa, the oldest 
township in the country, and Khayelitsha, a large sprawling township which has 
drawn residents from the former homelands that were created during apartheid (391).  
People living in these two townships, together with the residents of Guguletu, 
Crossroads and Nyanga, over 90% of whom are black Africans, comprised the 
current study population. These areas were selected for ease of comparison with 
previous cross-sectional studies (383, 392).  
A random sample of 25-74-year-old men and women was obtained for this cross-
sectional study. Based on the 2001 census, the sample size in each area was 
proportionate to its population density. On account of its rapid expansion, Khayelitsha 
comprised 60% of the current study sample compared to the 1990 study on which 
the sampling methodology was based and where it formed 30% of the sample size. A 
sample size of 1260 was based on an estimated diabetes prevalence of 8% with a 
two-side 95% confidence interval (CI) extending 0.015 from the observed prevalence. 
Using aerial maps from 2007, a 3-stage cluster sampling stratified by area and 
housing type was undertaken to select the sample. Each map was divided into a 
number of sectors (Figure 3.1) and the houses, hostels and flats, and informal 
dwellings within each sector were demarcated into blocks (Figure 3.2 and Appendix 
A). The blocks were numbered and then selected using simple random sampling. 
Units were thereafter systematically selected within these blocks (Figure 3.3 and 
Appendix B) with the sampling proportionate to the estimated number of people living 


















































Figure 3.3: Illustration of block 2 with the units selected 
 
If more than one dwelling/structure was found at the selected address for the houses, 
these were drawn on the back of the household form by the fieldworker and 
numbered from the bottom left hand corner in a clockwise fashion (Figure 3.4). Using 
random tables, a number was selected and the dwelling corresponding to that 




























Figure 3.4: Illustration of multiple dwelling structures at a selected address 
Specific flat and hostel units were selected by fieldworkers on site using random 
tables. For a multi-storeyed building, each level was assigned a number and selected 
using random tables. Thereafter, the units on the selected level were assigned 
numbers and again selected using random tables.   
Blocks of informal dwellings were selected using simple random sampling, as done 
for the houses and buildings. Thereafter, the fieldworkers randomly selected the 
required number of units in each selected block of informal dwellings ensuring that 
units close to the centre as well as the periphery of the arbitrarily demarcated blocks 
were included.   
If more than one household was living in a dwelling, the fieldworker assigned a 
number to each household. Thereafter, random tables were used to select a number 
and the household corresponding to that number was approached. A household was 
defined as a group of people who cooked and ate together as well as slept under the 
same roof. 
3.2. SELECTION OF PARTICIPANTS 
Individuals from households were selected on a quota for age and gender 
categorisation; the rationale being that the risk factors and disease prevalence 
differed among age groups and by gender. There were a minimum of 100 
participants in each of the 10 strata, stratified for age (25-34, 35-44, 45-54, 55-64 and 
65-74) and sex (men and women). Sampling across the age groups was 
disproportionate to ensure that at least 50 men and women, aged 65-74 years, were 
included in the oldest age groups within each area. 
The quota corresponded with the required sample from each township. The quota list 
for Langa is used to explain the process in detail (Table 3.1).  
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Table 3.1: Quota list for Langa 
 
 
Houses Houses Houses Hostels Hostels Shacks 
Age Strata 1 Strata 2 Strata 3 Strata 4 Strata 5 Strata 6 
 M F M F M F M F M F M F 
25-34 5 5 10 10 10 10 7 7 17 18 24 25 
35-54 4 4 8 8 8 8 6 7 14 15 21 22 
55-64 2 2 3 3 3 3 2 2 5 5 7 7 
65-75 1 1 3 3 3 3 2 2 5 5 7 7 
Total 12 12 24 24 24 24 17 18 41 43 59 61 
Block x 
Units 



































The Langa map was divided into three sectors, namely, A, B and C and strata 1, 2 
and 3 corresponded to the houses in sectors A, B and C, respectively. The hostels in 
sector A were labelled strata 4 and those in sectors B and C combined were labelled 
strata 5. Informal dwellings or shacks were only found in sectors A and B and these 
were combined into strata 6. 
The rows and columns illustrated the quotas required by age and gender from the 
housing type within each s ctor. For example, from strata 1, a total of 12 men and 12 
women were required with the numbers per age category shown in the table. These 
24 men and women were drawn from the six blocks listed in Table 3.1 which each 
had four units systematically selected on the map. 
Exclusions included those who were unable to give consent, on TB treatment, on 
ART, cancer patients having received treatment within the last year, bedridden, 
pregnant or lactating, or resident in Cape Town for less than 3 months. 
Replacements were allowed when confronted with individuals who met the exclusion 
criteria above, those who refused, or the randomly selected participant of the 
randomly selected household could not be contacted on the third attempt. 
Replacements were initially selected from the same household; failing that, the 
fieldworker approached the household immediately to the left for a replacement 
















The fieldworker recorded the details (name, sex, age, date of birth) of all household 
members on the household form (Appendix C) and selected an appropriate 
participant according to the quota sheet. If more than one person was eligible to 
participate, the person whose birthday was closest to the current date was selected. 
One person per household was selected except if there was an eligible older person 
aged 65-74 years who filled the quota requirement; two individuals were then 
selected from that household to enable the inclusion of older people, proportionately 
fewer of whom lived in these townships.  
The selected individual was screened (Appendix D) and an appointment date given if 
s/he agreed to participate. The participant was asked to fast overnight for at least 10 
hours, not to eat breakfast on the morning of their appointment and to carry his/her 
prescribed chronic medication. Together with a verbal explanation, the potential 
participant received a detailed information sheet describing the study and the 
overnight fasting procedure, and an appointment slip.  
3.3. DATA COLLECTION  
On the day of the examination, participants were collected from their homes by the 
study driver and brought to a central venue for the data collection. On arrival at the 
examination venue, fasting blood specimens were drawn followed by the 
administration of the OGTT, the study questionnaire (Appendix E) and clinical 
assessments, with the 2-hour blood sample drawn at the requisite time. Once the 
interviews were completed, participants were fed a meal and returned to their homes.   
The data collection was done by administered questionnaires, clinical measurements 
and biochemical assessments. The interviewer-administered questionnaires had 
been translated into Xhosa, the primary language of the participants, and back 
translated into English. The trained interviewers entered the data on standardised 
pre-coded forms which, to maximise quality control, were checked regularly for 
completeness, accuracy and consistency and referred back to the interviewers if 
required.  
The questionnaire included socio-demographic and migratory information, self-
reported medical and family history, physical activity patterns (GPAQ) (393), 
psychosocial stress, tobacco (WHO STEP-wise surveillance questionnaire) (394) and 
alcohol use. Problematic alcohol use was assessed using the CAGE set of four 
questions (186). Self-reported food intake during the preceding 24 hours was 
determined by a single 24-hour dietary recall using semi-structured interviews. 
















than income in developing countries (395), and included ownership of consumer 
items (durable goods), and the source of drinking water and toilet facilities. 
Psychosocial stress was examined using the three validated psychosocial measures 
of SOC, LOC and the Brugha life events questionnaire. Anatovsky’s SOC comprised 
13 items measuring comprehensibility (cognitive), manageability 
(instrumental/behavioural) and meaningfulness (motivational) (136, 137, 140). A low 
SOC score inferred a poor ability to cope with stressors and was deemed as high 
psychosocial stress. The LOC consisted of six questions and a low score was 
construed as poor perceived control and considered a measure of high psychosocial 
stress (90). The Brugha Life Events questionnaire contained 12 questions related to 
negative life events such as illness, death, financial or marital difficulties, among 
other problems and their impact (148). A higher score was indicative of a greater 
number of adverse events experienced with higher scores for impact representing a 
more profound impact. 
Three BP measurements were taken by trained nurses at two-minute intervals using 
an Omron M6 Comfort BP monitor with an appropriately sized cuff after the 
participant had been seated for five minutes. The average of the second and third BP 
measurements was used in the analysis.  
Height, weight, and waist and hip circumferences were measured. With the 
participant standing barefoot and in light clothing, measurements taken included 
weight to the nearest 0.1 kg using a calibrated scale (Adam CPW Plus 200) and 
height to the nearest 0.1 cm using a measuring tape fixed to the wall. Measured to 
the nearest 0.1 cm after normal expiration, the waist measurement was taken as the 
smallest circumference between the xiphi sternum and the umbilicus on expiration 
while standing. Hip measurements were taken to the nearest 0.1 cm at the maximum 
posterior protuberance of the buttocks (396). 
Blood samples, for glucose and lipid estimations, were drawn following an overnight 
fast of 10 hours. Thereafter, a standard OGTT, using 75 grams of anhydrous glucose 
in 250 ml of water, was administered, and blood samples taken 120 minutes later (for 
glucose estimation) (239). Blood samples were kept on ice and transported to the 
laboratory within six hours to be centrifuged, aliquoted and stored at -80° until the 
assays were performed. These were analysed at the internal laboratory of the 
Department of Endocrinology at Groot Schuur Hospital using the ACE Alera Clinical 
Chemistry System, Alfa Wassermann Diagnostic Technologies, Woerden, 


















BMI was calculated as the participant’s weight in kilograms divided by their height in 
metres squared (kg/m²). Underweight (<18.5), normal weight (18.5-24.9), overweight 
(25-29.9) and obesity (≥30) were defined using standardised international criteria. 
Raised WC was defined as >94 cm in men and >80 cm and in women, and raised 
WHR as >1.0 in men and >0.85 in women (397).  
Dysglycaemia:  
Diabetes, IGT and IFG were diagnosed according to the 1998 WHO definition. 
Diabetes was defined as fasting plasma glucose ≥ 7.0 mmol/l, 2-hour post glucose 
load ≥ 11.1 mmol/l or participants with known diabetes. IGT was defined as 2-hour 
post glucose load plasma glucose between 7.8-11.1 mmol/l, provided that fasting 
glucose was <7.0 mmol/l. IFG was diagnosed when fasting plasma glucose was 
between 6.1-7.0 mmol/l and the 2-hour glucose was <7.8 mmol/l (239).  
In addition, the 1985 WHO criteria (398) were used to compare the prevalence of 
diabetes in this study with that conducted in 1990 because the raw glucose/diabetes 
data for the initial study were unavailable for comparison. Diabetes by the 1985 
criteria was defined as fasting plasma glucose ≥7.8 mmol/l, 2-hour post glucose load 
≥11.1 mmol/l or participants with known diabetes. Fasting glucose <7.8 mmol/l with 
2-hour glucose between 7.8-11.1 mmol/l defined IGT. 
Dyslipidaemia: 
Dyslipidaemia was defined as follows (265): TC >5.0 mmol/l, triglycerides >1.5 
mmol/l, HDL-C <1.2 mmol/l, HDL-C/TC ratio <20% and calculated LDL-C >3.0 mmol/l 
using the Friedewald equation (399). 
Hypertension:  
Hypertension was defined as BP ≥140/90 mmHg or using antihypertensive 
medication (168, 400).  
Metabolic syndrome:  
MS was defined using the JIS criteria that required any three of five factors to be 
present: central obesity (raised WC: men ≥94 cm, women ≥80 cm), 
hypertriglyceridaemia (raised triglycerides ≥1.7 mmol/l), low HDL-C (men <1.0 
mmol/l, women <1.3 mmol/l), raised BP ≥130/85 mmHg, and raised fasting glucose 



















Alcohol use:  
Problematic alcohol use was deemed present if two or more CAGE questions were 
answered affirmatively (186). 
Tobacco use: 
Smoking status was defined as currently smoking ≥1 cigarette a day or as smoking 
daily/occasionally. 
Physical inactivity: 
Physical inactivity was defined as <150 minutes of moderate to vigorous activity per 
week (198, 393). 
High fat intake: 
High fat intake was defined when >30% of total dietary intake was contributed by fat 
(8).  
Table 3.2: Anatomical Therapeutic Chemical Classification (ATC) codes for 
CVD and associated risk factors 
Conditions and medications ATC codes 
Diabetes  A10 
Insulin A10A 
Biguanides A10BA 
Sulphonamides, urea derivatives A10BB 
Hypertension C02, C03, C07, C08, C09 
Diuretics (alone and in combination)  
C03A, C03B, C03C, C03D, C03E, 
C02AA52, C02AA53, C09BA, C07B, 
C07C, C07D 
Antiadrenergic agents- centrally acting  C02A 
Reserpine-containing agents  C02AA02, C02AA52 
Methyldopa  C02AB01 
Antiadrenergic agents – peripherally acting  C02C 
Arteriolar smooth muscle agents  C02D 
ACE Inhibitors  C09 
Beta-blocking agents  C07A, C07B, C07C, C07D 
Calcium-channel blockers  C08 
Hyperlipidemia  C10A 
Drugs for other atherosclerosis-related 
conditions  



















In lieu of the absence of an internationally agreed definition on what constitutes an 
urban environment (401), the proportion of life spent in the city, used in previous 
studies, defined the degree of urbanisation (391). Length of urban residence was 
recorded by summing the duration lived in a city, from birth until the date of data 
collection.  
Total cardiovascular disease risk assessment:   
The absolute risk of having a cardiovascular event, defined as IHD, stroke, transient 
ischaemic attack or heart failure, within 10 years was calculated using the 
Framingham equations (337). A score ≥20% was considered high risk and between 
10-19.99% was defined as moderate risk. 
Anatomical Therapeutic Chemical Classification for medicines: 
Participants’ medications for CVD and risk factors including diabetes, hypertension 
and hyperlipidaemia were coded according to the Anatomical Therapeutic Chemical 
Classification (ATC) categories as indicated in Table 3.2 (402).  
3.5. DATA ANALYSIS AND STATISTICAL INTERPRETATION 
Data were analysed using STATA, version 11.0 (403) and SAS software version 9.3 
(404). Descriptive statistics were calculated using the weights based on the sample 
design with the crude prevalence data adjusted for the realised sample. The SEGI 
World Population was used to calculate the age-standardised prevalence (405). The 
dietary data were analysed using the Medical Research Council (MRC) Food 
Composition Tables (406) and the MRC dietary analyses software Foodfinder. Only 
high fat intake as a proportion of total energy intake was examined in this thesis 
because the nutrition data form part of a master’s thesis. For the assets, a principal 
component analysis of the pooled data was used to develop an asset index and 
wealth tertiles (407).  
The 10-year risk of developing CVD was calculated using the laboratory and non-
laboratory based Framingham equations (337), and have been recommended in the 
South African lipid guidelines (322). The equations are gender-specific and include 
the variables of age, diabetes status, smoking status, treated and untreated systolic 
BP, TC and HDL-C levels for the laboratory-based equations. BMI replaced lipids in 
the non-laboratory-based equations (337).  
Laboratory-based equations: The 10-year CVD risk for women was calculated as ‘1-
0.95012exp(ΣßX - 26.1931)’ where ß is the regression coefficient and X is the level for each 
















Non-laboratory-based equations: The 10-year CVD risk for was calculated as 1-
0.94833exp(ΣßX - 26.0145) where ß is the regression coefficient and X is the level for each 
risk factor; the risk for men was calculated as 1-0.88431exp(ΣßX - 23.9388) (337). 
Univariate analyses (socio-demographic and cardiovascular risk characteristics) are 
presented as mean values for the continuous data and as percentages for the 
categorical data with standard errors by age category and with 95% CI for the total 
values. 
A direct comparison of the 2008/09 and 1990 datasets could not be conducted 
because of the geographic and demographic changes that occurred in Khayelitsha 
during this period; the population increased markedly with a concomitant expansion 
in area size. This necessitated the use of 95% CI for the comparison of the means 
and prevalence of the CVD risk factors between the two surveys.   
The CVD risk factors that were not compared between the two studies included 
problem drinking, physical activity and triglycerides. The different instruments used in 
2008/09 and 1990 to ascertain problem drinking and physical activity, the CAGE 
questions and GPAQ, respectively, used to assess these risk factors in 2008/09 but 
not 1990 precluded any comparisons of these measures. The blood samples 
obtained in the 1990 study were random and not fasting as drawn in 2008/09. Seeing 
that fasting blood samples are required to accurately measure triglyceride levels, 
these were not compared between the studies but triglyceride values <4.5 mmol/l 
were used to calculate LDL-C levels for the 1990 study.  
Survey multiple logistic regression analyses were used to determine the independent 
associations of the CVD risk factors as well as the MS and high total CVD risk. 
Variables included in all the models were age, sex, urbanisation and psychosocial 
factors, except for the high total CVD risk models where age and gender were 
omitted. Socio-demographic variables such as level of education, employment status, 
type of dwelling and wealth status (defined by asset index) were entered into the 
models for smoking, problem drinking, physical inactivity, high fat intake, adiposity, 
the MS and high total CVD risk. Potential predisposing risk factors for diabetes, 
hypertension and raised LDL-C were entered into these respective models. These 
included measures of adiposity, physical inactivity and high fat intake. A positive 
family history of diabetes or hypertension was also entered into the respective 
models.  
The model for diabetes, for example, was adjusted for a set of modifiable (physical 
















history, age, sex and urbanisation) risk factors for diabetes as well as a 
socioeconomic confounder, housing type. Gender-specific models were done 
because of substantial differences in associations. To fully account for the known risk 
factors in the survey models, the non-linearity of their associations were investigated 
by means of generalised additive models (gam). To reflect the observed non-
linearity, quadratic terms were added in the survey model for BMI and urbanisation in 
women. The waist and hip measurements, as well as their ratio, were highly 
correlated with BMI (r>0.85). Hence, only BMI was retained in the models to avoid 
multicollinearity. The three psychosocial measures were modelled independently as 
continuous variables. SOC demonstrated a non-linear association with diabetes in 
women (significant cubic term) and cut-points were selected to mimic this pattern to 
enable statistical interpretation. Gender-specific cut-points were used for SOC and 
are indicated in the text and table. 
For the models with hypertension, variable cut-points for age, physical activity and 
urbanisation were selected based on the smoothed values shown in the fractional 
polynomials. The three psychosocial measures were modelled independently as 
continuous variables. A positive history of current smoking and problem drinking was 
included in all three models.  
All the models are presented with the psychosocial measure of SOC in the tables. 
When LOC or adverse life events independently replaced SOC in the respective 
models the changes in the direction or significance of the other variables are noted in 
the table footnotes and the text.  
3.6. ETHICAL CONSIDERATIONS  
The University of Cape Town’s Research and Ethics Committee approved the study. 
A detailed explanation of the study procedure in Xhosa, the primary language of the 
study participants, was followed by written informed consent from each participant in 
the study and confidentiality was ensured (Appendix F). Participants were given their 
results with a referral letter to the appropriate health services if clinically relevant 
















CHAPTER FOUR: RESULTS AND DISCUSSION 
4.1. POPULATION CHARACTERISTICS  
4.1.1. SAMPLE REALISATION  
In this cross-sectional study among 25-74-year-old adults residing in the 
predominantly black townships of Langa, Guguletu, Crossroads, Nyanga and 
Khayelitsha in Cape Town, there were 1116 participants of whom 17 did not meet the 
inclusion criteria. The realised study sample of 1099 comprised 392 men and 707 
women (63.5% and 108.1% of the planned sample, respectively) (Table 4.1, p73). A 
major problem during the recruiting process was making the initial contact with 
potential male participants, leading to the lower sample realisation in men. 
Contributing to this difficulty was that a large portion of the study was conducted 
during a period of turmoil and unrest regarding xenophobia as well as taxi strikes in 
the townships. This is likely to account for the low sample realisation among 25-34-
year-old men (49.0%). The low sample realisation among 65-74-year-old men 
(43.1%) may be related to the oversampling required in this age category; this was 
also the lowest realised sample by age category in women (69%). The difficulty in 
recruiting male participants is, however, characteristic of epidemiological studies in 
this country and generally due to their reluctance for having blood samples drawn as 
well as their more frequent absences from home when compared to women. 
Nonetheless, the overall response rate of 85.7% for the study population was 
comparable between men (83.5%) and women (86.9%). Of the 187 non-responders 
(i.e. the selected people who did not participate), 79 (42.2%) were men.  
4.1.2. SOCIO-DEMOGRAPHIC CHARACTERISTICS  
The socio-demographic data reflect the socio-economic ills of inadequate education 
and high unemployment prevalent in South Africa as well as the shortage of 
adequate accommodation common in urban centres (Table 4.2, p74). Approximately 
a third (34.2%) of participants had less than seven years or no education with older 
participants less educated compared to their younger counterparts. Only 22.8% were 
employed and rates of unemployment were high at 61.0%; much higher than the 
official rate of unemployment (20.5%) among 15-64-year-olds in the Western Cape in 
2009 (408). These data are, however, not directly comparable because of the 
different age categories and definitions of unemployment used. Just over half of the 
participants (51.4%) lived in informal housing illustrating that the majority were of low 
















Table 4.1: Realisation of the planned sample (number and percentage) stratified by gender, area and age 
Age Men Women 
 Langa Guguletu Crossroads Nyanga Khayelitsha Total  Langa Guguletu Crossroads Nyanga Khayelitsha Total  
25-34:             
Planned number  73 28 10 20 116 247 75 28 11 20 128 262 
Realised number 22 14 3 5 77 121 71 29 10 13 112 235 
  % Realised  30.1 50.0 30.0 25.0 66.4 49.0 94.7 103.6 90.9 65.0 87.5 89.7 
35-54:             
Planned number  61 29 11 19 117 237 64 27 11 21 125 248 
Realised number 51 28 4 6 96 185 107                           41        10 27                         146 331 
  % Realised 83.6 96.6 36.4 31.6 82.1 78.1 167.2 151.9 90.9 128.6 116.8 133.5 
55-64:             
Planned number  22 9 4 8 25 68 22 12 4 9 26 73 
Realised number 17 6 1 9 25 58 21                                                                 16 3 20 32 92 
  % Realised  77.3 66.7 25.0 112.5 100.0 85.3 95.5 133.3 75.0 222.2 123.1 126.0 
65-74:              
Planned number  21 13 3 6 22 65 21 17 3 7 23 71 
Realised number 4 6 1 3 14 28 5                           16                                  6 8 14   49 
  % Realised   19.1 46.2 33.3 50.0 63.6 43.1 23.8 94.1 200.0 114.3 60.9 69.0 
Total:             
Planned number  177 79 28 53 280 617 182 84 29 57 302 654 
Realised number 94 54 9 23 212 392 204 102 29 68 304 707 

















Table 4.2: Socio-demographic profile and family and self-reported medical history of participants presented by age categories 
Socio-demographic variables: Age category in years 
 25-34 (n=356) 35-44 (n=262) 45-54 (n=254) 55-64 (n=150) 65-74 (n=77) Total (n=1099) 
  S.E.  S.E.  S.E.  S.E.  S.E.  95% CI 
Education, %:             
   None  1.5           0.9        2.2           0.0 8.2           2.6 20.7           3.7 18.1           5.0 5.6 4.0 - 7.6 
  1-7 years 12.8           2.1           30.7           3.7 43.5          3.5 47.5            5.0 55.7           6.3 28.6 25.6 - 31.7 
  8-12 years 76.4           2.7 62.4           3.8 45.3           3.7 30.3           4.0 25.1           5.3 60.0 56.8 - 63.2 
  Higher (tertiary or diploma) 9.4          1.7 4.8           1.4 3.0           1.0 1.6           0.9 1.1           1.0 5.9 4.3 - 7.9 
Employment Status, %:             
  Employed 23.4           2.4 31.5            3.6 20.4           2.7 15.7            4.1 2.1           1.5 22.8 20.2 - 25.7 
  Unemployed
 
71.9           2.7 59.7          3.4 63.6           3. 4 35.7           4.4 8.6              3.5 61.0 57.6 - 64.3 
  Other: homemaker 1.5           0.9 1.0           0.6 2.6           1.6 2.9                        1.6 0.0 0.0 1.6 0.7 - 3.8 
             pensioners  0.6           0.6 3.0           1.6 6.5           2.0 37.3          4.1 89.3           3.8 10.1 8.4 - 12.2 
             disabled 1.3           0.6 4.1           1.3 7.0           1.6 8.4                       2.3 0.0 0.0 3.7 2.7 - 4.9 
             students 1.4           0.6 0.8               0. 6 0.0 0.0 0.0 0.0 0.0             0.0 0.8 0.4 - 1.6 
Housing Type, %:             
  Built formal unit (private) 19.8           3.4 17.0           3.0 28.0           3.8 28.7           4.2 27.2           4.8 22.0 18.0 - 26.7 
  Council/core house/hostel 23.2            2.8 24.5           2.8 28.3           3.2 36.6           4.0 39.4           5.2 26.6 22.8 - 30.7 
  Informal shack 57.0           4.1 58.5           3.9 43.7           4.1 34.6           4.3 33.4            5. 8 51.4 45.9 - 56.9 
Occupancy rate (persons / room)  2.3  0.1 2.4    0.1 2.3     0.1 2.3    0.2 2.1    0.2 2.3 2.2 - 2.4 
% life in urban area, mean  60.6    2.1 60.4    2.3 64.4    2.5 66.8    3.0 62.8    3.9 62.0 59.1 - 64.9 
Asset Index by tertiles, %,              
  1
st
 (poorest)  36.5           3.4 33.4           3.7 31.5           3.6 27.3            3.9 23.3           5.0 33.2 28.6 - 38.2 
  2
nd
  32.7           3.0 41.8          4.1 24.5           3.0 37.0 4.9 38.4           5.6 33.7 29.9 - 37.6 
  3
rd
 (richest) 30.9           3.5 24.9              3.6 44.0           3.6 35.7           5.1 38.4            6.2 33.1 28.6 - 38.0 
Family medical history, %:              
  Diabetes mellitus 18.9          2.4 26.4            3.1 26.3           3.0 20.7           3.6 17.1           4.3 22.2 19.6 - 25.1 
  Hypertension  37.6           3.3 42.4           3.2 39.7           3.4 37.3           4.7 32.5           5.2 38.8 35.4 - 42.4 
  Ischaemic heart disease  8.2           1.6 5.4           1.3 9.5            1.8 12.4           3.0 5.3           2.2 8.0 6.4 - 10.0 
  Stroke  6.8           1.5 9.9           2.3 10.5            2.1 6.6            2.0 5.6           2.7 8.2 6.6 - 10.3 
Self-reported diagnosis, %:                
  Diabetes 3.3           0.9 4.0           1.2 11.7          2.0 12.7           2.7 22.0           4.9 7.0 5.7 - 8.6 
  Hypertension 6.7          1.3 15.7           2.3 39.8           3. 2 53.5           4.7 72.5           5.6 23.2 20.4 - 26.2 
  Hyperlipidaemia   0.6          0.4 0.5          0.4 4.3           1.3 2.6            1.3 4.9           2.4 1.8 1.1 - 2.7 
  Ischaemic heart disease 0.8          0.4 2.9            1.1 4.7            1.4 6.5          1.9 9.1           3.3 3.0 2.2 - 4.2 
  Stroke 1.8          0.9 0.7            0.4 6.5           1.6 6.9           2.3 9.0           3.6 3.4 2.4 - 4.8 
















While older participants were less educated and fewer were employed, a higher 
proportion received a pension or a disability grant. They also lived in better quality 
housing and were wealthier than their younger counterparts. The steady source of an 
income in the form of a welfare grant among the older participants may account for 
their better quality housing and relative greater wealth compared to younger 
participants as pensions have been found to improve living conditions (409). 
4.1.3. FAMILY AND MEDICAL HISTORY  
Family history of diabetes and hypertension were high, at 22.2% and 38.8%, 
respectively, with no trend by age category for either (Table 4.2, p74).  The self-
reported prevalence for diabetes and hypertension was 7.0% and 23.2%, 
respectively, and increased with age. The high prevalence of family and self-reported 
hypertension was in keeping with previous reports where hypertension was found to 
be the most prevalent CVD risk factor in adult black South Africans (385). 
Nevertheless, self-reported hypertension and diabetes is not likely to be a true 
reflection of the prevalence in the population, because the proportion of people 
aware of having either of these conditions is generally low. The ‘rule of halves’ 
predicts that of all those with hypertension, half are detected, half of those detected 
are treated and half of those treated are adequately controlled (410). 
The rates of family history of IHD and stroke were both approximately 8.0% with low 
self-reported rates of about 3.0% each. The similar rate of IHD and stroke, for family 
and self-reported, may reflect the changing pattern of CVD in this population. 
Previously, stroke was much more common in the black population of SSA, including 
South Africa, but IHD has been on the rise since the 1980s (306, 411). At 6.6% and 
6.5%, IHD and stroke, respectively, were the 2nd and 3rd most common causes of 
death in 2000 (262). 
The prevalence of self-reported hyperlipidaemia was only 1.8%; lower than might 
have been expected given the relative higher prevalence of self-reported IHD and the 
known strong association between these two conditions. The low self-reported rate of 
hyperlipidaemia is probably a reflection of the low level of screening and detection 


















Table 4.3: Pattern of healthcare utilisation presented by gender and age categories 
Healthcare utilisation pattern, % Age category in years 
 25-34  35-44  45-54  55-64  65-74  Total  
  S.E.  S.E.  S.E.  S.E.  S.E*  95% CI 
Men  n= 121 n= 99 n= 86 n= 58 n= 28 n= 392 
Payment for healthcare services:             
    Self  15.7           3.1 18.4           4.3 18.3           5.3 10.6           4.1 10.7           5.7 16.2 12.8 - 20.3 
    Family  5.2           2.1 1.4                        1.1 0.0 0.0 1.1                        1.1 0.0 0.0 2.6 1.3 - 5.2 
    Medical aid  3.6          2.1 1.8           1.3 3.2            1.8 3.7                       2.6 0.0 0.0 2.9 1.5 - 5.8 
    Employer   0.0 0.0 0.5          0.4 0.5               0.5 0.0 0.0 0.0 0.0 0.2 0.1 - 0.9 
    Public healthcare utilised 75.4           3.9 77.9           4.5 78.0           5.2 84.6           4.8 89.3           5.7 78.1 73.3 - 82.3 
Tested in past 1 year:             
     Glucose 7.7           2.3  4.8           3.0 15.7           4.6 26.8           6.3 39.3           9.2 12.0 8.8 - 16.3 
     Blood pressure 7.5           2.3 8.7           3.5 27.1          4.6 40.5           7.3 57.1           9.5 17.3 13.8 - 21.6 
Visited traditional healer in the past year for:             
    Diabetes 0.0 0.0 0.0 0.0 2.5               1.7 0.0 0.0 0.0 0.0 0.5 0.1 - 2.0 
    Hypertension 0.0 0.0 0.0 0.0 2.5           1.7 1.1                        1.1 0.0 0.0 0.6 0.2 - 2.0 
Using herbal/traditional medicine for:              
    Diabetes 0.8                      0.8 0.0 0.0 2.3                       1.6 0   0 7.1            4.9 1.2 0.5 - 2.7 
    Hypertension 0.0 0.0 0.0 0.0 5.1           2.7 4.8           2.8 10.7           5.9 2.0 1.1 - 3.9 
Women  n= 235 n= 163 n= 168 n= 92 n= 49 n= 707 
Payment for healthcare services:             
    Self  12.7            2.2 16.9           3.4 5.6            1.9 8.4           2.8 16.3           4.9 11.9 9.7 - 14.5 
    Family  2.6          1.0 1.8          0.9 0.5           0.4 2.5                        1.4 0.0 0.0 1.8 1.0 - 3.1 
    Medical aid  2.4           1.0 3.7           1.7 4.7           1.7 0.8                       0.8 0.0 0.0 2.9 1.9 - 4.5 
    Employer   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
    Public healthcare utilised 82.4           2.4 77.6           3.8 89.2            2.4 88.2           3.1 83.7           4.9 83.4 80.5 - 86.0 
Tested in past 1 year:             
     Glucose 7.8           1.9 14.7           3.2 37.5           3.8 37.4            4.9 44.9            7.7 20.2 17.1 - 23.7 
     Blood pressure 14.1           2.4  27.2            3.7 55.2           4.2 68.1           5.0 67.4           6.4 33.2 29.2 - 37.3 
Visited traditional healer in the past year for:             
    Diabetes 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 - 0.5 
    Hypertension 0.0 0.0 0.3           0.3       1.1           0.8 3.5                        2.0 0.0 0.0 0.6 0.2 - 1.3 
Using herbal/traditional medicine for:              
    Diabetes 0.0 0.0  0.6           0.4 3.4          1.4 3.6           1.8        4.1           2.9 1.4 0.8 - 2.4 
    Hypertension 0.0 0.0 1.9           1.1 8.5          2.3 10.9            3.2 10.2           4.3 3.7 2.6 - 5.3 
















4.1.4. HEALTHCARE AND HEALTH SERVICES UTILISATION  
The low socio-economic status of the study population is reflected in the utilisation of 
public healthcare services: men 78.1% and women 83.4% (Table 4.3, p76). These 
findings are in accordance with those from the SADHS where most participants 
nationally also utilised public healthcare services (361) and reveal the urban black 
population’s widespread dependence on government’s provision of healthcare. A 
negligible proportion (2.9%) was covered by health insurance while only 16.2% and 
11.9% of men and women, respectively, paid for their own healthcare. This 
underscores the need to provide an equitable, effective and efficient healthcare 
service. 
Approximately a quarter (25.6%) and one in six (16.3%) participants had their BP and 
blood glucose checked, respectively, in the previous year. As expected, more women 
than men had their BP (33.2% vs. 17.3%) and blood glucose (20.2% vs. 12.0%) 
measured with rates generally increasing with age (Table 4.3, p76).  
Very few men and women reported visiting traditional healers (<1%) or using 
herbal/traditional medicines (<4%) for diabetes or hypertension during the previous 
year. Nonetheless, treatment by traditional healers is known to be widespread in 
South Africa with an estimated 60-80% of the population currently using traditional 
healers as their first contact for advice and/or treatment of health concerns (412). 
The low self-reported use of traditional healers or herbal medications probably 
indicates a reluctance to disclose this to western health professionals and 
researchers for fear of disapproval.  
4.2. CARDIOVASCULAR DISEASES RISK FACTORS  
4.2.1. ENVIRONMENTAL AND BEHAVIOURAL RISK FACTORS 
The environmental and behavioural CVD risk factors in this study are modifiable and 
consist of psychosocial stressors, tobacco and alcohol use, physical inactivity and 
unhealthy diets. The tools used to measure these risk factors, in particular, physical 
inactivity and dietary fat intake, were reliant on participant recall and perception, and 
therefore potentially subject to bias. 
4.2.1.1. Psychosocial Stress 
The relationship between the SOC, LOC or adverse life events scores, which were 
the tools used to determine psychosocial stress in this study, and CVD risk factors 
have not previously been examined in this population. SOC has been used as one of 
















South Africa (413). The six-item LOC was among the psychosocial measures found 
to be associated with acute MI in the INTERHEART study, an international case-
control study that included South Africa (90, 414).  
There was no trend for perceived health status by age category with most of the men 
(52.5%) and women (54.8%) perceiving their health status to be average (Tables 
4.4a and 4.4b, p79-80). As expected, older participants reported poor health more 
frequently than the younger ones. More women (28.0%) than men (13.0%) reported 
living with HIV-infected individuals but few perceived their own healthcare to be 
compromised by family illness or death (4.0%).  
SOC scores were similar in men and women, and across age groups in men but not 
in women, in whom the lowest scores were in 45-54-year-olds and the highest in 25-
34-year-olds. Mean SOC scores at 54.8 in men and 54.2 in women were lower than 
those reported in Sweden where mean scores ranged from 68 to 72 in various 
studies (415-417). Higher SOC was also found in Finland where the mean score per 
question was 5.5 (418) compared to 4.2 in this study. Thus, based on SOC, 
participants in this study experienced more stress compared to those in Sweden and 
Finland. This was not surprising considering the numerous socio-economic obstacles 
such as unemployment and poor quality housing faced by many of these participants. 
Surprisingly, mean SOC in this study was similar to that of Sudanese diabetic 
patients with lower limb amputations whose scores were 53.1 in men and 52.0 in 
women (419). While it may be anticipated that individuals with lower limb 
amputations and diabetes may experience greater stress and have lower SOC 
scores compared to those without disabilities, the similar scores may be attributable 
to variations in interpretation of the questions between the cultures and the extent of 
social desirability with regard to responses (90). 
Mean LOC scores were significantly higher in men than in women (19.4 vs. 18.5 
p<0.001) (Tables 4.4a and 4.4b, p79-80) and may perhaps be related to the greater 
social standing afforded to men in traditional cultures. The youngest men and women 
had the highest LOC scores with the lowest scores in 55-64-year-old men and 65-74-
year-old women. The higher scores in younger participants may be related to the 
greater proportions of their lives, particularly during the impressionable adolescence 
stage, being spent in the post-apartheid era with its greater freedom, human rights 
and dignity; their older counterparts, in contrast, spent larger proportions of their lives 
















Table 4.4a: Pattern of psychosocial influences presented by age categories in men 
Psychosocial influences Age category in years 
 25-34  35-44  45-54  55-64  65-74  Total  
  S.E  S.E.  S.E.  S.E.  S.E.  95% CI 
 n= 121 n= 99 n= 86 n= 58 n= 28 n= 392 
Perceived health status, %:              
    Poor  12.3           3.0 14.3           4.4 26.4           5.4 29.6           7.8 21.4           7.9 17.7 13.8 - 22.3 
    Average 47.7           5.7 56.5           6.0 55.3            6.0 54.9           7.6 57.1 10.0 52.5 46.4 - 58.5 
    Good  33.3           4.9 27.2           5.4 18.3           4.6 13.9           5.0 21.4           8.8 26.5 21.4 - 32.3 
    Very good/excellent  6.8           2.2      2.0                       1.3 0.0   0.0   1.6                         1.6 0.0 0.0 3.4 2.0 -6.0 
Family illness/death limited own healthcare, % 5.6          2.7 3.9          2.0 1.1            1.2 3.7                         2.5 0.0 0.0 3.8 2.0 - 7.2 
Living with HIV/AIDS in the household, %  15.8           3.5 16.4           4.1 9.3           3.3 7.5                         3.7 0.0 0.0 13.0 9.6 - 17.5 
             
Psychosocial scores:             
  Sense of coherence (SOC), mean 54.7 1.1 55.3 1.3 55.1 1.0 53.0 2.1 55.4 1.9 54.8 53.6 - 56.1 
  SOC in tertiles, %:              
    Low 31.9           4.7 30.2           5.5 24.9            4.5 40.8           7.5 39.3            9.7 31.2 26.2 - 36.7 
    Moderate 34.1           4.8 27.4          5.2 33.7           5.7 25.0           5.6 17.9           7.1 30.7 25.9 - 36.1 
    High 34.1           4.8 42.5           5.3 41.4           5.5 34.2           6.7 42.9           9.4 38.1 33.1 - 43.3 
  Locus of control (LOC), mean  20.0 0.3 19.3 0.4 18.7 0.4 18.6 0.4 18.7 0.5 19.4 19.0 - 19.7 
  LOC in quartiles, %             
   1
st
 (lowest) 11.7           3.0 15.9           4.6 29.6           5.2 26.0           7. 7 21.4           7.9 18.1 14.1 - 22.9 
   2
nd
  19.3           3.8 19.6            4.2 18.9           4.2 28.2           6.3 28.6           8.8 20.5 16.8 - 24.8 
   3
rd
  27.1           3.7 29.8           5.5 21.6           4.4 28.2           6.2 28.6           8.9 26.8 22.2 - 32.0 
   4
th
 (highest) 42.0           4.5 34.7           5.5 30.0           5.5 17.7           5.4 21.4           7.6 34.6 29.4 - 40.2 
  Life events, mean:              
      Total number of life events  7.5    0.3 8.4    0.3 7.9    0.3 8.2    0.4 6.8    0.4 7.8 7.5 - 8.1 
      Impact: events <6 months ago 4.0    0.2 4.2    0.3 3.4    0.3 2.8    0.3 1.7    0.3 3.7 3.4 - 4.0 
                   events >6 months ago 9.3   0.4 11.5    0.5 11.0    0.6 12.0   0.9 9.9     0.7 10.5 9.9 - 11.0 
             
















Table 4.4b: Pattern of psychosocial influences presented by age categories in women 
Psychosocial influences Age category in years 
 25-34  35-44  45-54  55-64  65-74  Total  
  S.E.  S.E.  S.E.  S.E.  S.E.  95% CI 
 n= 235 n= 163 n= 168 n= 92 n= 49 n= 707 
Perceived health status, %:              
    Poor  11.2           2.2 14.1           2.7 39.2           3.9 34.3           5.5 36.7           7.1 21.2 18.1 - 24.7 
    Average 53.5            3.5 61.5           3.9 47.6           4.0 60.0           5.5 61.2           7.3 54.8 51.0- 58.6 
    Good  32.6           3.2  22.5           3.5 10.5           2.6 5.0               2.4 0.0           0.0           21.6 18.2 - 25.4 
    Very good/excellent  2.8           1.2 1.9           1.1 2.8           1.2 0.7           0.7 2.0           2.0 2.4 1.5 - 3.9 
Family illness/death limited own healthcare, % 2.2           1.1 1.8           1.1 6.5           2.0 12.0           3.2 8.2           3.9 4.2 2.9 - 6.0 
Living with HIV/AIDS in the household, %    27.1           3.3 27.2           3.9 29.2           4.0 35.0           5.6 22.5           6.0 28.0 24.1 - 32.2 
             
Psychosocial scores:             
  Sense of coherence (SOC), mean  55.6 0.8 53.8 0.8 52.2 0.9 53.0 0.9 54.7 1.4 54.2 53.3 - 55.2 
  SOC in tertiles, %:              
    Low 26.8           3.2 32.7           3.9 46.9           4.3 32.5           5.0 24.5            6.7 32.9 29.0 - 37.1 
    Moderate 32.4           2.8 35.1           4.2 22.5           3.5 35.3           5.6 38.8           6.9 31.3 28 - 34.9 
    High 40.8           3.8 32.3           4.0 30.5           3.7 32.2           5.1 36.7           6.6 35.8 31.7 - 40.1 
  Locus of control (LOC), mean  19.1 0.2 18.2 0.3 18.0 0.2 18.0 0.3 17.6 0.5 18.5 18.2 - 18.7 
  LOC in quartiles, %             
   1
st
 (lowest) 15.3            2.5 25.6           3.5 27.4           3.8 24.2           4.5 34.7           6.9 22.0 18.6 - 25.7 
   2
nd
  25.0           3.0 26.8           4.0 31.1           4.1 32.6           5.0 30.6           5.7 27.7 23.9 - 31.8 
   3
rd
  30.8           3.4 34.8           4.3 26.7           3.9 28.7           5.1 12.2            4.6 29.6 25.7 - 33.8 
   4
th
 (highest) 29.0           3.2 12.8           3.0 14.7           2.7 14.5           3.6 22.5           5.9 20.8 17.6 - 24.4 
  Life events, mean:              
     Total number of life events 6.8    0.2 7.5    0.3 8.0    0.2 7.2   0.3 6.6    0.3 7.3 7.0 - 7.5 
      Impact: events <6 months ago 4.2    0.2 4.2    0.3 4.2    0.3 3.0   0.3 2.7    0.3 4.0 3.8 - 4.3 
                   events >6 months ago 8.3    0.3 9.8    0.4 10.7    0.3 10.5    0.4 9.4   0.5 9.4 9.1 - 9.8 
             
















Men had experienced significantly more adverse life events than women (7.8 vs. 7.3 
p=0.002) (Tables 4.4a and 4.4b, p79-80). Men were more likely to have suffered a 
serious illness, injury or an assault, broken off a steady relationship, been fired from 
a job, experienced problems with the police and a court appearance, and to have had 
something valuable lost or stolen. The most number of adverse life events 
experienced among men were in 35-44-year-olds and among women in 45-54-year-
olds. 
4.2.1.2. Tobacco Use 
Cigarette smoking contributes to a large burden of preventable disease in South 
Africa. In 2000, smoking accounted for 8.0-9.0% of mortality, the third most common 
cause, after unsafe sex/sexually transmitted disease and high BP, among 17 risk 
factors evaluated. While lung cancer had the largest attributable fraction because of 
smoking, CVDs contributed the largest proportion of deaths caused by smoking 
(170). 
The prevalence of cigarette smoking was significantly higher among men than 
women (57.8% vs. 9.8% p<0.001) (Tables 4.5a and 4.5b, p83-84), in accordance 
with the worldwide male preponderance for tobacco use (156) including in SSA (153, 
376) and in national South African surveys (360, 361). That the prevalence of 
smoking was highest among the youngest men with two-thirds of 25-34-year-old men 
smoking daily or occasionally indicates the high uptake of cigarette use in this group 
and the widespread acceptance of this risky behaviour. 
Nonetheless, in keeping with the SADHS which reported a lower national smoking 
prevalence in 2003 compared to 1998 (420), there has been a decline in smoking 
between 1990 and the current study (Table 4.6, p85). For example, the prevalence of 
smoking ≥1 cigarette/day in 25-64-year-old men in 2008/09 in this study was 51.0% 
compared to 59.7% in 1990.   
The decline in smoking prevalence is likely to be a reflection of the effectiveness of 
the South African government’s anti-smoking initiatives (170, 421, 422);  
comprehensive tobacco control policies were introduced in the 1990s to address the 
growing epidemic of tobacco use. Furthermore, steep rises in excise taxes increased 
real cigarette prices by 115% between 1993 and 2003 (423). The biggest impact was 

















In 25-64-year-old women, although the prevalence of daily cigarette smoking was 
low, there was no reduction between 1990 (8.4%) and 2008/09 (8.0%) (Table 4.6, 
p85), in keeping with the pattern found in the SADHS (420). Also suggesting the lack 
of a major alteration in smoking patterns among women was that smoking cessation 
was low with only 3.0% of women reporting a past history of daily smoking; the 
highest being in 65-74-year-old women (16.3%) and may possibly be related to 
health reasons rather than the anti-smoking initiatives.  
The low smoking prevalence in women is probably attributable to the influence of 
gender norms and social disapproval (424), but with weakening social and cultural 
constraints, and greater female autonomy, women may be encouraged to smoke 
(425). This may be a key factor in the minimal influence of the tobacco control 
policies on the smoking rates in women. The steep rises in excise taxes that 
increased real cigarette prices, and probably contributed to lower smoking rates 
among men, appear to have not impacted on women; the increases in their spending 
power may have made cigarettes more affordable.  
Notably among women, although tobacco smoking was relatively low compared to 
men, their use of smokeless tobacco was 11.2%, much higher than that of men 
(2.1%). The prevalent use of smokeless tobacco was higher in older compared to 
younger women. Further, the daily use of smokeless tobacco among 25-64-year-old 
women rose from 3.1% in 1990 to 5.5% in 2008/09, in keeping with the SADHS 
(420). Many users of smokeless tobacco are unaware of the health hazards of 
smokeless tobacco use and need to be actively discouraged from continuing or 
initiating the habit (426). 
Despite the introduction of comprehensive legislative action to discourage tobacco 
use since the early 1990s, it still remains a major public health problem (170). The 
differential rates and pattern of tobacco smoking in men and women underscore the 
complex and multi-factorial influences including knowledge, perceptions and socio-
cultural norms that motivate tobacco use (427). The apparent lack of an effect of the 
current anti-tobacco measures on smoking rates in women suggests that novel 
approaches are required to encourage cessation and to prevent uptake of smoking in 
women. In addition to the current legislative measures, culturally relevant and 
gender-specific smoking prevention and cessation programmes are needed, as well 
as dissemination of information on the harmful effects of smokeless tobacco use. 
Moreover, additional measures may be required to encourage cessation and to 
















Table 4.5a: Lifestyle behaviours and anthropometry presented by age categories in men 
 Age category in years 
 25-34 (n=121) 35-44 (n=99) 45-54 (n=86) 55-64 (n=58) 65-74 (n=28) Total (n=392) 
Lifestyle/behavioural risk  factors:  S.E.  S.E.  S.E.  S.E.  S.E.  95% CI 
Tobacco consumption:             
  Smoke: daily/occasionally, %   66.8           4.3 58.0           6.0 54.3            5.3 37.8           7.0 32.1           9.2 57.8 52.4 - 62.9 
  Smoke: ≥1cigarette/day, %       56.9        4.9 51.6           6.0 45.7           5.2 33.0           6.7 21.4           8.8 49.4 43.8 - 54.9 
  Among daily smokers (n=183):                     
    Mean age when started smoking daily 18.1    0.5 18.3    0.9 20.0    1.3 22.5    2.3 19.5    1.4 18.8 17.9 - 19.7 
    % who smoke manufactured cigarettes  96.8            2.3 92.5           3.9 73.2           9.1 58.0           11.2 66.7           15.8 88.3 81.8 - 92.7 
  Past daily smokers, %  15.6           3.7 17.9           3.8 35.4           5.3 37.2           8.0 35.7 9.5 23.2 18.9 - 28.1 
  Current use of smokeless tobacco, % 3.6          2.2 1.6                        1.2 0.0 0.0 2.7                         1.9 0.0 0.0 2.1 0.9 - 5.0 
             
Alcohol consumption:              
  Alcohol consumption, % 72.4           4.4 70.2           6.2 65.7           6.1 51.0                       6.9 50.0 8.8 67.5 62.0 - 72.5 
  Problem drinking: CAGE positive ≥2, % 54.7           4.5 56.3           6.2 48.2          6.3 27.1                       6.3 25.0 8.0 49.7 44.6 - 54.9 
             
Total moderate to vigorous  physical activity:             
 Mean minutes per week  1314.7 102.9 1206.9   144.3 975.8 85.8 1041.4   113.1 477.0  84.3 1150.5   1030.1-1270.9 
 Physical activity: <150 minutes / week, %   4.7           1.9 5.7           2.4 5.7           2.4 9.9           3.9 17.9           7.1 6.3 4.3-9.1 
             
Diet:             
  % fat intake, mean 28.7 1.2 24.1 1.4 24.0 1.8 21.4 1.7 19.0 1.9 25.5 23.9-27.1 
  High fat intake: >30% of energy intake, % 45.6           5.5 33.1           5.3 35.0 6.0 16.7           5.1 7.1           4.7 36.0 30.4-42.0 
             
Anthropometry:             
  Height, mean (m)  1.71    0.007 1.70    0.009 1.69     0.008 1.69    0.009 1.69   0.013 1.70 1.69 - 1.70 
  Weight, mean (kg)  65.8    1.2 67.7   1.6 72.5    2.4 72.4    2.1 73.3   3.5 68.6 67.0 - 70.2 
  Waist circumference (cm), mean  79.0    0.9 82.5    1.3 91.0   1.9 91.7    1.7 94.4    3.0 84.2 82.8 - 85.6 
  Hip circumference (cm), mean  93.2    0.9 94.7     1.1 96.6   1.4 98.0     1.3 97.5     2.0 94.9 93.8 - 96.0 
  BMI (kg/m
2
), mean  22.4    0.4 23.3     0.5 25.5   0.7 25.4    0.7 25.7    1.1 23.7 23.1 - 24.2 
  Waist-to-hip ratio, mean  0.85    0.005 0.87   0.005 0.94  0.009 0.93   0.009 0.96  0.017 0.88 0.88-  0.89 
             
  BMI (kg/m
2
), %:             
    Underweight (<18.5) 7.2           2.7 9.5           3.0 7.8           2.8 2.9           2.1 7.1           4.9 7.5 5.1 -11.1 
    Normal weight (18.5-24.9) 74.3           4.0 64.5           5.3 47.7           6.0 60.6           6.2 42.9           9.3 63.6 57.8 - 68.9 
    Overweight (25-29.9) 14.1          3.4 17.7           4.0 26.7          5.6 19.1                       5.0    25.0   7.6 18.6 14.7 - 23.3 
    Obese (≥30) 4.4          1.7 8.3           3.2 17.8           4.8 17.4                        5.0 25.0 8.0 10.3 7.4 - 14.2 
  Raised waist circumference, %
 
10.1           2.7 14.2           4.3 34.1           6.2 32.4                      6.5 50.0  9.5 20.1 15.9 - 24.9 
  Raised waist-to-hip ratio,% 1.6           1.1 1.6          1.2 23.1            5.9 16.8           5.2 35.7           8.4 9.2 6.5 -12.9 
             
















  Table 4.5b: Lifestyle behaviours and anthropometry presented by age categories in women 
 Age category in years 
 25-34 (n=235) 35-44 (n=163) 45-54 (n=168) 55-64 (n=92) 65-74 (n=49) Total (n=707) 




  S.E.  S.E.  95% CI 
Tobacco consumption:             
  Smoke: daily/occasionally, %  9.5           2. 2 7.3           2.0 12.4           2.7 11.3           3.3 8.2           4.0 9.8 7.4 - 12.8 
  Smoke: ≥1cigarette/day, %      7.6           1.9 5.9           1.8 10.1           2.5 9.8           3.1 6.1          3.5 7.9 5.8 - 10.6 
  Among daily smokers (n=58):              
    Mean age when started smoking daily 19.7    1.4 21.6    1.4 31.6    3.6 37.8    3.9 22.0   3.3 25.3 22.2 - 28.3 
    % who smoke manufactured cigarettes  100.0           0.0 76.3           14.6 76.6           12.1 91.4                      8.4 100.0 0.0 88.6 75.6 - 95.1 
  Past daily smokers, %  2.2           1.0 1.1           0.5 2.2           1.1 5.9           2.8 16.3 6.8 3.0 1.9 - 4.8 
  Current use of smokeless tobacco, %  6.6          1.8 10.1           2.5 16.9           3.3 19.5           4.6 16.3          5.7 11.2 8.7 - 14.2 
             
Alcohol consumption:              
  Alcohol consumption, % 32.2           3.3 25.2           3.5 21.1           3.3 25.2           4.3 18.4           5.6 26.9 23.4 - 30.8 
  Problem drinking: CAGE positive ≥2, % 21.3           2.8 16.9           3.0 16.2           3.2 15.8           4.1 8.2           3.8 18.1 15.3 - 21.2 
             
Total moderate to vigorous physical activity:             
  Mean minutes per  week  1067.2    74.3 965.5    73.1 905.1   68.7 894.5 95.3 628.1  87.4 972.9  891.6-1054.1 
  Physical activity: <150 minutes per week, %   4.1           1.4 7.1           2.2 9.3           2.3 6.1           2.7 20.4           5.7 6.9 5.1-9.2 
             
Diet:             
  % fat intake, mean 26.9 0.9 25.8 0.9 23.2 1.1 25.2 1.5 24.8 1.7 25.6 24.6-26.7 
  High fat intake: >30% of energy intake, % 41.7           3.6 37.6           3.9 26.2           3.6 33.6           4.9 32.7           6.7 36.3 32.3-40.4 
             
Anthropometry:             
  Height, mean (m)  1.60    0.004 1.60    0.006 1.58    0.005 1.58     0.007 1.55    0.009 1.59 1.59 -1.60 
  Weight, mean(kg) 80.3  1.4 87.5    2.1 87.6   2.0 83.7   2.3 82.7    2.9 83.8 82.0 - 85.7 
  Waist circumference (cm), mean  92.5   1.1 98.6    1.4 101.7    1.2 99.6    1.5 100.5    1.9 96.8 95.5 - 98.1 
  Hip circumference (cm), mean  112.2  1.0 115.0   1.5 116.7     1.4 115.0     2.0 117.2    2.2 114.3 113.0 - 115.6 
  BMI (kg/m
2
), mean  31.3    0.6 34.0   0.7 34.9    0.7 33.4    0.9 34.4   1.1 33.0 32.3 - 33.7 
  Waist-to-hip ratio, mean  0.82     0.005 0.86  0.006 0.87  0.006 0.87  0.009 0.86 0.009 0.85 0.84 - 0.85 
             
  BMI (kg/m
2
), %:             
    Underweight (<18.5) 1.0          0.7 0.3            0.3 0.6                       0.6 0.0 0.0 2.0           2.0 0.8 0.3 -  1.9 
    Normal weight (18.5-24.9) 23.6           2.9 9.8           2.5 10.7           2. 6 14.8            3.9 10.2           4.4 16.4 13.5 - 19.8 
    Overweight (25-29.9) 21.7           2.8 25.5 3.7 15.9           3.2 20.6           4.1 14.3           5.5 20.8 17.4 - 24.6 
    Obese (≥30) 53.6           3.7 64.4           4.0 72.8           3.9 64.6           4.8 73.5           6.6 62.1 57.8 - 66.2 
  Raised waist circumference, %
 
78.4           2.7 90.5           2.3 92.5            2.2 92.8           2.9 91.8           3.9 86.0 82.9 - 88.6 
  Raised waist-to-hip ratio,% 32.7           3.0 55.1           4.0 63.1           3.9 60.2           5.3 57.1           7.6 47.7 43.7 - 51.7 
             
















  Table 4.6: Comparison of selected cardiovascular disease risk factors in 25-64-year-old men and women in 1990 and 2008/09 
 Men  Women  Total  
 1990 2008/09  1990 2008/09  1990 2008/09  
 % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI 
Tobacco consumption:             
Smoke: ≥1cigarette/day, %      59.7  53.8-65.4 51.0  45.2-56.7 8.4  6.0-11.8 8.0  5.9-10.7 35.0  31.3-39.0 28.4 24.8-32.3 
Daily use of smokeless tobacco, % 0.7  0.2-2.7 0.9  0.3-2.5 3.1  1.8-5.3 5.5  3.8-7.8 1.9 1.1-3.2 3.3 2.3-4.7 
             
Alcohol consumption:              
Alcohol consumption, % 56.7  50.7-62.5 68.5  62.7-73.7 15.1  11.7-19.3 27.4  23.7-31.5 35.5 31.7-39.5 46.9 43.1-50.7 
             
Adiposity:             
  BMI (kg/m
2
), mean  24.3  23.8-24.8 23.6  23.0-24.1 33.0  32.3-33.7 29.5  28.8-30.2 27.0 26.5-27.5 28.5 27.9-29.2 
  BMI (kg/m
2
),%:             
    Underweight (<18.5)  2.7 1.3-5.7 7.6 5.0-11.4 2.1 1.0-4.3 0.7 0.3-1.9 2.4 1.4-4.0 3.9 2.7-5.8 
    Normal weight (18.5-24.9) 60.0 54.1-65.7 64.8 58.9-70.2 25.3 20.9-30.2 16.8 13.7-20.3 42.3 38.4-46.3 39.5 35.5-43.7 
    Overweight (25-29.9) 27.8  22.8-33.4 18.2  14.3-23.0 30.0 25.3-35.1 21.1 17.7-25.0 28.9 25.4-32.7 19.7 16.8-23.1 
    Obese (≥30) 9.5  6.7-13.3 9.5  6.5-13.6 42.7  37.5-48.0 61.5 57.1-65.7 26.4 23.2-29.9 36.8 33.0-40.7 
             
Lipids:             
Total cholesterol, mmol/l 4.2  4.1-4.3 4.3  4.1-4.4 4.3  4.2-4.4 4.3  4.2-4.4 4.3 4.2-4.3 4.3 4.2-4.4 
HDL-C, mmol/l 1.37  1.33-1.42 1.26  1.20-1.32 1.41  1.37-1.45 1.12 1.08-1.15 1.39 1.36-1.42 1.18 1.15-1.22 
LDL-C,
 
mmol/l 2.1  2.0-2.2 2.8  2.7-2.9 2.4  2.3-2.5 3.0  2.9-3.1 2.3 2.2-2.3 2.9 2.8-3.0 
HDL-C:TC,% 34.1 32.9-35.3 30.0 28.8-31.1 33.7 32.6-34.7 26.3 25.7-27.0 33.9 33.1-34.7 28.1 27.4-28.8 
             
Total cholesterol  >5 mmol/l 16.7  12.8-21.5 24.4  19.1-30.7 21.8  16.4-22.5 22.2  19.0-25.7 19.3 16.4-22.5 23.3 20.0-26.8 
HDL-C <1.2mmol/l 37.3  31.7-43.2 55.1 49.4-60.6 30.0  25.3-35.1 67.7  63.6-71.6 33.5 29.9-37.4 61.7 58.0-65.3 
LDL-C
†
 >3 mmol/l 12.6  9.2-17.0 36.5  31.1-42.3 21.2  17.2-25.9 44.5  40.6-48.4 17.0 14.2-20.1 40.7 37.3-44.2 
HDL-C:TC
 
<20% 4.7  2.8-7.8 13.6  9.9-18.5 4.1  2.5-6.7 18.4  15.6-21.7 4.4 3.0-6.2 16.2 13.6-19.0 
             
Blood pressure (BP):             
  Mean (mmHg):             
Systolic BP 121.4 119.7-123.1 129.4 126.8-132.0 119.4 117.7-121.1 120.4 118.5-122.3 120.4 119.2-121.6 124.6 123.1-126.2 
Diastolic BP 79.1 77.7-80.5 81.6 79.8-83.4 78.0 76.7-79.3 80.9 79.7-82.1 78.6 77.6-79.5 81.2 80.2-82.3 
  %:             
Hypertension 20.7  16.4-25.7 35.8  30.0-42.1 22.4  18.5-26.9 35.4  31.6-39.4 21.6 18.6-24.9 35.6 32.3-39.0 


















4.2.1.3. Alcohol Use 
Alcohol misuse is a major social and health problem in South Africa with 
approximately one in four adult men and one in ten adult women experiencing 
symptoms of alcohol related problems (428). The health burden is considerable with 
7.1% of mortality attributable to alcohol misuse, which is more than double the global 
mortality average of 3.2% (174, 179). Of the deaths attributable to alcohol misuse, 
CVD ranked second after injuries (179). 
Approximately two-thirds of the men and just over a quarter of the women in this 
study reportedly consumed alcohol with the highest rates in the youngest men 
(72.6%) and women (32.2%) and the lowest in the oldest (50.0% and 18.4%, 
respectively) (Tables 4.5a and 4.5b, p83-84). A higher rate of alcohol consumption in 
men has been a consistent finding in South African studies, including the 1990 study 
conducted in this population (360, 361, 429, 430) and is also reported in Africa and 
other developing countries (183, 428). For example, in urban Tanzania, lifetime 
alcohol use was 38.5% in 15-59-year-old men compared to 23.7% in their female 
counterparts (431).  
The prevalence of self-reported alcohol consumption in 2008/09 was higher than in 
1990 in 25-64-year-old men (68.5% vs. 56.7%) and women (27.4% vs. 15.1%) (Table 
4.6, p85). This was also higher than in previous South African studies (360, 361, 429) 
suggesting a pattern of rising intake. Of concern is the steep rise in consumption 
among women, who traditionally had low rates of alcohol use. The increase in 
alcohol consumption predisposes this population to a higher risk for hypertension 
along with the other ills that accompany alcohol use.   
Traditionally, alcohol consumption was the preserve of elders and other senior or 
authority figures, and less common among the youth and women of childbearing age 
(432). Similar to the uptake of smoking in women, weakening of social and cultural 
barriers that may have previously prevented women from drinking, and increased 
female autonomy with greater spending power may contribute to a rise in the 
proportion of women, particularly younger women, who consume alcohol. That 
alcohol consumption was most prevalent in the youngest women, aged 25-34 years, 
with almost a third drinking alcohol, and lowest in 65-74-year-old women supports 
this suggestion. Moreover, this pattern contrasts with the 1990 study where alcohol 
consumption was most common among 45-54-year-old (19.0%) and least common 
















In keeping with the weakening of social and cultural traditions, the highest rate of 
alcohol consumption among men in 2008/09 was in the youngest and the lowest was 
in the oldest, unlike the findings in 1990. That almost three-quarter of the youngest 
men drank alcohol may point to the success of alcohol advertisements, which are 
usually aimed at young people and placed for maximum exposure to this market 
(433). Drinking is linked to notions of financial and social success (190), and 
promoted as a lifestyle associated with fun, popularity, partying and other evening 
activities (177, 434). Alcohol advertising is documented to influence young people’s 
behaviour by normalising drinking in many different settings, bringing about positive 
beliefs about drinking, and encouraging young people to drink alcohol sooner and in 
greater quantities (190). 
In this study, the prevalence of problem drinking, as measured by the CAGE 
questionnaire, was also significantly higher in men compared to women (49.7% vs. 
18.1% p<0.001) (Tables 4.5a and 4.5b). However, among those that drank alcohol, 
problem drinking was high in men (73.4%) and women (67.1%) (p=0.107). Despite 
the fact that most women did not drink alcohol, the bulk of those who did so were 
problem drinkers. Problem drinking was highest in 35-44-year-old men (54.7%) and 
in 25-34-year-old women (21.3%) and generally decreased with older age.  
The pervasive nature of this drinking pattern among alcohol consumers indicates a 
culture of problem drinking and the high rates observed are a manifestation of the 
prevailing societal norms and attitudes that favour erratic heavy drinking. Among 
South Africans in general there seems to be very little disapproval but a high level of 
acceptance of heavy drinking, particularly among men (432). Alcohol misuse places 
a major burden on the health, economic, and social well-being of the individual (177, 
429, 435, 436) and these need to be emphasised to change the South African 
attitude towards problem drinking.  
Problem drinking seems to be on the rise among those who consumed alcohol, 
because it was considerably higher in this study compared to that found in ≥15-year-
old urban black men (57.9%) and women (52.8%) in the 2003 SADHS (361). An 
increase in alcohol misuse among South Africans was also reported by Peltzer and 
colleagues (429).  
4.2.1.4. Physical Activity  
South African adults have a particularly high prevalence of physical inactivity 
compared to other regions globally and it was estimated to have caused 3.3% of all 
















stroke were responsible for 58.9% and 20.5% of the burden in men, and 40.6% and 
27.6% in women, respectively. Viewed differently, 30% of IHD, 22% of ischaemic 
stroke and 20% of type 2 diabetes in 2000 were caused by physical inactivity in ≥15-
year-old South African adults (200).  
Surprisingly, levels of self-reported physical activity using the GPAQ were high in this 
study; men and women engaged in 1150.5 and 972.9 minutes of moderate-to-
vigorous physical activity per week, respectively (p=0.006) (Tables 4.5a and 4.5b, 
p83-84). Conversely, the rates of inactivity were very low with only 6.3% of men and 
6.9% of women not meeting the minimum of 150 minutes of moderate-to-vigorous 
activity per week. These data are not congruent with previous studies that reported 
much higher levels of physical inactivity in South Africa, including the 2003 SADHS 
with use of the same GPAQ questionnaire (200, 361, 383, 437). As reported in 
previous studies, approximately half of the adults had insufficient levels of physical 
activity (200).  
Considering that there is no feasible explanation for the increases in activity levels in 
this population, it is mandatory to interpret these data with caution. It is highly unlikely 
that activity levels would have increased so dramatically, particularly in urban 
environments that are not conducive to encouraging physical activity, and probably 
reflects over-reporting. Numeracy skills as well as assessing the time spent doing 
physical activity may have posed challenges during data collection in this study 
(200).  
In view of the difficulties associated with measuring self-reported physical activity, 
there is a pressing need for a highly reproducible inexpensive and practical tool to 
objectively measure physical activity in South Africa and other developing regions as 
well as the need for a standardised methodological approach to reporting and 
analysing physical activity. While device-based tools such as accelerometers are 
commonly used in epidemiological studies in developed regions, the cost of these 
devices makes their widespread use in South Africa unlikely in the near future. Until 
that time, inconsistencies in self-reported activity levels are likely to continue. 
4.2.1.5. Fat Intake 
There are two distinct dietary patterns in the South African black population, with 
those residing in rural areas still consuming a traditional diet low in fats (<25% of 
energy intake) and sugar, and high in carbohydrates. In contrast, black urban 
residents have adopted a more western diet that is higher in fat consumption (>25% 
















Mean fat intake as a proportion of total energy consumed was similar in men (25.5%) 
and women (25.6%) (Tables 4.5a and 4.5b, p83-84). In men, fat intake was highest 
in the youngest men (28.7%) and decreased with age. Fat intake in women was also 
highest in the youngest women at 26.9% but was lowest in 45-54-year-old women 
(23.2%). The contribution of fat to total energy intake was within the recommended 
range of 15-30% of total energy intake (8). However, this was higher than that 
consumed in traditional diets and suggests that this population is entering the 
transitional phase between a ‘traditional’ diet where <25% of energy is derived from 
fat to a ‘western’ eating pattern where >35% of energy is from fat (193, 439). This is 
particularly true for the younger participants (Tables 4.5a and 4.5b, p83-84); among 
25-34-year-old men and women, 45.6% and 41.7%, respectively, had a high 
proportion (>30%) of fat intake demonstrating their shift away from the healthier 
traditional diets still present in the older study participants.  
The contribution of fat to total energy intake in this study was comparable to the 27% 
reported in this population in 1990 (440), the 24.3-27.7% among residents living in 
informal urban housing and townships in the Transition and Health during 
Urbanisation of South Africans (THUSA) study reported in 2005 (441) and the 21-
30% reported in urban blacks in 1974 (440). This suggests that the proportion of fat 
consumption seems to have remained stable over the past two to four decades. 
Nonetheless, despite the comparable proportions of fat consumed in this and the 
1990 study, it is possible that the absolute quantity of fat consumed may have 
increased during this period. The comparison of these data, however, is beyond the 
scope of this thesis as it forms part of a Master’s dissertation.  
4.2.2. PHYSIOLOGICAL RISK FACTORS 
The physiological CVD risk factors determined included measures of adiposity, 
dysglycaemia, dyslipidaemia and hypertension which each contribute to the overall 
risk for CVD.  
4.2.2.1. Adiposity 
In 2000, 7.0% of mortality in South Africa was attributable to excess body weight, 
with the burden approximately double in women compared to men. BMI ≥21 kg/m2, 
which is considered the optimal mean for health, was responsible for 87% of 
diabetes, 68% of hypertensive disease, 45% of ischaemic stroke and 38% of IHD, 
among other conditions. The proportions of diabetes, CVD and selected cancers 
attributable to excess body weight in South Africa were higher than global estimates, 
















The mean BMI among women in this study was 33.0 kg/m2, in the obese range, and 
approached that of women from Nauru who have the highest mean BMI (35.0 kg/m2) 
in the world (225). Even the youngest women who had the lowest mean BMI, at 31.3 
kg/m2, were generally obese (Table 4.5b, p84).  
Overweight/obesity has reached epidemic proportions, with 82.8% of women in the 
current study either overweight or obese, similar to that reported in a convenience 
sample recruited in the Heart of Soweto Study ‘Heart Awareness Days’ (82%) (442). 
The prevalence of overweight/obesity was lowest in 25-34-year-old women (75.3%) 
and highest in 35-44-year-olds (89.9%); however, the rate of obesity per se was 
highest in 65-74-year-old women (73.5%). The changes in 25-64-year-old women 
reveal that from 1990 to 2008/09, the mean BMI increased from 29.5 kg/m2 to 33.0 
kg/m2 (Table 4.6, p85) and the prevalence of overweight/obesity from 72.7% to 
82.6% (Figure 4.1). This was an increase in overweight/obesity of 13.6%. 
 
Figure 4.1: Prevalence of body mass index ≥25 kg/m
2
 in 25-64-year-old men and women 
in 1990 and 2008/09 
The overweight/obesity prevalence among women in this study is the highest found 
in SAA (Table 4.7, p92) and is even markedly higher than the 64.1% reported among 
≥20-year-old women in the US, a nation where overweight/obesity is known to be 
highly prevalent (231). Moreover, the obesity rate in this study was 1.8 times greater 
than the 35.5% prevalence in American women (231) and considerably higher than 
the global average of 13.8% (225). These data are extremely disconcerting 




































Not only is excess body fat per se, i.e. general adiposity as defined by BMI, 
associated with increased risk, but the distribution of fat also leads to different health 
consequences (182). The distribution of excess fat predominantly in the abdomen 
rather than in the pelvis conveys a significantly higher CVD risk (249). Compared 
with general adiposity, excess fat in the abdominal region is a better predictor of IHD, 
diabetes and other CVDs (204, 318). Of note is that abdominal or visceral adiposity 
also contributes to CVD risk in healthy, non-obese individuals (318). For example, for 
the same level of BMI, the cardiovascular risk may be significantly higher in an 
individual with excess body fat predominantly distributed in the abdomen rather than 
the pelvis or out of proportion to total body fat (249). 
Abdominal obesity, as defined by central adiposity and measured by WC and WHR 
(318), was also high in women (Table 4.5b, p84). At 96.8 cm, mean WC was the 
highest reported in the SSA region, as was the prevalence of raised WC (86.0%) 
when compared to studies using the same cut-off value (Table 4.7, p92). WC was 
reported to be a sensitive marker of insulin resistance in young black women without 
known disease in South Africa and has been shown to be a predictor of CVD risk in 
longitudinal studies in various ethnic groups (443). Therefore, the extremely high 
prevalence of raised WC among women in this study may contribute to high levels of 
dysglycaemia as shown in Section 4.3.6.  
Although the rates of general and central obesity were extremely high, raised WHR, 
an indicator of adipose distribution was present in <50% of women. Almost half of the 
women with overweight/obesity (47.7%) and raised WC (45.7%) did not meet the 
criteria for raised WHR. This suggests that, while these women have high levels of 
adiposity, they have a proportionate distribution of central and peripheral adiposity 
which may confer a lower cardiovascular risk when compared to women with both 
raised WHR and raised BMI or WC.  
The pattern of adiposity among men in this study was vastly different to that found in 
women (Table 4.5a, p83). Not only was mean BMI in men within the normal range at 
23.7 kg/m2, the prevalence of overweight/obesity (28.9%) was significantly lower than 
that in women (p<0.001). Overweight/obesity was least prevalent in the youngest 
(18.5%) and highest in the oldest men (50.0%). The other measures of adiposity in 
men, that is, raised WC rate of 20.1% and raised WHR of 9.2%, were also much 




















 author and year Mean BMI in kg/m
2
 BMI 25-29.9 kg/m
2
, % BMI ≥30 kg/m
2
, % WC in cm Raised WC, % 
 Men Women Men Women Men Women Men Women Men Women 
Benin           
Sodjinou (2008) (395) 23.4 28.1 - - 8.0 28.0 84.4 92.1 - - 
Cameroon            
Fezeu (2006) (444)  24.7 26.7 29.8 32.9 7.0 22.3 83.6 84.8 18.2 66.7 
Kamadjeu ( 2006) (230) 23.4 25.7 21.6 28.6 6.5 19.5 80.0 81.7 13.0 49.2 
Kengne (2007) (445) - - 23.7 28.8 7.5 21.2 - - - - 
Fezeu (2008) (446) 25.0 27.4 30.9 34.5 13.8 27.4 86.6 89.2 48.4 74.3 
Democratic Republic of Congo           
Kasiam Lasi On'kin (2007) (447) 23.4 23.6 - - 12.2 13.3 77.4 77.0 5.6 40.9 
Eritrea            
Usman (2006) (367) - - - - - - - - - 25-30 
Ethiopia           
Tesfaye (2009) (376)  22.3 24.1 18.2 26.9 2.0 10.8 - - - - 
Ghana           
Amoah (2003)
1 
(448) 22.6 25.6 17.5 27.1 4.6 20.2 - - - - 
Hill (2007) (449)  - - - 27.6 - 34.7 - - - - 
Mozambique           
Gomes (2010) (450) - - 16.3 23.0 5.2 16.4 78.8 79.4 - - 
Nigeria            
Ulasi (2010)
2
 (451) - - - - - - - - 16.7 70.7 
South Africa            




23.6 28.4 18.8 25.5 9.6 36.3 80.8 86.9 - - 




23.1 28.1 18.7 27.1 8.1 33.8 78.0 84.6 - - 
BMI: body mass index, WC: waist circumference, raised WC (IDF definition): men >94 cm; women >80 cm   
















The higher prevalence of excess body weight in women than in men is consistent 
with literature from the local national surveys (360, 361) and the SSA region (348, 
357). The reasons for the gender difference are numerous and include socio-
economic, environmental, behavioural and cultural factors. Nutrition deprivation in 
childhood is a risk for obesity in women but not in men (452); the lower caloric 
requirements in women compared to men as a result of their lower occupational and 
leisure time activity levels; and women’s retention of weight gained during pregnancy, 
reported to be more marked among ethnic groups such as African American women 
(453), are likely to be key contributors to excess body weight among women in this 
population.   
The prevalence of overweight/obesity in men, unlike the findings in women, was 
comparable to that found in ≥15-year-old urban black men in the national surveys 
conducted in 1998 (28.4%) (360) and 2003 (26.8%) (361). These rates were also 
within the range of those from other SSA countries where overweight/obesity in 
urban SSA men ranged from 20.2% in Ethiopia to 44.7% in Cameroon (Table 4.7, 
p92). The prevalence of obesity among men in this study, at 10.3%, was comparable 
to the global rate of 9.8% among ≥20-year-old men in 2008 (225).  
Also in stark contrast to women, the prevalence of overweight/obesity in 25-64-year-
old men was lower in 2008/09 (27.7%) than in 1990 (37.3%) (Table 4.6, p85). This 
was unexpected as the evidence from studies in both developed and developing 
regions showed that overweight/obesity usually increased over time, sometimes 
remained constant, but rarely decreased (446). Globally, stable or decreasing BMI 
trends were found only among women in central and Eastern Europe and among 
men in central Africa and south Asia (225). The lower prevalence in 2008/09 in men 
compared to 1990, despite living in an obesity-enabling environment, is difficult to 
explain. However, this may be attributed to the high burden of HIV/AIDS and TB in 
the country. While these conditions affect men and women equally, more women 
may be screened and treated, particularly at antenatal clinics. Men may be more 
reluctant to agree to screening for HIV/AIDS; consequently HIV-infected men not on 
treatment may lose weight compared to HIV-infected women on treatment who 
regain weight lost and are able to maintain a stable weight. However, all individuals 
who replied in the affirmative to the question on HIV status and the use of ART 
during screening were excluded from the current study. Further investigation is 
required to explain the lower current prevalence of overweight/obesity in men 
















Table 4.8a: Glucose, lipid and blood pressure profiles presented by age categories in men 
 Age category in years 
 25-34 (n=121) 35-44 (n=99) 45-54 (n=86) 55-64 (n=58) 65-74 (n=28) Total (n=392) Total
1
  
  S.E.  S.E.  S.E.  S.E.  S.E.  95% CI  95% CI 
Number                
Glucose
2
:                
  mean (mmol/l):               
Fasting glucose  4.8     0.1 4.8    0.1 5.6   0.3 5.6    0.3 6.4   0.7 5.1 4.9 - 5.3 5.2 5.0 - 5.4 
2-hr glucose  5.4    0.3 5.6    0.2 7.3    0.4 7.7     0.6 8.6    0.8 6.2 5.9 - 6.6 6.3 5.9 - 6.7 
  %:               
Impaired fasting glycaemia  0.5           0.5  2.1           1.3 2.6            1.7 1.8                        1.7 0.0 0.0 1.4 0.6 – 3.0 1.4 0.3 - 2.5 
Impaired glucose tolerance  4.7           1.8 8.8           3.0 19.3            4.5 19.1           5.5 21.4           7.6 10.8 8.0 - 14.4 11.2 8.0 - 14.4 
Diabetes mellitus 5.7          2.1 1.9           1.2 17.5           4.3 17.3 5.4 42.9           9.8 10.2 7.5 - 13.8 11.3 8.0 - 14.6 
               
Lipids:               
  Mean:               
Total cholesterol, mmol/l 4.0    0.1 4.4    0.1 4.7    0.1 4.4   0.2 4.8    0.2 4.3 4.2 - 4.4 4.3 4.2 - 4.4 
HDL-C, mmol/l 1.2    0.0 1.4    0.1 1.3    0.1 1.2    0.1 1.2   0.1 1.3 1.2 - 1.3 1.3 1.2 - 1.3 
LDL-C,
 
mmol/l 2.6    0.1 2.7   0.1 3.1    0.1 2.9    0.1 3.3    0.2 2.8 2.7 - 2.9 2.8 2.7 - 2.9 
Triglycerides,  mmol/l  1.1    0.1 1.1    0.1 1.4    0.1 1.5    0.2 1.3    0.1 1.2 1.1 - 1.3 1.2 1.1 - 1.3 
HDL-C:TC,% 29.8   0.7 32.4    1.3 28.1    1.4 28.8    1.4 26.3   1.9 29.8 28.7 - 30.9 29.8 28.7 - 30.9 
  %:                 
Total cholesterol  >5 mmol/l 13.9           3.6 30.4           5.9 38.0 5.8 26.0           6.0 39.3           9.4 25.2 20.0 - 31.3 25.8 20.1 - 31.4 
HDL-C <1.2mmol/l 61.3           4.1 43.2           6.1 55.7           5.9 55.5 6.5 57.1           8.7 55.2 49.9 - 60.4 54.7 49.4 - 60.0 
LDL-C
†
 >3 mmol/l 29.3            4.2 38.0           5.2 51.1           6.1 32.9 6.1 57.1           9.2 37.8 32.5 - 43.4 37.9 32.6 - 43.4 
Triglycerides >1.5 mmol/l 12.4           3.3 22.2 4.6 28.6           5.4 26.6           6.2 32.1           8.7 20.3 16.0 - 25.4 20.6 16.0 - 25.2 
HDL-C:TC
 
<20% 11.6           3.1 2.5    1.3 28.3           5.6 18.5           4.9 28.6           8.9 14.4 10.2 - 18.6 14.4 10.3 -18.4 
               
Blood pressure (BP):               
  Mean (mmHg):               
Systolic BP 122.2     1.6 129.7    2.0 136.8    2.9 146.6    3.6 134.5    4.9 129.7 127.2-132.2 130.2 127.7 - 132.7 
Diastolic BP 76.6    1.1 83.4   1.4 87.4 1.8 86.9    1.7 79.4    2.3 81.4 79.7 - 83.2 81.5 79.8 - 83.2 
  %:               
Hypertension
3
 19.3        3.9 35.8           4.8 58.2          6.3 63.6           6.3 67.9           9.1 37.6 31.8 - 43.7 39.3 33.4 - 45.2 
               
1. Age standardised to the SEGI world population; 2. Glycaemic categories based on 1998 WHO criteria; 3. Hypertension: BP ≥ 140/90 mmHg or using antihypertensive agents    

















Table 4.8b: Glucose, lipid and blood pressure profiles presented by age categories in women 
 Age category in years 
 25-34 (n=235) 35-44 (n=163) 45-54 (n=168) 55-64 (n=92) 65-74 (n=49) Total (n=707) Total
1
 
  S.E.  S.E.  S.E.  S.E.  S.E.  95% CI  95% CI 
Number                
Glucose
2
:               
  mean (mmol/l):               
Fasting glucose  4.8     0.1 5.1   0.2 6.3    0.3 6.1    0.3 6.7   0.5 5.4 5.2 - 5.6 5.5 5.2 - 5.7 
2-hr glucose  5.8    0.2 6.6     0.3 8.8   0.5 8.5    0.5 9.4      0.8 7.0 6.7 - 7.3 7.1 6.8 - 7.5 
  %:               
Impaired fasting glycaemia (IFG) 1.0           0.7 2.2           1.3 0.3               0.3 0.0           0.0           2.0           2.0 1.1 0.5 - 2.4 1.1 0.3 - 1.9 
Impaired glucose tolerance (IGT) 5.2           1.5 10.6                      2.8 18.0   3.1 14.8           4.2 18.4          5.7 10.7 8.4 - 13.4 11.1 8.5 - 13.7 
Diabetes mellitus 5.9           1.5 10.1           2.5 23.3           3.3 26.9          4.5 34.7           6.3 13.8 11.6 - 16.5 14.7 12.1 - 17.3 
               
Lipids:               
  Mean:               
Total cholesterol, mmol/l 4.0    0.1 4.3   0.1 4.8   0.1 5.0    0.1 4.9    0.2 4.4 4.3 - 4.4 4.4 4.3 - 4.5 
HDL-C, mmol/l 1.1 0.0 1.2 0.0 1.2 0.0 1.2 0.0 1.2    0.0 1.1 1.1 - 1.2 1.1 1.1 - 1.2 
LDL-C, mmol/l 2.8    0.0 2.9   0. 1 3.4     0.1 3.5     0.1 3.4   0.2 3.0 3.0 - 3.1 3.1 3.0 - 3.1 
Triglycerides, mmol/l  0.8   0.0 1.1    0.1 1.3    0.1 1.3    0.1 1.4   0.1 1.1 1.0 - 1.1 1.1 1.0 - 1.1 
HDL-C:TC,% 26.6    0.4 27.3    0.7 25.2    0.8 25.6     0.8 27.2   2.8 26.4 25.7 - 27.1 26.4 25.7 - 27.1 
  %:               
Total cholesterol  >5 mmol/l 11.1           2.1 19.5           3.2 38.0           3.7 45.8           5.4 38.8           7.5 23.1 20.0 - 26.5 24.1 20.8 - 27.5 
HDL-C <1.2mmol/l 71.7          3.0 69.3           3.9 61.3           3.8 59.7           5.6 51.0           7.9 66.8 62.9 - 70.5 66.1 62.3 - 69.9 
LDL-C >3 mmol/l 33.5 3.3 41.6 4.0 64.5           3.7 68.8           4.9 73.5           6.4 47.0 43.1 - 50.9 48.3 44.5 - 52.2 
Triglycerides >1.5 mmol/l 5.6           1.5 10.6           2.7 19.0           3.3 25.1           5.0 30.6           5.3 12.5 10.1 - 15.4 13.3 10.6 - 16.0            
HDL-C:TC
 
<20% 17.3           2.5 15.3           3.0 20.7           3.1 27.3           4.9 26.5           5.4 18.9 16.0 - 21.9 19.2 16.3 - 22.1 
               
Blood pressure (BP):               
  Mean (mmHg):               
Systolic BP 111.6   1.0 122.6   1.9 129.6    2.0 137.0  2.6 143.3   4.5 121.6 119.6-123.5 122.7 120.6 - 124.7 
Diastolic BP 76.3   0.8 83.8    1.1 84.9   1.1 87.2    1.4 84.6 1.9 81.1 79.9 - 82.3 81.4 80.2 - 82.6 
  %:               
Hypertension
3
 14.9 2.5 35.4           3.9 60.6           4.0 77.1 4.2 75.5           6.1 37.5 33.7 - 41.4 39.4 35.5 - 43.4 
               
1. Age standardised to the SEGI world population; 2. Glycaemic categories based on 1998 WHO criteria; 3. Hypertension: BP ≥ 140/90 mmHg or using antihypertensive agents   


















In South Africa, diabetes was the 7th most common cause of death in 2000 when 
excess mortality attributable to IHD, stroke, hypertensive and renal diseases were 
taken into consideration (454). Over 20 000 deaths, accounting for 4.3% of all 
mortality, were estimated to be caused by diabetes and a significant proportion (47%) 
occurred in the working-age population aged <65 years. Diabetes morbidity further 
exacerbates the burden of the disease. In South Africa, it is the most common cause 
of non-traumatic amputations, a leading cause of blindness and accounts for a 
significant proportion of end-stage renal disease requiring dialysis and 
transplantation (454). The unacceptably high burden of diabetes can be ascribed to 
late diagnosis and inadequate management of the condition and its predisposing 
factors (245, 250).  
Diabetes Mellitus 
Mean fasting plasma glucose was higher but not significantly so in women (5.4 
mmol/l) than men (5.1 mmol/l) (p=0.069), but the 2-hour glucose was significantly 
higher in women than men (7.0 mmol/l vs. 6.2 mmol/l, p=0.001). The crude and age-
standardised prevalence of diabetes by the SEGI world population was 12.1% (95% 
CI: 10.2-14.0) and 13.1% (95% CI: 11.0-15.1), respectively, with higher rates found in 
women (crude: 13.8%, 95% CI: 11.4-16.3; age-standardised: 14.7%, 95% CI: 12.1-
17.3) compared to men (crude: 10.2% (95% CI: 7.1-13.4); age-standardised: 11.3% 
(95% CI: 8.0-14.6)) (Tables 4.8a and 4.8b, p94-95).  
The age-standardised diabetes prevalence, by the 1985 WHO criteria, was 12.2% 
(95% CI: 10.2-14.2) compared with the 8.0% (95% CI: 5.8-10.3) prevalence found in 
1990 in the same population in those aged >30 years (383). Figure 4.2 demonstrates 
that the diabetes prevalence in 2008/09 was higher for men and women by all age 
categories, except for men aged 35-44 years, than in 1990. 
The age-standardised diabetes prevalence of 13.1% in this study by the 1998 WHO 
criteria was among the highest reported in SSA. Comparable diabetes prevalence 
was only reported in 25-64-year-old adults in Seychelles (11.5%), where about two-
thirds of the population is of predominantly African descent (455). Though, a small 
opportunity sample (n=281) of 17-68-year-old urban Kenyans in whom a 12.2% 
prevalence with a high degree of uncertainty (95% CI: 5.4-23.2) was found, is not 
directly comparable (456). In 1990 too, the prevalence of diabetes was considerably 

















Figure 4.2: Diabetes prevalence based on 1985 WHO criteria presented by age 
categories for men and women in 1990 and 2008/09.  *65+ years: 1990, 65-74 years: 
2008/09 
Another notable finding was the sharp increase in diabetes prevalence in participants 
older than 45 years, peaking in 65-74-year-old men (42.9%) and women (34.7%). 
The steep rise in those older than 45 years has implications for the country’s 
economy with a potential loss of productivity because of diabetes-related morbidity 
and mortality occurring in individuals who are still part of the workforce. The peak 
diabetes prevalence in this study was in keeping with SSA studies with most 
reporting a peak at either 65 years or older, indicating that the effect of ageing of this 
population on diabetes was already evident (243). This is similar to developed 
countries where diabetes occurs predominantly in those ≥65 years (240, 457).  
The low diabetes prevalence in 35-44-year-old men (1.9%) was unexpected and an 
explanation is not readily apparent. It is unlikely to be related to a small number of 
participants in this age group as they numbered approximately 100. However, it is, 
conceivable that this may be a survivor effect, in that those who had AIDS at an 
earlier age have died and this may subsequently reduce the number of individuals at 
risk for diabetes (240). Supporting this theory is death notifications in South Africa 
which indicate that HIV has contributed to mortality, particularly in 35-39-year-old 
men (458).  
Impaired Glucose Tolerance  
The crude and age-standardised prevalence of IGT by the 1998 WHO criteria (10.7% 
















































p94-95) was among the highest found in SSA where IGT has generally been 
reported to be <10% (243, 459). As with diabetes, the prevalence of IGT increased 
markedly in those over 45 years. This demonstrates the increased risk for diabetes in 
the working-age population.  
The age-standardised IGT prevalence, according to the 1985 WHO criteria, rose 
from 7.0% (95%CI: 4.9-9.1) in 1990 (383) to 11.7% (95%CI: 9.8-13.7) in 2008/09. 
Considering that up to 70% of those with IGT may progress to diabetes (456), this 
increase over time may indicate a dramatic rise in future diabetes in this population.  
Impaired Fasting Glucose  
The crude and age-standardised prevalence of IFG was low (1.2% (95%CI: 0.6-1.9) 
and 1.2% (95%CI: 0.6-1.9), respectively) and unexpected (Tables 4.8a and 4.8b, 
p94-95). This underscores the need for the OGTT in epidemiological studies to 
identify those with IGT when estimating future trends in diabetes. IGT and IFG are 
not interchangeable and denote different abnormalities of glucose regulation, one in 
the fasting state (IFG) and one post–prandial (IGT) (239). Their determinants differ 
with raised hepatic glucose output and a defect in early insulin secretion 
characteristic of IFG, while peripheral insulin resistance is most characteristic of IGT 
(460). The low IFG prevalence in this study would be related to low mean fasting 
glucose levels, in accordance with the reported levels from SSA for men and women 
(241). Globally, SSA men had the lowest mean fasting glucose levels, while women 
had the 2nd lowest levels after the high-income Asia-Pacific region.  
This, together with the finding that only 16 (27.1%) of the newly diagnosed diabetic 
participants (n=59) in this study were diagnosed on fasting glucose levels, in keeping 
with previous studies from SSA in which diabetes prevalence rates were lower when 
based only on fasting glucose compared to the OGTT (243, 388), emphasises the 
need for OGTT in epidemiological studies in the region. However, OGTTs are 
cumbersome and inconvenient (461, 462).  
An alternative diagnostic option may be the use of HbA1C, which is convenient as it 
can be performed in the non-fasting state and is much less time consuming than an 
OGTT (242, 462). However, the discordant diagnosis of diabetes with HbA1C and the 
glucose criteria used are of concern (242). Numerous studies have demonstrated a 
lower prevalence of undiagnosed diabetes using HbA1C compared to OGTT criteria. 
The HbA1C criteria have high specificity (>90%) but lower and great variability in 
















from 17% in Australians to 78% in Asian Indians for HbA1C ≥6.5%. The use of 
alternative HbA1C cut-points as well as ethnic-specific cut-points has been proposed.  
Furthermore, the wide adoption of HbA1C as a diagnostic criterion would inevitably 
result in different prevalence estimates to that found with OGTT. The use of different 
methodologies to diagnose diabetes would therefore impact considerably on the 
ability to compare longitudinal changes in dysglycaemia in populations (242). 
Table 4.9: Prevalence of awareness, treatment, control and drug use in men 
and women with diabetes, hypertension and raised low-density lipoprotein 
cholesterol (LDL-C)   
 Total Men Women P 
     
Diabetes mellitus (n=160) 12.1 10.2 13.8 0.099 
% of diabetic participants that were:      
    Aware of diagnosis 57.9 48.2 64.4 0.077 
    Receiving treatment  38.6 31.3 43.5 0.233 
    Receiving combination therapy  22.4 16.6 26.4 0.260 
     
% of diabetic participants on treatment with (n=68):     
Fasting glucose <7 mmol/l 26.8 22.6 28.8 0.619 
     
% of diabetic participants that used:     
     Insulin (A10A) 10.5 8.8 11.7 0.621 
     Oral agents: Biguanides (A10BA) 28.2 17.9 35.0 0.064 
                          Sulphonylureas (A10BB) 25.0 21.1 27.5 0.487 
     
Hypertension (n=461) 37.5 37.6 37.5 0.984 
% of hypertensive participants that were:      
   Aware of diagnosis 52.0 32.7 69.5 <0.001 
   Receiving treatment  39.6 21.9  55.7 <0.001 
   Controlled on treatment  (BP<140/90 mmHg) 22.0 10.4 32.4 <0.001 
     
% of hypertensive participants that used:     
     Diuretics (C03)  35.5 19.4 50.1 <0.001 
     ACE inhibitors (C09AA) 23.5 14.2 31.8 <0.001 
     β-Blockers (C07A) 7.2 4.4 9.8 0.029 
     Calcium channel blockers (C08) 15.8 9.6 21.4 0.001 
     Other (reserpine: C02AA02, hydralazine: C02DB02)  3.6 2.3 4.9 0.182 
     
Raised LDL-C >3 mmol/l or on lipid lowering drugs (n=520) 42.6 37.8 47.0 0.008 
% of these participants that were:      
   Aware of diagnosis 2.6 2.3 2.8 0.703 
   Receiving treatment  2.7 2.0 3.2 0.455 
   Controlled on treatment  (LDL-C ≤3mmol/l) 1.5 0.4 2.3 0.049 


















The prevalence of known diabetes in this study, at 57.9% (Table 4.9), was 
comparable to the 58.8% reported in ≥40-year-old diabetic participants in Nigeria 
(463) and the 54.0% in Seychelles (455). The minimal improvement in the proportion 
of participants with a prior diagnosis of diabetes compared to the 1990 study (52.2%) 
(383) indicates that screening for this increasingly common condition may not be 
receiving the necessary attention. Diabetes awareness and education is also crucial 
to enable regular screening and early detection, especially considering that over 80% 
of those with diabetes in this study were <65 years old.  
The minimally higher prevalence of those with diabetes who were on treatment in 
2008/09 (38.6%) (Table 4.9, p99) compared to 1990 (35%) (383) supports the notion 
that PHC for diabetes is still inadequate. Further, of those on treatment in this study, 
only 26.8% had fasting glucose levels <7.0 mmol/l as recommended by the Society 
for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) (464). 
Reinforcing the suboptimal management of patients with diabetes in this community 
was the low level of controlled diabetes in the public sector community health 
centres. Steyn and colleagues reported that only 42% had non-fasting blood glucose 
levels <11.1 mmol/l (465).  
4.2.2.3. Dyslipidaemia  
A substantial amount of CVD in South Africa can be attributed to non-optimal 
cholesterol levels, resulting in a high proportion of deaths and disability. High 
cholesterol was estimated to cause 4.6% of all deaths in South Africa in 2000. 
Approximately 59% of IHD and 29% of ischaemic stroke burden in ≥30-year-old 
adults were attributable to raised cholesterol (≥ 3.8 mmol/l) with deaths attributable to 
the latter in women double those in men (262).  
Of the so-called racially defined population groups (black, white, coloured and Indian) 
in South Africa, dyslipidaemia affects some groups more than others (389). The 
prevalence in ≥30-year-old adults was lowest in the black population (27.6%) 
compared to the other South African population groups whose rates exceeded 80% 
(262). Even among South Africans with diabetes, black men and women had 
significantly lower mean TC levels compared to their white counterparts (466). The 
black population usually has lower TC and higher HDL-C levels than other 
populations; indicative of a protective pattern against developing atherosclerosis and 
















Mortality attributable to non-optimal TC was only 1.8% in the black population. Most 
of the burden attributable to non-optimal TC was on account of IHD (74.0%-91.4%) in 
the other three population groups compared to the black population, where IHD 
accounted for 58.1% and ischaemic stroke for 41.9%, with approximately similar 
proportions contributing to the burden of raised TC (262).  
In contrast to previous findings, this study reveals that dyslipidaemia was a major 
CVD risk factor in this population. Low HDL-C was the most prevalent dyslipidaemia 
abnormality and more common in women than in men (66.1% vs. 54.7% p<0.001) 
(Tables 4.8a and 4.8b, p94-95). Further, there has been a marked change in the 
prevalence of low HDL-C since 1990, when in 25-64-year-old men and women the 
prevalence was 37.3% and 30.0% (p=0.060), respectively, compared to 55.1% and 
67.7% (p<0.001), respectively, in 2008/09 (Table 4.6, p85). Sumner and colleagues 
state that over the last four decades HDL-C levels have been gradually declining in 
Africa as documented by various studies and may be attributed to urbanisation and 
the attendant changes in BMI, diet and physical activity patterns (467). Although 
lower than the findings in this study, low HDL-C was also the most prevalent 
dyslipidaemia in Ghanaian women (59.1%) (449) and in urban Tanzanian men 
(10.3%) (468).  
The prevalence of low HDL-C peaked in 24-34-year-old men (61.3%) and women 
(71.7%). The trend in men echoed other studies which found that age does not 
appear to be associated with HDL-C levels (469). In women, however, the 
prevalence of low HDL-C decreased with age.  
The higher prevalence of low HDL-C as well as the lower mean HDL-C levels in 
women (1.1 mmol/l) compared to men (1.3 mmol/l) was unexpected considering that 
generally more men than women are identified as having low HDL-C (469) as was 
found in this population in 1990 (Table 4.6, p85 and Figure 4.3c). The causes of low 
HDL-C levels are largely unknown (469) and the reasons for worse HDL-C profiles in 
women compared to men can only be speculated. The considerably higher 
prevalence of overweight/obesity in women may be a contributory factor. On the 
other hand, smoking prevalence, a contributory factor to low HDL-C levels, was 
higher in men than in women. Among African-Americans, higher mean HDL-C levels 
were found in men compared to women and this was thought to be related to a 
genetic/racial predisposition to reduced activities of hepatic lipase (324). 
Among both men and women, an additional contributor to the markedly low HDL-C 
















known to have altered lipid profiles, in particular low HDL-C levels, which are 
exacerbated with ART specifically regimens that contain protease inhibitors (470, 
471). This is especially relevant in South Africa, as the country has the highest 
prevalence of HIV/AIDS in the world with over 30% of the sexually active population 
infected with HIV (472). Although known HIV-infected individuals and those receiving 
ART were excluded from the study, many South Africans are not aware of their HIV 
status. Therefore, it is likely that a proportion of study participants may have been 
HIV-positive.  
       
 a) TC >5.0 mmol/l                                          b) LDL-C >3.0 mmol/l   
        
 c) HDL-C <1.2 mmol/l     d) HDL-C/TC <20% 
Figure 4.3: Prevalence of raise total cholesterol (TC), low high-density lipoprotein 
cholesterol (HDL-C), high low-density lipoprotein cholesterol (LDL-C) and low HDL-C/ 
TC ratio in 25-64-year-old men and women in 1990 and 2008/09 
The prevalence of low HDL-C/TC was also significantly higher in women compared 
to men (18.9% vs. 14.4% p<0.001). Low HDL-C/TC peaked in 65-74-year-old men 
(28.6%) and in 55-64-year-old women (27.3%). 
The steep rise in the prevalence of low HDL-C/TC over the past two decades, with 
rates being 4.5 times higher in women and 2.9 times higher in men in 2008/09 
compared to 1990, is worrying (Table 4.6, p85 and Figure 4.3d). HDL-C/TC has been 
























































parameter, and was more than twice as informative as TC (473, 474). Low HDL-
C/TC was shown to be associated with higher BP, increased triglycerides and 
hyperinsulinaemia; each of these an independent risk factor for CVD (473). The 
additional protective effect of their previously high HDL-C/TC levels against 
atherosclerosis-related diseases in the black population, compared to the other three 
South African population groups (389), is now likely to be reduced.   
Raised LDL-C was the second most common lipid abnormality with rates of 37.8% in 
men and 47.0% in women (p=0.008) (Tables 4.8a and 4.8b, p94-95). Once again, 
the prevalence of raised LDL-C was significantly higher in 2008/09 (men: 36.5%, 
women: 44.5%) compared to 1990 (men: 12.6%, women: 21.2%) among 25-64-year-
old participants (Table 4.6, p85 and Figure 4.3b).  
Despite the significant differences in HDL-C and LDL-C between men and women, 
mean TC levels were comparable at 4.3 mmol/l and 4.4 mmol/l, respectively. Mean 
TC levels and hypercholesterolaemia peaked in 65-74-year-old men and 55-64-year-
old women. The prevalence of hypercholesterolaemia was 25.2% and 23.1% in men 
and women, respectively. Between 1990 and 2008/09, the prevalence of 
hypercholesterolaemia among 25-64-year-old participants remained similar in women 
(21.8% vs. 22.2%) but rose in men (16.7% vs. 24.4%) (Table 4.6, p85 and Figure 
4.3a). 
The markedly higher rates of raised LDL-C and low HDL-C, compared to the lesser 
changes in raised TC, between 1990 and 2008/09 illustrates the importance of 
measuring all the lipid parameters and not just TC, particularly in individuals of 
African descent. If only TC was measured in this study, almost half (48.5%) of the 
participants with raised LDL-C would have been missed and the deterioration in lipid 
profiles from 1990 would have remained unrecognised. Therefore, to accurately 
assess the lipid-related risk for IHD in this population, it would be prudent to focus on 
measuring LDL-C levels (262) as this is the usual target of treatment, along with the 
other lipid components, which are independently related to cardiovascular risk. Other 
studies have also shown that the disadvantage of using only TC as a screening tool 
is that it overlooks specific lipid parameters that are important in determining IHD risk 
(473).  
Previously, the favourable lipid profile has been cited as the reason for the slower 
emergence of IHD compared to stroke among the black South African population, 
despite the presence of other CVD risk factors, particularly hypertension (475). 
















C and low HDL-C levels now prevalent. This may well be a pointer to an eventual 
increase in IHD in this population as raised LDL-C is known to be the driving force for 
atherosclerosis (262, 389, 476). Indeed, a rise in the caseload of IHD in the urban 
black population of South Africa has already been noted (389, 477).   
The treatment of dyslipidaemia is one of the cornerstones of CVD prevention with the 
association of lower blood cholesterol with a reduced risk of IHD demonstrated in 
studies (476). The dyslipidaemic patterns of high levels of LDL-C and/or low HDL-C, 
characteristic of many participants in this study, impart a high risk for developing IHD 
and justify aggressive treatment to reduce cardiovascular risk (262). For every mmol/l 
reduction in LDL-C, mortality is reduced by 10%, all-cause morbidity by 20%, major 
cardiac events by 23% and stroke by 17% (322). Nonetheless, in the current study 
dyslipidaemia is mostly unrecognised and consequently not treated; only 14 
participants (2.6%) were aware of their diagnosis (Table 4.9, p99).  
Of those with raised LDL-C, only 2.7% (n=16) were on treatment and 1.5% (n=10) 
had LDL-C ≤3mmol/l (Table 4.9, p99). The management of dyslipidaemia in South 
Africa has also been shown to be suboptimal in other studies (477-480). Few patients 
in South Africa are treated for hyperlipidaemia with lipid-lowering agents (480) or are 
even aware of their cholesterol status. This particularly evident among participants on 
treatment, where less than half (45.2%; n=7) were aware of their condition, 
highlighting the lack of awareness even among those receiving treatment. The lack of 
awareness of poor lipid profiles would likely translate into a failure to modify lifestyles 
such as diets high in saturated fats and minimal attempts at weight loss, which are 
the cornerstone of management (322). Medication is not a substitute for a healthy 
diet and lifestyle (322, 389, 473) and the emphasis of management is to reduce 
cardiovascular risk by healthy diets and regular exercise (322).  
4.2.2.4. Hypertension 
Studies have demonstrated that hypertension is a strong contributor to CVD in 
individuals of African descent (376) including in South Africa where high BP 
contributes substantially to the CVD burden (481). In the SADHS of 1998, using 
140/90 mmHg as the cut-off, a hypertension prevalence of 21.5% and 25.4% in 
urban black African men and women was reported, respectively (360). In 2000, after 
sexually transmitted diseases, high BP was the second leading risk factor 
contributing to mortality in South Africa. Almost 47 000 deaths or 9% of total mortality 
was attributable to high BP indicating the profound effect of this disease burden on 
















disease and 22% of other CVD burden in ≥30-year-old adults was on account of high 
BP. Moreover, a significant proportion of mortality attributable to high BP occurred in 
those aged <60 years (481).  
Mean systolic BP was higher in men (129.7 mmHg) compared to women (121.6 
mmHg) (p<0.001) but their diastolic BP was similar (81.4 mmHg vs. 81.1 mmHg, 
p=0.750) (Tables 4.8a and 4.8b, p94-95). The crude and age-standardised (SEGI 
world population) prevalence of hypertension was 37.5% (95%CI: 34.2-40.9) and 
39.4% (95%CI: 36.0-42.7), respectively, representing an enormous burden in this 
population. The similar prevalence in men and women (p=0.984) agreed with findings 
in developing regions in a systematic review of 35 countries by Pereira and 
colleagues (281). In contrast, hypertension prevalence in developed regions was 
usually higher in men compared to women.  
However, the hypertension prevalence among men in this study was higher than the 
32.2% shown in developing regions, but comparable to the 40.8% in developed 
countries. The rates in women were also higher than those found in developing 
regions (30.5%) and, unlike in men, higher than that reported in developed regions 
(33.0%) (281). Nevertheless, the high hypertension burden in this population is not 
unique in SSA as demonstrated by high rates in other SAA centres (Table 4.10, 
p106). Higher rates compared to this study were found among 25-64-year-old men in 
Seychelles (44.0%) but rates in their female counterparts were lower (36.0%) (482). 
In the current study, there was a sharp increase in hypertension prevalence in ≥45-
year-old men and women. The peak age for hypertension by sex was in 65-74-year-
old men (67.9%) and in 55-64-year-old women (77.1%) (Tables 4.8a and 4.8b, p94-
95). 
Among 25-64-year-old participants, the hypertension prevalence was much higher in 
2008/09 (35.6%) than in 1990 (21.6%) (Table 4.6, p85). The prevalence in 2008/09 
was significantly higher than in 1990 for men and women but by age category it 
reached significance only in those younger than 45 years (Figure 4.4). 
That the disease burden associated with raised BP is high in South Africa (481), 
notwithstanding the availability of safe and effective treatment, indicates that the 
detection and management of hypertension has been suboptimal. Confirming this 
were the low levels of hypertension awareness, treatment and control found in this 
study, particularly in men. In 2008/09, hypertension awareness, treatment and control 
among participants with hypertension were 32.7%, 21.9% and 10.4% in men, and 
















Table 4.10: Hypertension prevalence, awareness, treatment and control in some SSA countries from population-based studies (urban and 
rural combined except where indicated) 
Country, 1st author and year Hypertension prevalence Awareness among hypertensives Treatment among hypertensives Control among hypertensives 
 Men Women Total Men Women Total Men Women Total Men Women Total 
Benin              
Houinato (2012) (483)   27.9          
Cameroon             
Kamadjeu ( 2006) (300) 25.6 23.1 24.6 - - 23.0 - - 10.8 - - 2.0 
Kengne (2007) (445) - - 20.8 - - - - - - - - - 
Fezeu (2010) (295) 39.6 37.2 - - - - - - - - - - 
Ethiopia              
Tesfaye (2009)
1
 (376) 31.5 28.9 - - - 35.2 - - 11.0 - - <0.1 
Eritrea             
Usman (2006) (367) - - 16.0 - - 20.0 - - - - - - 
Ghana              
Amoah (2003) (448) 27.6 29.5 28.3 - - 34.0 - - 18.0 - - 4.0 
Cappuccio (2004)
2
 (484) 29.9 29.0 28.7 13.9 27.3 22.0 7.8 13.6 11.3 4.4 1.7 2.8 
Agyemang (2006)
1
 (378) 33.4 28.9 - 27.2 44.2 - 22.8 34.9 - 5.1 7.0 - 
Hill (2007)
1
 (449) - 40.2 - - - - - - - - - - 
Mozambique             
Damasceno (2009)
1
 (485) 40.0 41.0 - 15.2 32.2 - <0.1 20.4 - <0.1 0.1 - 
Namibia             
Hendriks (2012)
1
 (486) - - 38.0 - - 38.0 - - 17.0 - - 18.0 
Nigeria             
Adedoyin (2008)
3
 (487) - - 36. 7 - - - - - - - - - 
Seychelles             
Danon-Hersch (2007) (482) 44.0 36.0 40.0 55.0 75.0 64.0 49.0 72.0 59.0 12.0 30.0 20.0 
South Africa              
Department of Health (1999)
4
(360) 21.5 25.4 - 23.7 54.3 - 17.5 35.6 - 8.2 18.7 - 
Tanzania             
Edwards (2000)
1
 (488) 37.3 39.1 - - - 18.0 - - 10.0 - - 0.4 
Bovet (2002)
1
 (489) 27.1 30.2 - 22.8 37.0 31.0 7.6 13.7 11.2 2.6 4.3 6.5 
Hendriks (2012)
1
 (486) - - 23.7 - - 18.0 - - 9.0 - - 5.0 


















Figure 4.4: Prevalence of hypertension presented by age categories (25-64 years) in 
1990 and 2008/09  
The sub-optimal management of hypertension prevailing in this study is a common 
thread in other South African studies. Poor rates of hypertension control of only 18% 
were reported in the African Programme on Genes in Hypertension study in Soweto, 
while approximately 51% of hypertensive patients received treatment (490). In the 
1998 SADHS, rates of hypertension awareness, treatment and control among 
hypertensive urban black men and women were 23.7%, 17.5% and 8.2% vs. 54.3, 
35.6% and 18.7%, respectively (360). In a study among urban black hypertensive 
patients attending Ga-Rankuwa day clinics hypertension control rates of only 41.4% 
were found (491). 
The differentially better management of hypertension in women compared to men 
accounts for the lower systolic BP in women despite the similar hypertension 
prevalence between the sexes in this study. The better hypertension management in 
women is in keeping with findings from the SADHS (360), SSA (Table 4.10, p106) 
and other developing regions (37) as well as developed nations (281). Of interest is 
that this pattern was evident even in populations where hypertension management 
was very poor (485). The likely explanation is that women are more in contact with 
healthcare services because of maternal and child health programmes, and display 
greater health-seeking behaviour resulting in greater chances for BP measurements 










































employment and consequently time constrained from attending healthcare clinics 
during office hours. 
In other regions of SSA, despite an increasing prevalence of hypertension, 
hypertension awareness, treatment and control remains very low in most countries 
(298, 300, 306) with reported rates lower than that found in this study (Table 4.10, 
p106). The lower levels in the region are probably a reflection of more limited access 
to healthcare both in terms of inadequate provision of healthcare services by 
governments and the inability of individuals to pay for healthcare. Along with this is a 
lack of awareness among those with hypertension of the need to treat a condition 
with essentially no symptoms (281, 378, 492-494). 
Two SSA countries with comparable or higher rates of hypertension awareness and 
treatment to this study include Seychelles (482) and Ghana (492). In the former, 
hypertension prevalence was similar to the current study (40.0%), hypertension 
awareness (64.0%) and treatment (59.0%), were much higher but hypertension 
control was equally poor (20.0%) (482). Among Ghanaian civil servants aged 25-68 
years with a hypertension prevalence of 30.3%, the rate of awareness at 54.1% was 
similar to this study, but rates of treatment (31.3%) and control (12.7%) were lower 
(492). The low levels of hypertension management in SAA, including South Africa 
present a serious challenge for the prevention of morbidity and mortality from 
hypertension complications.  
Suboptimal hypertension management is a worldwide problem with inadequate rates 
of hypertension control found in developed and developing regions (281). 
Nonetheless, reports from high-income countries demonstrate that it is possible to 
achieve better hypertension management. While far from optimal, in recent reports 
from the US, the prevalence of hypertension awareness, treatment and control was 
found to be 70%, 59% and 30%, respectively (134). Whereas in the NHANES 2003–
2006 study, rates among African-Americans were 79.5%, 71.8% and 44.6%, 
respectively (495). In each instance these rates were much higher than those found 
in this study. 
Figure 4.5 illustrates the rising prevalence of hypertension awareness, treatment and 
control by age category, with significantly higher rates in older compared to younger 
participants (p<0.001 for all). The highest rates were among 65-74-year-old 
hypertensive participants: awareness: 85.5%, treatment: 75.7% and control: 43.7%. 
The differential hypertension management by age, with better management in older 
















Older participants may utilise healthcare services more frequently resulting in greater 
opportunities for BP testing and may be more adherent with their treatment. Then 
again, healthcare professionals may consider younger individuals to have lower 
cardiovascular risk, compared to older people, and may therefore screen and treat 




Figure 4.5: Prevalence of hypertension awareness, treatment and control presented by 
age categories in men and women with hypertension in 2008/09  
There was no improvement in the rate of hypertension awareness and treatment 
among 25-64-year-old hypertensive men in 2008/09 compared to 1990 (Figure 4.6). 
In fact, even though not statistically significant, their prevalence of hypertension 
















































































(95% CI: 6.3-23.5)). Despite the higher hypertension prevalence in 2008/09, the 
availability of newer medications and increasing awareness of the consequences of 
even mildly elevated BP, the recognition and appropriate management of 
hypertension with optimal BP control remains extremely poor in men.  
 
Figure 4.6: Prevalence of hypertension awareness, treatment and control among 25-64-
year-old men and women with hypertension in 1990 (n=166) and 2008/09 (n=405)  
In contrast, among 25-64-year-old hypertensive women, the prevalence of 
hypertension awareness, treatment and control was higher in 2008/09 compared to 
1990 (Figure 4.6). However, only hypertension control improved significantly: 
2008/09: 31.5% (95% CI: 25.9-37.7); 1990: 14.3% (95% CI: 8.4-23.2).  This may be 
because of the availability of better antihypertensive agents or enhanced compliance 
in that women may be more likely to accept treatment or lifestyle changes more 
readily (492). To identify ways to achieve optimal hypertension treatment and control, 
further research is required to understand the dynamics that differentially influence 
hypertension control in men and women in this population.  
4.2.3. SUMMARY OF THE CARDIOVASCULAR DISEASE RISK FACTOR 
PATTERNS  
Prevalence  
The prevalence of CVD risk factors in the urban black population of Cape Town was 
high and among the highest reported in South Africa as well as SSA. There were 
gender differences with smoking and problem drinking more prevalent in men, and 
dyslipidaemia and overweight/obesity higher in women. Diabetes prevalence was 

















































hypertension and high fat intake were similar by gender. Most risk factors were 
higher in 2008/09 than in 1990, with the exception of smoking and overweight/obesity 
in men, which were lower. The prevalence of self-reported physical inactivity was low 
in men and women, and is likely to have been underestimated.  
Treatment  
The high burden of these CVD risk factors represents a major public health challenge 
because of their magnitude, difficulty in management and associated complications 
and costs. These and other data have demonstrated that prevention, early detection 
and management of CVD risk factors are inadequate (245, 465, 477, 497, 498). The 
management of diabetes and hypertension was suboptimal, while awareness, 
detection and treatment of dyslipidaemias were almost non-existent in this 
population. There are currently no concerted efforts to encourage weight loss or 
smoking cessation through effective community-based programmes.  
Comprehensive multi-facetted intervention strategies are urgently required to combat 
the high levels of CVD risk factors and prevent the predicted CVD epidemic in South 
Africa (387). CVD programmes need to be population-based, culturally appropriate, 
and gender and age-orientated for optimal effectiveness (249). An integrated 
approach is required for the control of all major risk factors and the reduction of total 
cardiovascular risk; the treatment of each risk factor must be seen within the broader 
framework of CVD prevention (306, 322). 
4.3. ASSOCIATIONS AMONG CARDIOVASCULAR DISEASE RISK 
FACTORS  
The importance of determining the variables associated with each CVD risk factor is 
to gain a better understanding of the dynamics related to the development of CVD. 
Additionally, a combination of risk factors markedly increases the risk for CVD, as will 
be discussed later in this chapter. 
In the multiple logistic models, the three psychosocial measures were entered 
independently for all risk factors discussed. The models with SOC are presented in 
the tables. The association of the other psychosocial variables with the CVD risk 
factors are also presented at the bottom of the table and any changes in the direction 
of association of the other variables in the models have been noted.  
The psychosocial variable SOC was modelled as a continuous or categorical variable 
with different cut-points based on the association demonstrated between SOC and 
















controlled for in the best way possible which meant different cut-points for different 
outcomes.  
4.3.1. Smoking  
Figure 4.7 illustrates the prevalence of the physiological CVD risk factors by smoking 
status. The prevalence of diabetes (14.7 vs. 5.2, p<0.001), high LDL-C (46.7% vs. 
31.8%, p<0.001) and overweight/obesity (70.6% vs. 22.1%, p<0.001), but not 
hypertension (38.9% vs. 34.0, p=0.247) was significantly higher in those who did not, 
compared to those who did, smoke daily. This may be because fewer women 
smoked but had higher rates of overweight/obesity, raised LDL-C and diabetes 
compared to men.  
 
Figure 4.7: Prevalence of diabetes, raised LDL-C, hypertension and overweight/obesity 
presented by presence or absence of daily smoking in 25-74-year-old adults in 2008/09  
The multiple logistic models examined the associations of socio-demographic and 
psychosocial variables with smoking ≥1cigarette/day (Table 4.11, p113). Age and 
asset index were entered as continuous variables while urbanisation was defined as 
having spent ≥50% of one’s life in the city. SOC was defined as low, moderate and 









































Table 4.11: Multiple logistic regression models for socio-demographic associations with behavioural risk factors of smoking, problem 
drinking and physical inactivity  
 Smoke ≥1cigarette/day (n=241) Problem drinking: CAGE ≥2 (n=318) Physical activity <150 min/week (n=77) 
 Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value 
  Lower limit Upper limit    Upper limit  Lower limit   Upper limit Lower limit  
Age (years): decreasing  1.04 1.02 1.06 0.001 1.02 1.00 1.49 0.106 - - - - 
                     increasing  - - - - - - - - 1.04 1.02 1.06 0.001 
Sex: male 12.31 8.41 18.01 <0.001 4.98 3.62 6.86 <0.001 0.88 0.54 1.43 0.607 
Education: ≤7 years 1.65 1.06 2.57 0.027 - - - - 1.14 0.64 2.05 0.652 
                  >7 years - - - - 1.61 1.05 2.47 0.030 - - - - 
Urbanised: ≥50% life in city  1.98 1.28 3.06 0.002 1.80 1.23 2.64 0.003 0.82 0.50 1.34 0.423 
Work: Employed 1.00    1.00    1.00    
          Unemployed  1.29 0.82 2.05 0.271 1.72 1.06 2.78 0.029 1.83 0.73 4.56 0.193 
          Pensioners 1.24 0.53 2.92 0.614 0.76 0.37 1.59 0.469 1.87 0.70 4.97 0.209 
          Other * 1.14 0.52 2.52 0.745 1.34 0.67 2.70 0.401 0.89 0.21 3.76 0.873 
House:  Informal shack 1.00    1.00    1.00    
             Council/core house/hostel 1.40 0.89 2.22 0.144 1.12 0.74 1.70 0.579 0.30 0.12 0.73 0.009 
             Built formal unit (private) 0.90 0.48 1.70 0.745 1.43 0.81 2.52 0.222 1.01 0.54 1.90 0.973 
Decreasing asset index: 1.09 1.01 1.17 0.032 1.10 1.02 1.18 0.015 1.01 0.91 1.12 0.850 
Sense of coherence (SOC): Low 1.00    1.00    1.00    
                                              Moderate 0.63 0.40 0.99 0.045 0.78 0.52 1.19 0.255 0.99 0.48 2.01 0.970 
                                              High  0.66 0.44 0.98 0.038 0.52 0.34 0.78 0.002 1.61 0.83 3.13 0.155 
             
Increasing locus of control (LOC)** 0.99 0.93 1.06 0.831 0.95 0.90 1.00 0.068 1.02 0.94 1.12 0.632 
             
Increasing number of adverse life events**  1.01 0.94 1.08 0.829 1.14 1.08 1.21 <0.001 0.86 0.77 0.97 0.016 
             
*Other: housewives, disabled, students.  **When LOC and adverse life events independently replaced SOC in above models, there were no changes in the 
















Men were more likely to smoke than women (odds ratio (OR): 12.31, 95% CI: 8.41-
18.01, p<0.001). Smokers were more likely to be younger rather than older (OR: 
1.04, 95% CI: 8.41-18.01, p=0.001). This indicates that despite comprehensive 
tobacco control measures in the country smoking uptake has not been adequately 
curtailed. Participants who had spent ≥50% of their lives in urban areas, compared to 
those who had spent less, were more likely to be daily smokers (OR: 1.98, 95% CI: 
1.28-3.06, p=0.002), in accordance with the higher rates of smoking in urban 
compared to rural areas reported in the SADHS (420).  
The poorer and less educated participants in this study smoked significantly more 
than their counterparts. The odds for smoking increased with declining wealth (as 
defined by the asset index) (OR: 1.09, 95% CI: 1.01-1.17, p=0.032) and in those with 
≤7 years of education compared to more educated participants (OR: 1.65, 95% CI:  
1.06-2.57, p=0.027). This was in line with the national surveys (420), the THUSA 
study (499), SSA studies (153), and with 74 studies from high-, medium- and low 
income economies, which showed that poorer men (according to income, education 
or profession) were more likely to smoke, regardless of each economy’s level of 
development (13). The concentration of smoking in individuals with lower socio-
economic status may be attributable to a lack of awareness of the health hazards of 
smoking among these less educated and poorer individuals (153, 164).  
Compared to participants in the lowest SOC tertile, those with moderate (OR: 0.63, 
95% CI:  0.4-0.99, p= 0.045) and high (OR: 0.66, 95% CI:  0.44-0.98, p= 0.038) SOC 
scores were significantly less likely to smoke. Current smokers compared to former 
or never smokers also had lower SOC by the 3-item SOC questionnaire in a British 
study (138). It is possible that those with higher SOC scores and less psychosocial 
stress may more easily resist smoking uptake or find smoking cessation easier. 
4.3.2. Alcohol Use   
Figure 4.8 illustrates the prevalence of the physiological CVD risk factors by CAGE 
scores. There was no trend by CAGE scores for any CVD risk factor; however, 
diabetes, raised LDL-C and overweight/obesity were much higher in participants with 
no CAGE components compared to those with any combination of components. This 
may be because of the lower likelihood of women consuming alcohol but having 
significantly higher rates of overweight/obesity and raised LDL-C as well as diabetes 


















Figure 4.8: Prevalence of diabetes, raised LDL-C, hypertension and overweight/obesity 
presented by CAGE scores for problematic alcohol intake in 25-74-year-old adults in 
2008/09  
The multiple logistic models examined the associations of socio-demographic and 
psychosocial variables with problematic alcohol intake defined as CAGE ≥2 (Table 
4.11, p113). The continuous variables were age and asset index, as were LOC and 
adverse life events in their respective models. Among the categorical variables were 
urbanisation defined as having spent ≥50% of one’s life in the city and SOC defined 
in tertiles of low, moderate and high. 
Similar to the pattern for smoking, in the model with SOC, men were more likely than 
women to be problem drinkers (OR: 4.96, 95%CI: 3.62-6.86, p<0.001) as were 
unemployed (OR: 1.72, 95%CI: 1.06-2.78, p=0.029), poorer (OR: 1.10, 95%CI: 1.02-
1.18, p=0.015) but better educated (OR: 1.61, 95%CI: 1.05-2.47, p=0.030) 
participants, compared to their employed, wealthier  and less educated counterparts, 
respectively. A review by Henkel that found risky alcohol consumption (associated 
with hazardous, binge and heavy drinking) was more prevalent among the 
unemployed (500) confirmed findings in this study. In a recent study in Finland, a 
significant association between prolonged unemployment and risky alcohol intake 
was also found (501). The association of poverty with problematic alcohol intake 
speaks to the relative low real price of alcohol in South Africa, with easy access to 
alcoholic beverages likely contributing to easier uptake and over-indulgence (432).  
The significant association of higher education level with problem drinking in men 

































no significant difference in unemployment level (p=0.832) among men with no 
education (58.9%), 1-7 years of education (60.6%), 8-12-years education (61.4%) 
or a tertiary education/diploma (52.0%). The higher odds for problem drinking 
among more educated men may possibly be related to greater frustration at being 
unemployed. In the model with adverse life events, the association of education with 
problem drinking was no longer significant (OR: 1.49, 95% CI: 0.97-2.28, p=0.067).  
Participants who had spent more than half their lives in the city were more likely to be 
problem drinkers than participants who had spent less (OR: 1.80, 95%CI: 1.23-2.64, 
p=0.003). Urbanisation is accompanied by a unique set of advantages and 
disadvantages with rapid and often unplanned urban growth frequently found to be 
associated with poverty and alcoholism (502). 
Unemployment, poverty and urban living are likely to be associated with psychosocial 
stress, which may also predispose individuals to problematic alcohol intake. 
Supporting an association between psychosocial stress and problem drinking in this 
study was the finding that participants with high SOC, and thus less stress, were 
about half as likely to be problem drinkers (OR: 0.52, 95% CI: 0.34-0.78, p=0.002) 
compared to those with low SOC. Similarly, in the model with adverse life events, 
participants who experienced greater adversity (and consequently more stress) were 
also more likely to be problem drinkers (OR: 1.14, 95% CI: 1.08-1.21, p<0.001).  
4.3.3. Physical Activity 
Figure 4.9 illustrates the prevalence of the physiological CVD risk factors by levels of 
physical activity. Although the absolute level of activity seems to have been 
overestimated in this study, as pointed out earlier, the expected protective impact of 
the highest levels of physical activity is observed in these data. Diabetes was least 
prevalent in participants who spent ≥1000 minutes on moderate to vigorous physical 
activity/week compared to those who spent less (p=0.041), although there was no 
clear pattern by activity levels. The prevalence of hypertension decreased with rising 
levels of physical activity and was most prevalent among the least (53.6%) compared 
to the most active (33.0%) (p=0.013). Overweight/obesity decreased, but not 
significantly, with increasing physical activity levels and there was no pattern by 

















Figure 4.9: Prevalence of diabetes, raised LDL-C, hypertension and overweight/obesity 
presented by physical activity levels (minutes of moderate to vigorous activity per 
week) in 25-74-year-old adults in 2008/09  
The multiple logistic models examined the associations of socio-demographic and 
psychosocial variables with <150 minutes of physical activity per week (Table 4.11, p 
113). In their respective models, SOC was entered as a categorical variable while 
LOC and adverse life events as continuous variables. In the model with SOC, older 
age (OR: 1.04, 95% CI: 1.02-1.06, p=0.001) was significantly associated with 
physical inactivity as would be expected. Participants who lived in council houses or 
hostels were less likely to be inactive (OR: 0.29, 95% CI: 0.12-0.71, p=0.007) 
compared to those living in informal areas. In the multiple logistic model where 
adverse life events replaced SOC, participants who had experienced a greater 
number of adverse events were less likely to be inactive after adjusting for the other 
factors (OR: 0.86, 95% CI: 0.77-0.97, p=0.016). 
4.3.4. Fat Intake 
Figure 4.10 illustrates the prevalence of the physiological CVD risk factors by dietary 
fat intake as a proportion of diet. The prevalence of diabetes was lowest in 
participants with dietary fat intake comprising <10% of diet compared to those with 
higher intake but there was no trend with rising fat intake. Raised LDL-C and 
overweight/obesity increased with rising fat intake although these were not 
significant.  
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Figure 4.10: Prevalence of diabetes, raised LDL-C, hypertension and 
overweight/obesity presented by proportion of dietary fat intake in 25-74-year-old 
adults in 2008/09  
The observation that overweight/obesity was prevalent in half the participants that 
reported <10% intake of dietary fat is in keeping with the findings of Kruger and 
colleagues from the THUSA study conducted in the North-West Province, South 
Africa. They found high rates of overweight/obesity with relatively low fat intake 
among black women (390). These data suggest that overweight/obesity can occur 
even with relatively low fat intakes with other factors contributing to the development 
of the condition. Nonetheless, difficulties in obtaining accurate dietary data from a 
free-living population cannot be excluded (390). Ideally at least three dietary intake 
data should be documented, instead of a single intake as obtained in this study.  
The multiple logistic models examined the associations of low physical activity, and 
socio-demographic and psychosocial variables with a high fat diet (Table 4.12, p119). 
The continuous variables entered were age, asset index and the psychosocial 
variables in their respective models. Urbanisation was defined as having spent ≥65% 
of one’s life in the city. In the models, fat intake comprising ≥30% of the diet was 
significantly associated with younger age (OR: 1.02, 95% CI: 1.01-1.04, p=0.003), 
which may be related to a differential generational response to social and economic 
changes, in the model with SOC. Younger individuals may adopt new dietary 
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Table 4.12: Multiple logistic regression model for socio-demographic 
associations with high fat intake  













Decreasing age (years) 1.02 1.01 1.04 0.003 
Sex: female 1.04 0.76 1.42 0.800 
Physical activity <150 minutes/week 0.90 0.49 1.67 0.743 
Urbanised: ≥65% life in city 1.42 1.05 1.92 0.024 
Education >7 years 1.67 1.12 2.49 0.013 
Work: Employed 1.00    
          Unemployed  1.05 0.73 1.51 0.780 
          Pensioners 0.89 0.46 1.72 0.725 
          Other*  1.28 0.74 2.21 0.378 
House:  Informal shack 1.00    
             Council/core house/hostel 1.14 0.77 1.70 0.503 
             Built formal unit (private) 1.10 0.68 1.77 0.706 
Increasing asset index  1.09 1.02 1.16 0.014 
Decreasing sense of coherence (SOC) 1.02 1.01 1.03 0.034 
     
Increasing locus of control (LOC)** 0.98 0.93 1.04 0.577 
     
Increasing number of adverse life events**  1.06 1.01 1.12 0.020 
     
*Other: housewife, student, disabled  
**When LOC and adverse life events independently replaced SOC in above model, there were no changes 
in the direction or significance of the other variables  
Spending ≥65% of life in urban centres (OR: 1.42, 95% CI: 1.05-1.92, p=0.024), >7 
years of education (OR: 1.67, 95% CI: 1.12-2.49, p=0.013) and increasing wealth 
(OR: 1.09, 95% CI: 1.02-1.16, p=0.014) were also significantly associated with high 
fat intake. The association of urbanisation with high fat intake was in keeping with the 
1990 study conducted in this population which found a positive association between 
the proportion of life spent in urban settings and increasing dietary atherogenicity 
(440). Urbanisation and socio-economic advancements are known to be associated 
with westernisation of lifestyles and increased uptake of energy-dense foods high in 
fats (227). These foods are likely to be more affordable to individuals with higher 
socioeconomic status (the affluent and better educated) but may still be out of the 
price range of lower socio-economic groups, particularly in developing regions (503). 
A lower SOC, indicative of higher psychosocial stress, was significantly associated 
with high fat intake (OR: 1.02, 95% CI: 1.01-1.03, p=0.034). In the model where 
















was significantly associated with high fat intake after adjusting for the other factors 
(OR: 1.06, 95% CI: 1.01-1.12, p=0.020). Seeing that many factors impact on food 
choices and methods of preparation (439), it is possible that individuals with higher 
stress levels may not have the time or the inclination to cook healthier meals and 
therefore select easy-to-prepare foods and snacks which are high in fats.  
4.3.5. Adiposity 
Figure 4.11 illustrates the prevalence of the physiological CVD risk factors by BMI 
categories. Obesity is known to markedly increase the risk of diabetes, hypertension 
and dyslipidaemia (233) and the higher prevalence of these conditions in participants 
with overweight/obesity was as expected. The observed higher prevalence of these 
physiological CVD risk factors in overweight/obese participants together with the 
marked rise in overweight/obesity over the last two decades, as discussed in Section 
4.2.2., suggest that these diseases are likely to increase in the future.  
 
Figure 4.11: Prevalence of diabetes, raised LDL-C and hypertension presented by BMI 
categories (kg/m
2
) in 25-74-year-old adults in 2008/09  
The multiple logistic models examined the associations of physical activity, fat intake, 
and socio-demographic and psychosocial variables with raised BMI, central obesity 
and raised WHR (Table 4.13, p122). The categorical variables included high fat 
intake defined as ≥30% of diet, and asset index and SOC in tertiles. Urbanisation 
was entered as a continuous variable as were LOC and adverse life events in their 
respective models. The association of older age with all measures of adiposity in the 









































BMI in women in the THUSA study (390). The increased odds in women compared to 
men for all measures of adiposity were expected and the reasons for this association 
have been discussed in Section 4.2.2. 
The richest compared to the poorest participants, as defined by the asset index, were 
significantly more overweight/obese by all measures of adiposity in the models with 
SOC: BMI ≥25 kg/m2: OR: 4.33, 95% CI: 2.55-7.33, p<0.001, raised WC: OR: 3.29, 
95%CI: 1.74-6.22, p<0.001, raised WHR: OR: 1.92, 95% CI: 1.15-3.21, p=0.013. This 
is in keeping with other South African studies where socio-economic status defined 
by various measures including education, occupation, income and household 
amenities was related to increased BMI (390, 497, 499) as well as with studies from 
many SSA countries (227, 348, 395, 444, 503, 504). In contrast, in developed 
regions, there is an inverse relationship between overweight/obesity and measures of 
socio-economic status (227, 230, 444, 450). The positive relationship between 
overweight/obesity and asset index in this study population is suggestive of the early 
stages of the nutrition transition. Excess weight initially presents among the affluent 
before progressively shifting to lower-income groups, as has been demonstrated in 
middle-income developing and developed countries at later stages of the 
epidemiologic and nutrition transitions (395, 505).  
High dietary fat intake was associated with overweight/obesity defined by raised BMI 
(OR: 1.46, 95% CI: 1.05-2.04, p=0.026) but not raised WC (OR: 1.41, 95% CI: 0.95-
2.09, p=0.087) or raised WHR (OR: 1.12, 95% CI: 0.79-1.58, p=0.520). This confirms 
the observations of Kruger and colleagues, who found a significant association 
between fat intake and BMI, but not WC, in black South African women in the 
THUSA study (390). That dietary fat intake is usually positively related to body weight 
(390) is probably because fats compared with protein or carbohydrates have a higher 
caloric density (223). Nonetheless, it must be noted that high fat intake is not a proxy 
for high energy consumption and does not promote overweight/obesity independently 
of total energy intake (390).  
The measures of psychosocial stress were not related to adiposity except in the 
model with raised WHR and SOC. The least stressed participants, as represented by 
the highest SOC tertile, were approximately half as likely as those with the lowest 
















Table 4.13: Multiple logistic regression models for associations with adiposity: overweight/obesity, raised waist circumference and 
raised waist-to-hip ratio 
 Overweight/Obesity: BMI ≥25 kg/m
2
 Waist: men >94 cm; women >80 cm  Waist-to-hip ratio men >1.0; women >0.85 
 Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value 
  Lower limit Upper limit    Upper limit  Lower limit   Upper limit Lower limit  
Increasing age (years) 1.05 1.03 1.07 <0.001 1.06 1.04 1.08 <0.001 1.07 1.05 1.09 <0.001 
Sex: female 17.42 11.81 25.70 <0.001 39.41 24.90 62.38 <0.001 13.36 9.17 19.47 <0.001 
Fat intake ≥30% of diet 1.46 1.05 2.04 0.026 1.41 0.95 2.09 0.087 1.12 0.79 1.58 0.520 
Physical activity <150 minutes/week 0.95 0.45 2.00 0.894 1.26 0.58 2.74 0.564 0.84 0.45 1.59 0.592 
Education: <7 years 0.79 0.50 1.27 0.333 1.06 0.58 1.95 0.844 1.12 0.75 1.69 0.573 
Increasing urbanisation  1.00 0.99 1.00 0.261 1.00 0.99 1.00 0.34 1.00 1.00 1.01 0.735 
Work: Employed 1.00    1.00    1.00    
          Unemployed  0.64 0.39 1.03 0.067 0.68 0.37 1.25 0.216 1.32 0.93 1.88 0.121 
          Pensioners 0.81 0.31 2.09 0.660 0.92 0.36 2.40 0.871 0.68 0.29 1.57 0.362 
          Other*  0.54 0.24 1.19 0.127 0.77 0.28 2.12 0.616 2.38 1.13 5.03 0.023 
House:  Informal shack 1.00    1.00    1.00    
             Council/core house/hostel 0.83 0.53 1.32 0.433 0.91 0.56 1.47 0.697 0.42 0.27 0.65 0.000 
             Built formal unit (private) 0.95 0.58 1.57 0.843 0.88 0.51 1.51 0.634 0.66 0.38 1.15 0.144 
Asset index: 1st (poorest) 1.00    1.00    1.00    
                        2
nd
 2.13 1.42 3.19 <0.001 2.09 1.27 3.43 0.004 1.39 0.98 1.97 0.062 
                        3
rd
 (richest) 4.33 2.55 7.33 <0.001 3.29 1.74 6.22 <0.001 1.92 1.15 3.21 0.013 
Sense of coherence (SOC): Low 1.00    1.00    1.00    
                                                   Moderate 1.16 0.75 1.81 0.499 0.98 0.59 1.62 0.923 0.76 0.45 1.29 0.311 
                                                  High  1.29 0.86 1.96 0.221 1.10 0.71 1.72 0.663 0.58 0.40 0.84 0.004 
             
Increasing locus of control (LOC)** 1.05 0.98 1.12 0.18 1.08 0.99 1.17 0.082 0.98 0.92 1.04 0.547 
             
Higher number of adverse life events** 1.00 0.93 1.07 0.990 0.99 0.92 1.08 0.850 1.00 0.95 1.05 0.882 
             
*Other: housewife, student, disabled;  
















The lack of association between urbanisation and any measure of adiposity in this 
study was surprising, but may be related to the definition of urbanisation as the 
proportion of life spent in the city, which is a blunt proxy. There is, however, no 
international agreed definition on how urbanisation should be measured (401). 
The lack of association between urbanisation and adiposity may also reflect the 
rapidity with which new migrants to the city adopt unhealthy lifestyle behaviours that 
predispose to adiposity. In Tanzania, declines in physical activity, dietary changes 
and weight gain in rural migrants occurred within six months to a year of arrival in the 
city (363, 506). Furthermore, with frequent population flows between urban and rural 
areas, lifestyle habits may be changing with uptake of unhealthier diets and 
sedentary lifestyles that contribute to obesity occurring even in rural settings. 
The lack of association between physical inactivity and adiposity was contrary to the 
expected beneficial effect and reiterates the importance of using an objective 
instrument to ascertain activity levels rather than the self-reported measure used in 
this study. Nevertheless, if found to be valid, these findings may suggest that 
physical activity at levels reported in this study may not influence the risk of obesity 
and will have implications for strategies to reduce overweight/obesity in this 
population (507). While greater physical activity should be encouraged, obesity 
control programmes should encompass interventions beyond promoting primarily 
physical activity; nutritional interventions may be of greater benefit than increasing 
the intensity or duration of physical activity.  
4.3.6. Diabetes Mellitus 
Other CVD risk factors are known to cluster with diabetes and accords with the 
higher prevalence in this study of overweight/obesity, hypertension and raised LDL-C 
in participants with, compared to those without, as illustrated in Figure 4.12. In 
addition to hyperglycaemia, these factors exacerbate the development of 
atherosclerosis and macro-vascular complications in diabetes (257, 269).  
Survey multiple logistic regression analysis was used to determine the independent 
associations of diabetes with the psychosocial factors, adjusting for a set of 
modifiable (physical inactivity, fat intake, BMI, waist and hip circumference) and non-
modifiable (family history, age, sex and urbanisation) risk factors for diabetes as well 
as a socioeconomic confounder, housing type.  Gender-specific models were done 
due to substantial differences in associations. To fully account for the known risk 
factors in the survey model, the non-linearity of their associations was investigated by 
















quadratic terms were added in the survey model for BMI and urbanisation for 
females. The waist and hip measurements as well as their ratio were highly 
correlated with BMI (r>0.85) and hence only BMI was retained in the models to avoid 
multicollinearity. The three psychosocial measures were modelled independently as 
continuous variables. SOC demonstrated a non-linear association with diabetes in 
women (significant cubic term) and cut-points were selected to mimic this pattern so 
as to enable statistical interpretation.  Gender specific cut-points were used for SOC 
and are indicated in the text and in Tables 4.14a and 4.14b, p125-126. 
 
Figure 4.12: Prevalence of overweight/obesity, raised LDL-C and hypertension 
presented by presence or absence of diabetes in 25-74-year-old adults in 2008/09 
The importance of age as a relevant risk factor for diabetes in SSA and elsewhere  
(243) is in keeping with this study findings where age was shown to be independently 
associated with diabetes. In the multivariate logistic regression analyses (Table 
4.14a, p125), older age was significantly associated with diabetes in men (OR: 1.05, 
95% CI: 1.02-1.08, p=0.002) and women (OR: 1.05, 95% CI: 1.03-1.08, p<0.001) in 
the models with SOC. 
A positive family history of diabetes was associated with diabetes in women (OR: 
3.13, 95% CI: 1.92-5.12, p<0.001) but not in men (OR: 1.09, 95% CI: 0.51-2.32, 
p=0.829). This gender difference may be related to a lack of awareness in men or to 
the small number of men with diabetes (n=45). A positive family history of diabetes 
was reported to be an independent risk factor for the disease in rural South Africa 







































Table 4.14a: Multiple logistic regression models for associations with diabetes in women and men (model with body mass index 
(BMI)) 
Variables Women (n=115) Men (n=45) 
 Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value 
  Lower limit Upper limit    Lower limit Upper limit   
Increasing age (years) 1.05 1.03 1.08 <0.001 1.05 1.02 1.08 0.002 
Family history of diabetes (yes) 3.13 1.92 5.12 <0.001 1.09 0.51 2.32 0.829 
BMI: linear (kg/m2)  1.48 1.20 1.82 <0.001 1.10 1.04 1.18 0.003 
        quadratic (kg/m2)2 0.995 0.992 0.998 0.001 NA - - - 
Moderate to vigorous physical activity(<150 min/week) 1.99 0.90 4.42 0.090 NA - - - 
Moderate to vigorous physical activity (min/week) N/A - - - 1.00 0.98 1.02 0.734 
Dietary fat intake (%) 1.01 0.99 1.03 0.554 0.99 0.97 1.01 0.403 
Urbanisation: linear (% of life in city) 1.04 0.98 1.10 0.111 1.00 0.99 1.01 0.552 
                     quadratic (% of life in city)
2
 1.00 0.99 1.00 0.130 N/A - - - 
Housing Type: Informal shack/other 1.00    1.00    
                       Council/core house/hostel 1.56 0.86 2.86 0.144 2.28 0.98 5.33 0.057 
                       Built formal unit (private) 1.75 1.01 3.04 0.047 1.24 0.54 2.86 0.613 
Sense of coherence score (SOC): scored ≤40  2.57 1.37 4.80 0.003 NA - - - 
                                                     scored ≤68 N/A - - - 2.18 0.49 9.64 0.301 
         
Increasing locus of control (LOC) 1.03 0.95 1.12 0.450 1.07 0.93 1.22 0.354 
         
Increasing number of adverse life events 1.00 0.96 1.03 0.857 1.02 0.98 1.06 0.448 
         
N/A: this factor is not applicable for the gender specific model. Men: quadratic terms for BMI and urbanisation not used in the model. Physical activity used as a continuous 
variable in men because too few had <150 min/week of activity. Gender specific cut-points used for SOC score. When LOC and adverse life events independently replaced 

















Table 4.14b: Multiple logistic regression models for associations with diabetes in women and men (model with waist circumference) 
Variables Women (n=115) Men (n=45) 
 Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value 
  Lower limit Upper limit    Lower limit Upper limit   
Increasing age  (years) 1.05 1.03 1.07 <0.001 1.04 1.01 1.08 0.016 
Family history of diabetes (yes) 3.06 1.87 5.02 <0.001 1.09 0.51 2.36 0.821 
Waist circumference: linear increase (till 110 cm)  1.29 1.09 1.51 0.003 1.04 1.01 1.07 0.004 
                                quadratic (cm)
2
 0.999 0.998 0.999 0.006 NA - - - 
Moderate to vigorous physical activity(<150 min/week) 1.94 0.85 4.44 0.116 NA - - - 
Increasing moderate to vigorous physical activity (min/week) N/A - - - 1.00 0.98 1.02 0.734 
Increasing dietary fat intake (%) 1.01 0.99 1.03 0.520 0.99 0.97 1.01 0.423 
Urbanisation: linear increase (% of life in city) 1.05 0.99 1.10 0.096 1.00 0.99 1.01 0.547 
                     quadratic (% of life in city)
2
 1.00 0.99 1.00 0.111 N/A - - - 
Housing Type: Informal shack/other 1.00    1.00    
                       Council/core house/hostel 1.72 0.93 3.20 0.084 2.29 0.98 5.39 0.057 
                       Built formal unit (private) 1.85 1.06 3.24 0.030 1.28 0.56 2.93 0.560 
Sense of coherence score (SOC): scored ≤40  2.67 1.42 5.02 0.002 NA - - - 
                                                   scored ≤68 N/A - - - 2.18 0.49 9.84 0.306 
         
N/A: this factor is not applicable for the gender specific model. Men: quadratic terms for waist circumference and urbanisation not used in the model. Physical activity used as a 
















The high prevalence of diabetes and IGT in this study may be attributed to the high 
rate of some diabetes risk factors, in particular overweight/obesity. Raised adiposity, 
the most potent of the risk factors (249), was present in ≥50% of the total study 
sample, and in over 80% of participants with diabetes when measured by BMI ≥25 
kg/m2. This is concordant with reports from the Study to Help Improve Early 
evaluation and management of risk factors Leading to Diabetes (SHIELD) and the 
National Health and Nutrition Examination Surveys (NHANES) in the US that found 
≥75% of those with diabetes were overweight/obese (508). In 2000, in South Africa,  
94% of the diabetes burden in women and 75% in men was attributable to BMI ≥21 
kg/m2 (229). Centralisation of fat, as evidenced by WC and WHR, was also common 
in the whole sample and higher in those with compared to those without diabetes.  
Of note is that both increasing BMI and WC were associated with diabetes in the 
regression analyses for men and women. In the model with SOC for women, higher 
BMI levels were significantly associated with diabetes (OR: 1.48, 95% CI: 1.20-1.82, 
p<0.001) reaching a plateau after 30 kg/m2 while in men the odds were 1.10, 95% CI: 
1.04-1.18, p=0.003.  
When WC replaced BMI in the model with SOC, the odds for diabetes with higher 
WC in women, after adjusting for the other factors (age, family history, physical 
activity, dietary fat intake, urbanisation and housing type), was 1.29, 95% CI: 1.09-
1.51, p=0.003; the risk increased till 110 cm then remained high (Table 4.14b, p126). 
When WC replaced BMI in the model with SOC for men, the risk for diabetes, after 
adjusting for the other factors, increased 4.0% for every centimetre around the waist 
(OR: 1.04, 95% CI: 1.01-1.07, p=0.004). There was no change in the significance or 
direction of the other variables in either of these models. The association of adiposity 
with diabetes in this study is in agreement with findings from other South African 
studies, including the last diabetes prevalence study conducted in this community in 
1990 (383, 388), as well as most SSA studies (243).  
In men, although overweight/obesity was significantly associated with diabetes in this 
study, other factors are likely to have also contributed to the higher diabetes 
prevalence in 2008/09 compared to 1990 given the marked fall in overweight/obesity 
prevalence during this period. Factors such as foetal and early life nutritional status, 
diet quality and physical activity may possibly have contributed to the higher diabetes 
prevalence in men (241). Metabolic changes induced by HIV/AIDS may be worth 
considering as another potential influencer of glucose levels in view of its high 
prevalence in South Africa although known HIV positive individuals were excluded 
















include inflammation and viral factors, among other influences, while ART causes 
insulin resistance and decreased insulin secretion (509).  
The lack of an overall significant association between low physical activity levels and 
diabetes in the regression models was unexpected and may reflect over-reporting of 
activity as discussed earlier in Section 4.2.1.4. This reiterates the need for an 
objective measure of physical activity.  
The absence of a significant independent association between high fat intake and 
diabetes in men and women may be attributed to the use of a single rather than 
multiple 24-hour dietary recall assessments that should ideally be obtained to 
improve accuracy when collecting data in free-living populations (390). Nonetheless, 
as already mentioned, high fat intake is not a proxy for high energy consumption.  
Urbanisation was, surprisingly, not associated with diabetes in the regression models 
for men or women. The reasons may be similar to that discussed for the absence of 
an association between urbanisation and adiposity in Section 4.3.5., namely, the 
‘bluntness’ of the proxy used for urbanisation and the rapid adoption of unhealthy 
lifestyle behaviours. Other SSA studies have found higher rates of diabetes in urban 
compared to rural areas (243, 250).  
Housing was used as a proxy for urbanisation in the model for diabetes as most 
newcomers to urban areas usually lived in informal shacks (475) and participants 
living in built formal units were likely to be more urbanised. In the regression analysis, 
diabetes was significantly associated with women living in the built formal housing 
compare to those living in informal housing (OR: 1.75, 95% CI: 1.01-3.04, p=0.047) 
(Table 4.14a, p125). Better quality housing may also be an indicator of higher socio-
economic status and suggests the increased likelihood of diabetes among more 
privileged women. 
In the multiple logistic models with SOC, women with SOC scores ≤40 had an 
increased risk for diabetes (OR: 2.57, 95% CI: 1.37-4.80, p=0.003). The crude 
diabetes prevalence in women with low SOC was 27% (18-39%, observed 
frequency: 21/70) compared to 13% (11-16%, observed frequency: 94/615) in 
women with higher scores. In the model for men, however, SOC was not related to 
diabetes: SOC ≤68: OR: 2.18, 95% CI: 0.49-9.64, p=0.301 (Table 4.14a, p125).  
The association of low SOC with diabetes in women in this study was similar to that 
reported in 35-56-year-old women in Sweden (120). It has been postulated that 
individuals with low SOC may be more likely to lead unhealthy lifestyles, thereby 
















SOC and WC or BMI, reported in Table 4.13, as well as the absence of an 
association between SOC and high fat intake (Table 4.12, p119) suggests that SOC 
may exert an independent risk for the development of diabetes. Other factors related 
to low SOC such as higher chronic stress and inadequate coping skills have been 
suggested to also contribute to the association with diabetes (115). 
As this is a cross-sectional study, no causal relationship can be assumed between 
SOC and diabetes in women. Local cohort studies investigating the development of 
diabetes in individuals with high stress are needed to further our understanding of the 
association of psychosocial stress with diabetes. If proved instrumental in the 
development of diabetes in this setting, optimal diabetes care will ideally need to 
include approaches to tackle these psychosocial influences. Strengthening SOC in 
women may possibly play a role in attempts to curtail the rising diabetes prevalence 
(136). 
Although there was no relation between SOC and diabetes in men, similar to that 
reported in the Stockholm Diabetes Prevention Program study (120), this may 
possibly be because of the small number of men with diabetes (n=45) in the current 
study. A cohort study in Finland reported a 46% higher risk of diabetes in men with 
low SOC who were ≤50 years old on entry into the study (136). Interestingly, the 
Copenhagen City Heart Study, which used different stress measures, found that 
while stress was not associated with diabetes at baseline, stressed men were more 
than twice as likely to develop diabetes during follow-up compared to men with low 
stress (118). 
4.3.7. Raised Low-Density Lipoprotein Cholesterol  
Other CVD risk factors were shown to cluster with raised LDL-C; participants with 
LDL-C ≥3 mmol/l had significantly higher rates of adiposity, dysglycaemia and 
hypertension. Figure 4.13 demonstrates the higher prevalence in participants with, 
compared to those without, raised LDL-C of overweight/obesity (70.6% vs. 47.3%, 
p<0.001), diabetes (17.1% vs. 8.6%, p<0.001) and hypertension (47.4% vs.30.2%, 
p<0.001).  
The multiple logistic models examined the associations of age, sex, BMI, fat intake, 
physical activity and psychosocial variables with LDL-C ≥3 mmol/l. Apart from sex 
and high fat intake, the socio-demographic variables were modelled as continuous 
variables as were the three psychosocial measures which were modelled 
independently. In the model with SOC for raised LDL-C (Table 4.15, p131), older age 
















p<0.001). Therefore, with demographic changes and ageing of this population raised 
LDL-C will likely increase in the future. 
 
Figure 4.13: Prevalence of overweight/obesity, diabetes and hypertension presented by 
presence or absence of LDL-C ≥3 mmol/l in 25-74-year-old adults in 2008/09 
Increasing BMI correlated positively with raised LDL-C (OR: 1.03, 95%CI: 1.01-1.05, 
p=0.004) and is in line with the relationship between obesity and LDL-C reported in 
the THUSA study conducted in another South African province (441). The link 
between adiposity and dyslipidaemia is an important one with dyslipidaemia found to 
progressively develop with BMI ≥21 kg/m2 (205). The significant association between 
BMI and raised LDL-C also suggests that the higher obesity levels in 2008/09 
(36.8%) compared to 1990 (26.4%), and attributable to the higher prevalence in 
women, may have contributed to the worsening lipid profile in this population.  
Another significant variable associated with raised LDL-C was high fat intake (OR: 
1.37, 95%CI: 1.01-1.85, p=0.042) which strengthens the importance of dietary 
modifications to improve lipid profiles. A recent analysis of the impact of dietary 
trends on TC in Sweden over 25 years showed that changes in dietary fat intake 
resulted in parallel shifts in TC levels with increased fat intake correlating with higher 
TC levels (510). Other studies have also reported the association of dietary fat intake 
with TC including the Dietary Approaches to Stop Hypertension (DASH) trials (205).  
Variables not associated with raised LDL-C included sex, physical inactivity, 
urbanisation, problematic alcohol use and the psychosocial stressors. The absence 
of an association between physical activity and raised LDL-C is in agreement with 
findings from other studies (206). The evidence suggests that regular physical activity 
may increase LDL-C particle size but there is no significant reduction in LDL-C levels 







































Table 4.15: Multiple logistic regression model for associations with raised low-
density lipoprotein cholesterol (LDL-C) 
Variable 





95% Confidence Interval p-value 
  Lower limit Upper limit   
Increasing age (years) 1.04 1.03 1.05 <0.001 
Sex: female 1.16 0.83 1.61 0.384 
Increasing BMI (kg/m
2
) 1.03 1.01 1.05 0.004 
Fat intake ≥30% of diet 1.37 1.01 1.85 0.042 
Increasing moderate to vigorous 
activity (min/week) 1.00 0.99 1.00 0.158 
Increasing urbanisation 1.00 1.00 1.01 0.503 
Increasing sense of coherence 
(SOC) 1.00 0.98 1.01 0.516 
     
Increasing locus of control (LOC)* 1.03 0.99 1.09 0.639 
     
Increasing number of adverse life 
events* 
1.03 0.97 1.08 0.327 
     
*When LOC and adverse life events independently replaced SOC in above model, there were no 
changes in the direction or significance of the other variables 
4.3.8. Hypertension  
 
Figure 4.14: Prevalence of overweight/obesity, diabetes and raised LDL-C presented by 
presence or absence of hypertension in 25-74-year-old adults in 2008/09 
The clustering of the physiological CVD risk factors is a common theme shown 
earlier for overweight/obesity, diabetes and raised LDL-C, and now for hypertension 








































higher (p<0.001) in participants with compared to those without hypertension. 
Hypertension rarely occurs in isolation and the association with other CVD risk 
factors increases the overall risk for CVD and contributes to its progression (486, 
511). The association of various CVD risk factors with hypertension conforms with 
reports from other SSA populations (357, 486, 512, 513) and South Africa (514).  
Table 4.16: Multiple logistic regression model for associations with 
hypertension  













Age category: ≤30 years 1.00    
                       31-40 years 3.30 1.79 6.07 <0.001 
                       41-50 years          7.71 4.13 14.38 <0.001 
                       51-60 years 19.51 10.55 36.07 <0.001 
                     >60 years   23.68 11.57 48.47 <0.001 
Sex: female 0.85 0.56 1.30 0.444 
Family history of hypertension: yes 1.49 1.10 2.03 0.011 
Increasing BMI (kg/m
2
) 1.04 1.02 1.07 0.002 
Moderate to vigorous physical activity:  
                                               <150 min/week 
1.00    
                      150-500 min/week 0.52 0.31 0.87 0.012 
                                               500-1000 min/week 0.47 0.25 0.88 0.018 
                            >1 000 min/week 0.41 0.24 0.69 0.001 
% life in city: <50%   1.00    
                     50-90% 1.62 1.13 2.34 0.010 
                     90-100% 1.55 1.04 2.31 0.033 
Problem drinking : CAGE ≥2  1.50 1.05 2.16 0.027 
Current smoking : daily/occasionally  0.96 0.61 1.51 0.855 
Sense of coherence (SOC): higher  1.02 1.01 1.04 0.011 
     
Locus of control (LOC)*: higher 0.98 0.93 1.04 0.509 
     
Number of adverse life events*: higher 1.00 0.98 1.02 0.810 
     
*When LOC and adverse life events independently replaced SOC in above model, there were no 
changes in the direction or significance of the other variables 
The multiple logistic models examined the associations of the potential predisposing 
factors, including psychosocial stress, with hypertension. Cut-points for variables 
















based on the smoothed values shown in the fractional polynomials. The three 
psychosocial measures were modelled independently as continuous variables.  
In the three models for hypertension, where the psychosocial variables were entered 
independently, the model with SOC is shown in Table 4.16, p132. Similar to the 1990 
study (392), older participants were more likely to have hypertension; the odds of 
being hypertensive in >60-year-old participants were 23.68, 95% CI: 11.57-48.47, 
p<0.001 compared to those ≤30 years old. The well-known association of increasing 
age with hypertension or BP in SSA studies (357, 378, 445, 482, 489, 492, 504, 515-
522) is highly relevant in the region, and particularly in South Africa, because future 
increases in hypertension will likely be fuelled by demographic shifts towards older 
age following better medical care and the control of infectious diseases, especially 
HIV/AIDS.  
The association of a positive family history of hypertension, present in this study, is 
well established (OR: 1.49, 95% CI: 1.10-2.03, p=0.011).  
The risk for hypertension with higher BMI rose 4.0% for every unit increase in BMI 
(OR: 1.04, 95% CI: 1.02-1.07, p=0.002) and accords with the well-documented 
strong association between BP and body weight reported in various populations 
(482) including in developing regions (37), SSA (286, 295, 378, 445, 449, 482, 489, 
492, 504, 515-522) and South Africa including the 1990 study (392, 514). Indeed, 
68% of hypertensive disease in South Africa was attributable to BMI ≥21 kg/m2 in 
2000 (229).  
Higher mean BMI among women in 2008/09 compared to 1990 (33.0 kg/m2 vs. 29.5 
kg/m2) was likely an important contributor to their higher hypertension prevalence in 
2008/09. Similarly, rising BMI levels were also associated with hypertension and 
increasing BP in Cameroon over a 10-year period (295). Even in men, participants 
with hypertension had significantly higher mean BMIs (30.4 kg/m2) than those without 
hypertension (27.5 kg/m2) (p<0.001), reinforcing the relationship between higher BMI 
and hypertension. 
However, despite the much lower levels of overweight/obesity in men compared to 
women, their prevalence of hypertension was similar; comparable to findings in rural 
South Africa where men were slimmer than women but had same BP levels (523). 
Given that the mean BMIs in men were similar in 2008/09 (23.6 kg/m2) and 1990 
(24.3 kg/m2), other hypertensive risk factors probably contributed to their rising 
hypertension prevalence during this period. The contributors to hypertension are 
















consumption in 2008/09 than in 1990; problematic alcohol intake was present in 
about half (49.7%) of all the men in this study. However, direct comparison of 
problematic alcohol use between the current and the 1990 study was not possible 
owing to the different measures used to assess alcohol intake. Nonetheless, it must 
be noted that factors not examined in this study, such as high salt intake, may be 
responsible for the high hypertension prevalence. Numerous studies support the 
concept that salt consumption is the major factor contributing to increasing BP in 
populations (37, 307) with black individuals reported to be particularly sodium 
sensitive (37, 284). Overconsumption of salt is responsible for up to 30% of all cases 
of hypertension (80).  
In line with the known linear relationship between alcohol consumption, BP levels 
and hypertension (524), problematic drinking, as defined by CAGE ≥2, was 
significantly associated with hypertension (OR: 1.50, 95% CI: 1.05-2.16, p=0.027). 
Other SSA countries reporting a significant direct association between alcohol intake 
and hypertension or BP included Uganda (517), Seychelles (482) and Ghana (men 
only) (378) although others have reported no association (519). The absence of an 
association may be as a result of an inaccurate ascertainment of alcohol intake as 
many individuals are reluctant to reveal this history. This may likely have contributed 
to the absence of a relationship between alcohol intake and hypertension in the 1990 
study (392).  
Compared to physically inactive participants (<150 minutes/week of moderate to 
vigorous activity), those with higher activity levels were approximately half as likely to 
have hypertension; the odds with >1 000 minutes/week of activity was 0.41, 95% CI: 
0.24-0.69, p=0.001. This was in keeping with the well-known inverse association of 
physical activity with hypertension (525) and also reported in the THUSA study where 
overweight/obese women with moderate activity levels had lower systolic BP levels 
compared to inactive overweight/obese women (437).    
Participants who had spent more than half their lives in urban centres, compared to 
those who had spent less, had a greater likelihood of having hypertension: 50-90% of 
life spent in city: OR: 1.62, 95% CI:  1.13-2.34, p=0.010; >90% of life spent in city: 
OR: 1.55, 95% CI:  1.04-2.31, p=0.033. In addition to reports from other South 
African studies including the 1990 study (392, 514), this finding was consistent with 
the available literature from SSA (353, 357, 378, 395, 484, 488, 504, 516) and other 
developing regions where urbanisation is considered to be a key driver of the 
















inevitable increase in urbanisation and the adoption of unhealthy lifestyles the future 
hypertension prevalence in this population will likely rise (516, 521). 
The positive association of higher SOC (OR: 1.02, 95% CI: 1.01-1.04, p=0.011), an 
indicator of lower stress, with hypertension was unexpected and may be attributable 
to the complex relationship between psychological stress and hypertension (96). 
Additionally, psychosocial stress is difficult to define objectively and consists of 
several different (and inter-related) elements resulting in the measurement of stress 
being complex and difficult (90). Reinforcing this, is that when LOC (OR: 0.98, 95% 
CI: 0.93-1.04, p=0.509) and adverse life events (1.00, 95% CI: 0.98-1.02, p=0.810) 
replaced SOC in their respective models, neither were related to hypertension after 
adjusting for the other factors. Further research, including longitudinal studies, is 
required to identify a suitable psychosocial instrument to assess the association 
between stress and hypertension in this population. 
4.3.9. Summary of the Interrelationships among Cardiovascular Disease Risk 
Factors 
The salient findings include the independent correlation of older age and adiposity 
with diabetes, raised LDL-C and hypertension. Regarding gender, being male was 
significantly related to smoking and problem drinking, while being female was 
associated with all measures of adiposity. Smoking and problem drinking were more 
prevalent in poorer participants whereas high fat intake and all measures of adiposity 
were correlated with wealth. Urbanisation was significantly associated with 
hypertension and the unhealthy behaviours of smoking, problem drinking and high fat 
consumption but not diabetes. Measures of psychosocial stress were independently 
associated with diabetes, raised WHR, smoking, problem drinking and high fat 
intake. Unexpectedly, lower stress was related to hypertension. These associations 
need to be interpreted with care because the associations between the variables in a 
cross-sectional study such as this do not imply causality.  
Should psychosocial factors be found to be instrumental in the development of 
diabetes and other CVD risk factors in this population in future cohort studies,  
educating high-risk individuals to cope with the stressors may be beneficial in 
reducing the incidence of CVDs (111).  
4.4. METABOLIC SYNDROME  
As was shown in the previous sections, individuals are highly likely to have more 
than one CVD risk factor; because of the subsequent greater risk for macro- and 
















patients for other CVD risk factors if one is present (45). Clustering of the cardio-
metabolic risk factors commonly occur in the MS, a multiplex risk factor for 
atherosclerotic CVD (324). 
There are minimal data available on the prevalence of MS in South Africa, 
particularly according to the JIS criteria. Using the ATPIII criteria, MS was present in 
31% of 30-60-year-old non-diabetic corporate executives (526) and in 33.5% of non-
diabetic participants in Guguletu (527).  
The prevalence of the MS in this study, particularly among women, was high and 
reflected the high rates of CVD risk factors in this population (Table 4.17, p137). The 
crude and age-standardised rates of the MS were 30.7% and 31.7%, respectively, 
much higher than the age-standardised prevalence of 22.1% reported in rural South 
Africans using the same criteria (331). The current prevalence was comparable to the 
30.3% age-standardised prevalence of the MS by the JIS criteria reported in 25-64-
year-old adults in Seychelles (528) and the crude rate of 34.6% in ≥18-year-old 
Kenyans living in Nairobi (335). 
Reports from some other SSA countries showed a low MS prevalence of <10% by 
various criteria (359, 529, 530). However, rates ≥10.0%, using the IDF criteria, were 
found in urban Benin (11.0%) (530), Nigeria (15.9%) (451), urban Ethiopian bankers 
and teachers (17.9%) (531) and Seychelles (30.3%) (528). 
Crude and age-standardised rates were significantly higher among women (43.5% 
and 44.9%, respectively) than men (16.5% and 17.3%, respectively) (p<0.001) 
(Table 4.17, p137). Even in the multiple logistic models, the odds for women having 
the MS were much higher than for men: OR: 5.29, 95% CI: 3.48-8.04, p<0.001 
(Table 4.18, p138). So too was the MS more common in women (25.0%) than in men 
(10.5%) in rural South Africa (331). In the Kenyan study, while the prevalence of the 
MS was comparable to this study among women (crude: 40.2%), the prevalence in 

















Table 4.17: Metabolic syndrome prevalence and total cardiovascular disease risk scores using the Framingham laboratory and non-
laboratory risk estimates  
 Age category in years 
 25-34 35-44 45-54 55-64 65-74 Total Total* 
  S.E.  S.E.  S.E.  S.E.  S.E.  95% CI  95% CI 
Men  n= 121 n= 99 n= 86 n= 58 n= 28 n= 392 n=392 
Metabolic syndrome, % (any 3+ variables) 8.3 2.6 9.2 3.3 28.1 5.5 32.4 6.6 42.9 9.3 16.5 12.7 - 21.2 17.3 13.4-21.9 
               
Framingham CVD risk using lipid profiles: n=118 n=98 n=78 n=51 n=24 n=369 n=369 
    Mean, SE 2.4 0.2 5.1 0.3 15.3 1.3 23.9 2.0 38.9 3.3 9.0 7.7-10.3 10.1 8.5-11.7 
    Moderate (10-19.99), % 1.1 1.1 4.7 2.0 37.4 5.6 31.5 7.0 16.7 7.7 12.2 9.2-16.0 12.7 9.7-16.5 
    High (≥20), % 0.0 0.0 0.0 0.0 24.2 5.3 55.9 7.6 83.3 7.7 13.0 9.9-17.0 15.6 11.9-20.2 
Framingham CVD risk using BMI:               
    Mean, SE 3.0 0.2 7.0 0.4 18.6 1.4 29.9 2.1 43.8 3.7 11.1 9.6-12.6 12.3 10.5-14.1 
    Moderate (10-19.99), % 1.1 1.1 19.3 4.4 41.1 6.3 29.3 6.2 12.5 6.8 16.2 12.6-20.7 16.7 13.0-21.2 
    High (≥20), % 0.0 0.0 0.0 0.0 39.9 6.4 70.7 6.2 87.5 6.8 17.4 13.8-21.8 20.2 16.1-25.0 
               
Women  n= 235 n= 163 n= 168 n= 92 n= 49 n= 707 n=707 
Metabolic syndrome, % (any 3+ variables) 21.7 2.8 46.6 4.2 66.4 3.9 74.3 4.3 67.4 6.3 43.5 39.2 - 47.9 44.9 40.5-49.3 
               
Framingham CVD risk using lipid profiles: n=230 n=153 n=150 n=82 n=41 n=656 n=656 
    Mean, SD 1.1 0.1 3.1 0.2 9.2 0.7 15.6 1.4 23.8 2.6 5.4 4.7-6.1 6.1 5.3-7.0 
    Moderate (10-19.99), % 0.0 0.0 2.1 1.0 19.2 3.6 33.8 5.5 26.8 6.9 8.3 6.3-10.9 9.4 7.2-12.2 
    High (≥20), % 0.0 0.0 0.0 0.0 9.5 2.6 23.7 4.9 48.8 7.5 6.1 4.6-8.0 7.6 5.7-10.0 
Framingham CVD risk using BMI:                
    Mean, SE 1.3 0.1 4.0 0.3 11.3 0.9 20.5 1.8 30.7 3.0 6.8 5.9-7.7 7.7 6.6-8.8 
    Moderate (10-19.99), % 0.5 0.5 2.6 1.3 23.9 3.9 37.0 5.7 34.2 7.2 10.3 8.2-12.8 11.5 9.3-14.2 
    High (≥20), % 0.0 0.0 1.2 0.9 14.7 3.2 32.8 5.6 53.7 7.0 8.4 6.4-10.9 10.1 7.8-12.9 
               
*Age standardised to the SEGI world population; S.E: standard error; CI: confidence interval   
Participants with a self-reported history of IHD (n=42) or stroke (n=40) were excluded from the Framingham risk estimates; Non-laboratory CVD risk scores used BMI instead 

















Table 4.18: Multiple logistic regression models for associations with the metabolic syndrome and high Framingham risk scores  
 Metabolic Syndrome (n=406) Laboratory-based risk scores ≥20% (n=114) Non-laboratory-based scores ≥20% (n=152) 
 Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value Odds Ratio 95% Confidence Interval p-value 
  Lower limit Upper limit    Upper limit  Lower limit   Upper limit Lower limit  
Increasing age 1.07 1.05 1.09 <0.001 - - - - - - - - 
Sex: female 5.30 3.48 8.06 <0.001 - - - - - - - - 
Education: <7 years 1.15 0.74 1.81 0.534 2.47 1.57 3.90 <0.001 2.36 1.48 3.77 <0.001 
Increasing urbanisation  1.00 1.00 1.00 0.927 - - - - - - - - 
% life in city: <50%   - - - - 1.00        
                     50-90% - - - - 1.97 1.12 3.46 0.018 2.23 1.33 3.73 0.002 
                     90-100% - - - - 0.91 0.47 1.77 0.791 1.01 0.57 1.80 0.973 
Work: Employed 1.00    1.00        
          Unemployed  0.73 0.47 1.15 0.174 2.05 1.03 4.07 0.042 2.06 1.13 3.74 0.018 
          Pensioners 0.76 0.38 1.52 0.431 16.58 8.22 33.42 <0.001 14.28 7.34 27.78 <0.001 
          Other  1.18 0.56 2.47 0.662 1.82 0.60 5.53 0.288 2.73 0.90 8.31 0.076 
House:  Informal shack/other 1.00    1.00        
             Council/core house/hostel 0.97 0.67 1.41 0.876 1.92 1.16 3.17 0.011 1.69 1.06 2.68 0.028 
             Built formal unit (private) 1.24 0.80 1.91 0.342 1.93 1.07 3.48 0.028 1.90 1.16 3.11 0.011 
Asset index: 1st (poorest) 1.00    1.00        
                        2
nd
 1.64 1.10 2.44 0.015 0.66 0.41 1.07 0.092 0.65 0.41 1.03 0.066 
                        3
rd
 (richest) 1.90 1.17 3.07 0.009 0.96 0.52 1.79 0.900 1.17 0.68 2.02 0.562 
Increasing sense of coherence 
(SOC) 1.02 1.01 1.03 0.049 1.00 0.98 1.02 0.845 1.00 0.98 1.02 0.841 
             
Increasing locus of control (LOC)* 1.07 1.01 1.14 0.028 0.96 0.90 1.03 0.243 0.94 0.88 1.01 0.110 
             
Higher number of adverse life 
events* 1.00 0.95 1.06 0.981 1.03 0.95 1.11 0.513 1.02 0.96 1.10 0.476 
             
















The higher prevalence of MS in women has been reported in several SSA countries 
(335, 528, 530, 531) as well as in African-Americans (324, 330). However, non-
African-Americans (324, 330) and other developed nations do not demonstrate a 
clear trend for the MS between the sexes (324, 528). The reason for the clear gender 
differences in the MS rates in SSA and African-Americans may be related to cultural 
values and positive social attitudes toward fatness (335), which will be discussed in 
Chapter 5. 
The key contributing factors to the higher MS prevalence in women compared to men 
was central obesity (86.0% vs. 20.1%) and low HDL-C (75.0% vs. 33.4%) (Figure 
4.15). These were also the most prevalent of the MS components in women in the 
rural South African (331) and urban Kenyan studies (335), and were associated with 
an increased prevalence of the MS in African-American women. This may reflect a 
sex-specific effect of overweight/obesity on glucose homeostasis, lipid profiles and 
atherosclerosis (532).  
 
Figure 4.15: Prevalence of the metabolic syndrome components in men and women  
Metabolic syndrome traits: Raised waist: men ≥94cm, women ≥80cm; raised triglycerides: >1.7 mmol/l; 
Low HDL-C: men <1.0 mmol/l, women <1.3 mmol/l; hypertension: BP ≥130/85 mmHg or on 
hypertension treatment; dysglycaemia: raised fasting glucose ≥5.6 mmol/l or on diabetes treatment.  
In men, the most frequent component of the MS was raised BP (51.4%) (Figure 4.15) 
and, notwithstanding the different prevalence, was also most prevalent in rural South 
Africa (331) and urban Kenya (335). Low HDL-C and central obesity were the 













































The high prevalence of the MS in women is of concern; even the youngest women 
had rates >20.0% whereas in men only those ≥45 years of age had rates over 20.0% 
(Table 4.17, p137). Younger women with MS are at a significantly higher risk of MI 
compared with younger and older men (533). Furthermore, the association between 
MS and CVD death was reported to be more than two-fold higher in women as in 
men, possibly on account of the stronger diabetes-CVD association in women (532).  
While the MS prevalence was different in men and women, the pattern by age group 
was similar. The lowest rates were in the youngest participants while the oldest 
participants, aged 65-74 years, had the highest MS prevalence (men: 42.9%, 
women: 67.4%). Also, in the multiple logistic model with SOC, MS was significantly 
associated with increasing age (OR: 1.07, 95% CI: 1.05-1.09, p<0.001) (Table 4.18, 
p138). The changing demography with ageing populations in South Africa will 
probably result in higher rates of the MS in the future. Also fuelling the escalation of 
the MS may be the widespread use of ART and the high prevalence of HIV/AIDS in 
South Africa (248).   
The odds for the MS were higher in the wealthier compared to the poorest 
participants; middle tertile: OR: 1.64, 95% CI: 1.10-2.44, p=0.015, richest tertile: OR: 
1.89, 95% CI: 1.16-3.07, p=0.011. This reflected the pattern demonstrated in Section 
4.3.5 for adiposity with wealth.  
In their respective models, both higher SOC (OR: 1.02, 95% CI: 1.01-1.03, p=0.048) 
and higher LOC (OR: 1.07, 95% CI: 1.01-1.14, p=0.029), representing lower 
psychosocial stress, were significantly associated with the MS after adjusting for the 
other factors. These associations were unexpected and with no plausible explanation 
apparent. Longitudinal studies are needed to delineate the nature and direction of the 
relationship between psychological stress and the MS over time. 
While the merits of the MS in clinical practice may be argued, it undoubtedly 
highlights the clustering of cardiovascular risk factors and underscores the need for a 
comprehensive and integrated approach to tackle CVD. This also reiterates the 
importance of total CVD risk assessment and the need to determine other CVD risk 
factors if a single risk factor is present.  
4.5. TOTAL CARDIOVASCULAR DISEASE RISK ASSESSMENT 
The conventional single risk factor approach with each CVD risk factor managed as a 
distinct entity unrelated to the other risk factors often results in an unacceptably high 
risk of cardiovascular events. This is because of suboptimal control, as shown in this 
















prevention warrants a paradigm shift from the treatment of single risk factors in 
isolation to the management of total cardiovascular risk (44) with an improvement in 
the profile of all risk factors that will lead to the development of CVD.  
Guidelines for individual-based interventions now recognise the multi-factorial 
involvement of CVD risk factors and screen for those at high risk for CVD on the 
basis of multiple risk factors (5). The South African Heart Association (SA Heart) and 
the Lipid and Atherosclerosis Society of Southern Africa (LASSA) (322) as well as 
the Southern African Hypertension Society (SAHS) in conjunction with the National 
Department of Health (DOH) (400) have adopted a cardiovascular risk stratification 
approach. In the absence of locally validated total CVD risk assessment tools and 
seeing that the Framingham risk scores have been validated in white and black 
populations and are transportable to other culturally diverse populations, this 
approach was considered more appropriate for local use than, for example, the 
European guidelines whose scoring system is based on an exclusively European 
population (322).  
The age-standardised mean 10-year risk for a CVD event, estimated using the 
laboratory-based lipid profiles, was 10.1% in men, significantly higher than in women 
(6.1%) (p<0.001) (Table 4.17, p137). This difference is a function of the equation 
which allocates greater weight to men. Nonetheless, the lower scores in women do 
not necessarily imply low risk and factors beyond the risk scores need to be 
considered when determining therapy (340).    
The age-standardised prevalence of high risk (≥20) at 15.6% in men and 6.3% in 
women (p<0.001) in this study was modest. This suggests that for cost-effective 
management a relatively smaller proportion of participants require treatment 
compared to those with prevalent individual risk factors. This is especially relevant in 
light of the potential burden that maybe imposed on healthcare services if all 
individuals with, for example, high BP were treated with medication. Basing treatment 
decisions on a total CVD risk-assessment approach enables the identification of 
individuals who would benefit the most from treatment and also results in optimal and 
cost-effective management, as shown by Gaziano and colleagues in an analysis of 
the South African hypertensive guidelines (45, 534). 
That the mean risk scores were low and the prevalence of high risk was nil in those 
<45-years-old was not surprising. All younger individuals will have low absolute 10-
year risk, regardless of their risk factor levels, because age is the most heavily 
















and modest elevations in risk factors would therefore have little effect on 10-year risk 
(30, 338, 535). Some younger individuals will, nonetheless, have a high risk relative 
to their peers, which will not be identified when applying the 20-% risk threshold for 
intervention (535). 
Lloyd-Jones comments that low-risk scores in younger individuals are not because of 
the 10-year risk score per se nor incorrect risk prediction, but rather that they are 
related to the decision thresholds imposed on the risk estimates and the short time 
span imposed by 10-year risk estimations (338). An alternative to address these 
limitations may be to lower the treatment thresholds in younger adults, for example, 
treat those under 50 years with 10-year risk >5% (338). If the cut-point of >5% was 
used, almost a fifth more men below 45 years (19.0%) and women below 55 years 
(18.6%) would be treated. Younger individuals with an adverse risk profile, but low 
10-year risk, may benefit more if interventions are started at a younger age rather 
than waiting until they cross the 20-% threshold (535). However, in resource-limited 
settings like South Africa such an approach cannot be recommended. As medical 
interventions carry risks, the net potential gain, acceptability, and cost effectiveness 
of early intervention is unclear. Further research is required to understand the clinical 
utility and impact of risk estimations (338, 535).  
As expected, considering that age is the strongest determinant of 10-year risk, the 
mean risk scores increased with age peaking in the oldest men (38.9%) and women 
(23.8%) as did the prevalence of high risk (83.3% and 48.8%, respectively). 
Compared to younger individuals, assessment of risk in the elderly poses a different 
challenge (30). Using current thresholds in older individuals may result in 
overmedication; therefore, further investigation is required to define the optimal 
threshold for high risk in the elderly. 
The interval of 10 years for risk estimation was selected because this time horizon 
identifies those individuals who are most likely to benefit from medical intervention in 
the short-term, thereby improving cost-effectiveness and safety of therapy (338). 
While there are some recognised limitations, 10-year risk estimations represent an 
improvement over clinical judgment alone for appropriate risk stratification. A 
systematic approach to total CVD risk estimation seems to result in better risk factor 
control (30).  
The age-standardised mean 10-year risk for a CVD event using non-laboratory 
parameters was 12.3% in men and 7.7% in women (p<0.001) (Table 4.17, p137). 
















and women, respectively (p<0.001) peaking in the oldest men (87.5%) and women 
(53.7%). A very high proportion of participants identified with high risk on the 
laboratory-based estimates was also identified by the non-laboratory estimates 
(97.2%) confirming that the use of the non-laboratory scores in clinical practice may 
be a feasible alternative in this setting. Eliminating the need for costly laboratory 
measurements will enhance accessibility and utility of the total CVD risk assessment 
tool (30) and is particularly relevant in low-resource settings such as South Africa that 
face a high burden of multiple diseases.  
The independent associations with laboratory-based high risk scores (≥20%) in the 
multiple logistic model with SOC included <7 years of schooling (OR: 2.47, 95% CI 
1.57-3.90, p<0.001), spending 50-90% of life in the city compared to <50% (OR: 
1.97, 95% CI 1.12-3.46, p=0.018) and being unemployed (OR: 2.05, 95% CI 1.03-
4.07, p=0.042) or a pensioner (OR: 16.58, 95% CI 8.22-33.42, p<0.001) compared to 
being employed (Table 4.18, p138). Living in a council house/hostel (OR: 1.92, 95% 
CI 1.16-3.17, p=0.011) or a private residence (OR: 1.93, 95% CI 1.07-3.48, p=0.028) 
was significantly associated with higher risk compared to living in informal dwellings. 
Similarly, these variables were also significantly associated with high risk scores by 
the non-laboratory estimates. These associations are mainly a reflection of the socio-
demographic characteristics of older participants who were more likely to be less 
educated, pensioners and live in better quality housing compared to their younger 
counterparts.  
4.6. STRENGTHS AND LIMITATIONS OF THE STUDY 
Strengths  
Conducting this study in the same areas surveyed in 1990 allowed for more accurate 
comparisons of the CVD risk factors between the two studies. The detailed sampling 
strategy to ensure proportionate representation by area, age and sex contributed to 
the increased likelihood of accurate estimations of the CVD risk factors prevalent in 
this population. The administration of the OGTT to determine diabetes is the gold 
standard for use in population-based studies and strengthens the findings of this 
study as opposed to the use of fasting glucose levels only. The drawing of fasting 
blood specimens to determine dyslipidaemia provided an accurate assessment of 
triglycerides and LDL-C estimates. The use of three psychosocial tools to determine 
psychosocial stress increased the likelihood of ascertaining associations between the 


















The cross-sectional design of this study precludes the inference of causal 
associations with variables significantly associated with the CVD risk factors. The low 
sample realisation in men (64%) necessitated higher sampling weights and a loss of 
precision. The difficulty in recruiting male participants is, however, characteristic of 
epidemiological studies in this country and is probably because of their reluctance for 
having blood samples drawn as well as their more frequent absence from home 
when compared to women.  
In the clinical context, hypertension is usually diagnosed from BP measurements 
taken on at least three separate occasions. However, in this study three BP readings 
were taken on one occasion and the average of the second and third measurements 
used to diagnose hypertension, which was the same method used in 1990. This may 
have led to some overestimation of the hypertension prevalence.    
For greater accuracy, at least three 24-hour dietary recalls should be obtained when 
assessing food intake, but a single 24-hour dietary recall of the previous day’s food 
intake was obtained in this study and may have contributed to a lack of significant 
associations with high fat intake. Additionally, the definition of high fat intake was a 
relative measure as a proportion of total dietary intake instead of an absolute 
measurement. For example, two individuals with the same proportion of dietary fat 
intake may have vastly different absolute amounts of fat consumption. Also, this 
study did not differentiate between good (polyunsaturated) and bad (saturated) fat 
intake, which would differentially influence the CVD risk factors. Diet was not 
assessed in detail for the purpose of this thesis as the nutrition data is being 
analysed for a Master’s dissertation.  
The use of self-reported rather than objectively measured ambulation or physical 
activity is likely to have resulted in an overestimation of activity. In fact, the 
unexpected low levels of inactivity strongly suggest inadequate assessment of actual 
physical activity. This may have contributed to the absence of an association 
between variables when one was expected, namely, between inactivity and 
measures of obesity, diabetes or raised LDL-C level. 
The self-reported histories of tobacco and alcohol use may have resulted in an 
underestimation of these risky behaviours on account of their perceived social 
unacceptability, particularly for smoking in women and for alcohol in general. 
However, the CAGE questionnaire used to assess excessive alcohol intake is an 
















In some cases the different instruments used in 1990 and 2008/09 to assess certain 
CVD risk factors precluded a comparison across time. For example, the CAGE 
questionnaire used to ascertain problem drinking and the GPAQ for physical activity 
were used in 2008/09 but not 1990. 
Glycaemic control among known diabetic participants would have been better 
determined by analysing HbA1C levels. However, this blood test was not done and 
fasting glucose levels were used instead. 
Since HIV testing was not done in this study, it is possible that some study 
participants could be infected with the virus. This could potentially influence the 
prevalence of dyslipidaemia with possible higher rates compared to those in a HIV 
negative population but is unlikely to have a significant impact on the prevalence of 
diabetes (Prof Levitt, personal communication).  
The absence of a gold standard to measure psychosocial stress necessitated the use 
of several instruments to measure this variable. The lack of an association between 
psychosocial stress and some CVD risk factors found in this study does not preclude 
a relationship with other psychosocial tools. Therefore, the associations or lack 
thereof shown for SOC, LOC and adverse life events are not generalizable to other 
psychosocial instruments. 
These study findings are not generalizable to rural settings on account of the differing 
lifestyle behaviours as well as healthcare access but may be generalizable to other 
urban black populations in South Africa. Notably, however, the diabetes prevalence 
in this population two decades ago was found to be higher than similar studies 
conducted in Durban (384) and the Free State (385) at that time, and may have 
remained higher.  
The townships selected for inclusion in this study were those included in the 1990 
studies for ease of comparison. The numerous new townships and informal 
residential areas that have arisen in the Cape Peninsula were not included and 
people in these newer areas may potentially have different CVD risk factor patterns 
than those in the more established townships. 
These limitations notwithstanding, this study provides valuable data on the 
prevalence of diabetes, hypertension, dyslipidaemia, other CVD risk factors and their 

















CHAPTER FIVE: MANAGEMENT OF CARDIOVASCULAR 
DISEASE RISK FACTORS IN SOUTH AFRICA: POPULATION-
BASED AND INDIVIDUAL HIGH-RISK APPROACHES 
5.1. INTRODUCTION  
The findings reported in this study illustrate the current high prevalence of modifiable 
lifestyle risk factors such as high fat intake, tobacco and problematic alcohol use. The 
resultant high prevalence of the metabolic CVD risk factors of diabetes, hypertension, 
dyslipidaemia and overweight/obesity in the urban black African population of Cape 
Town is of considerable concern. So too is the observation that most of these risk 
factor rates have risen from two decades ago. Moreover, given the high rates of IGT 
(predictive of future diabetes), hypertension and dyslipidaemia, and the extremely 
high levels of overweight/obesity, in an increasingly urbanising country with an 
ageing population, the burden of CVD is likely to increase exponentially in the future. 
The high prevalence of CVD risk factors and low levels of care in this population 
underline the importance of developing strategies for primary prevention, detection, 
and the urgent need for effective treatment options. Evidence from numerous 
countries suggests that premature cardiovascular events can be postponed and 
reduced with maximum impact, efficiency and cost-effectiveness via a combination of 
interventions that target high-risk individuals and population-based strategies (37, 44, 
536).  
5.2. POPULATION-BASED APPROACHES   
Notwithstanding scarce healthcare resources and an underperforming healthcare 
system, there is much that South Africa can do to address the CVD epidemic and 
reduce the risk factor burden (536). CVD as well as other NCDs are largely 
preventable through attention to the four major modifiable risk factors of tobacco use, 
excessive alcohol consumption, unhealthy diets and physical inactivity. Access to, 
affordability and awareness of, as well as attitudes toward tobacco, alcohol, and 
unhealthy and processed food products are largely influenced by system factors such 
as national taxation policies, advertisements, global rules and ethics of marketing 
(29). Legislations that incorporate population-based primary prevention strategies to 
tackle the surge in CVD and other NCDs are the most cost-effective instruments with 
the potential to yield the greatest benefits (25, 29, 306, 536). In addition, it is crucial 
to impart the skills to make healthy choices so as to facilitate the uptake of healthier 
















5.2.1. TOBACCO USE 
One of the most effective population-based strategies for CVD and other NCD 
prevention is a comprehensive tobacco control programme. South Africa has been a 
frontrunner in this regard with the introduction of comprehensive legislation in the 
form of the Tobacco Products Control Act of 1993 (536, 537). This legislation 
introduced health warnings on cigarette packs and advertising material, and the 1999 
amendment banned tobacco advertising and the sale of tobacco to minors (537, 
538). The effectiveness of these policies are reflected in the lower smoking rates 
among men in 2008/09 compared to 1990, as well the lower rates reported in the 
2003 compared to the 1998 SADHS (420). While it cannot definitely be attributed to 
the legislation, there has been a decrease and stabilisation in the number of 
smoking-related CVD deaths, consistent with the declining smoking trend (536). 
Although the tobacco control legislation has influenced a decline in smoking 
prevalence, this has plateaued in recent years. This suggests a need for the 
strengthening of interventions and a review of tobacco control policies. The aim is a 
further 10% reduction in tobacco use by 2016 and a 20% reduction by 2020 (539).  
Recent amendments to the act in 2007 and 2008 include stringent restrictions on 
smoking in public places (540) and prohibiting the sale of tobacco products to those 
younger than 18 years, thereby raising the minimum age from 16 years (541). The 
Government Notice of March 2012 plans to prohibit smoking in public spaces, 
particularly in the presence of children (542). Additionally, the regulations on the 
display of tobacco products at the point of sale were published for public comment in 
August 2012 (543). Further legislation in the formative phase includes graphic health 
warnings with pictorial messages on cigarette packages (539). Such initiatives will 
hopefully further deter smoking uptake in the young and enable current smokers to 
stop or at least decrease their cigarette consumption.  
Anti-smoking campaigns are imperative to prevent smoking uptake in women and the 
young. These need to link the abstinence of tobacco use with values prized, 
particularly among black women, such as upward mobility or access to personal and 
social development, personal dignity and family welfare (424).   
Tobacco use is a powerful addiction that requires support to stop, necessitating 
smoking cessation programmes to assist smokers to quit. Nicotine replacement 
treatments and other pharmacological aids to quit smoking can approximately double 
















half the male participants in this study smoked daily, smoking cessation programmes 
have the potential to drastically reduce the smoking prevalence in this population.  
5.2.2. ALCOHOL USE 
The successful reduction in tobacco control is in stark contrast with the failure to 
acknowledge and address alcohol as an increasingly important factor, not only for 
CVD and other NCDs, but also for the current extremely high burden of violence and 
injury in the country (544). South Africa has thus far approached alcohol policy 
development in a piecemeal fashion (191). A comprehensive national alcohol 
strategy that cuts across different sectors including health, social welfare, crime 
prevention, trade and industry, and agriculture, and is supported by a broad grouping 
of stakeholders, is urgently required to curtail the misuse of alcohol in South Africa 
(428, 436). Furthermore, there needs to be increased awareness among the general 
population of the problems associated with alcohol abuse (179). In addition, 
multilevel interventions are required to target high-risk drinkers.  
Evidence shows that the most cost-effective ways to reduce the harm caused by 
alcohol is to make alcohol less available and more expensive and to prohibit alcohol 
advertising (190, 434). These measures are supported in WHO policy documents 
such as the Global Strategy to Reduce the Harmful Use of Alcohol and the Global 
Status Report on NCDs, 2010 (190). A broad public health approach is emphasised 
to address alcohol misuse rather than simply seeking to change individual behaviour, 
as advocated by the liquor industry. 
There has been a renewed interest in addressing the problem of rising alcohol 
misuse in South Africa (545). The Minister of Health has suggested a ban on alcohol 
advertising and sponsorship, and to increase the age of legal alcohol consumption 
from the current 18 to 21 years (190, 546). The Minister’s stance is based on the 
decrease in smoking that followed the ban on tobacco advertising. The extent to 
which this will translate into meaningful policies is unclear (545).  
Nevertheless, to this end the Inter Ministerial Committee has mandated the DOH to 
introduce legislation banning alcohol advertisements and sponsorships. The target 
for reducing alcohol consumption in South Africa is a litre reduction from 20 to 19 
litres in the per capita consumption of alcohol by 2016 and a 20-% reduction in the 
relative per capita consumption of alcohol by 2020 (539). Such targets can only be 
achieved through multiple interventions including effective legislation that deters the 
consumption of alcohol through increased taxation that makes alcohol less affordable 
















5.2.3. DIETARY INTERVENTIONS 
To provide for individuals with nutrition-related CVD risk factors such as 
overweight/obesity, diabetes, hypertension and the MS, it is imperative to improve 
dietary patterns (222). Focusing on medical management, smoking reduction, and 
regulating sodium in the diet will not necessarily halt the rising epidemic of obesity 
and other cardio-metabolic problems. The findings of this study reinforce the urgent 
need to highlight the prevention of overweight/obesity, particularly in women, as well 
as the development of diabetes, dyslipidaemia and hypertension as relevant topics 
for the public health agenda in South Africa. Effective interventions require evidence-
based, carefully evaluated programmes and policies (222).  
Public measures need to extend beyond the healthcare sector and address the 
physical, economic and socio-cultural environment to enable individuals to make 
healthier choices concerning diet and physical activity (444, 505). So far, measures 
introduced by the South African DOH to address nutrition-related CVD risk factors 
have included specific objectives in the Integrated Nutrition Programme of 2002 
aimed at reducing obesity in women to 25% by 2007 (229, 547). In 2004, the 
National Food-Based Dietary Guidelines were launched (229, 548), and revised in 
2012, for the prevention and management of overweight/obesity.   
As observed by the spiralling rates of obesity among women in this study, as well as 
the higher rates of diabetes, hypertension and dyslipidaemia compared to two 
decades ago, the current measures to curb the CVD epidemic have been dismally 
ineffective. Awareness campaigns often elude their target audience, particularly in 
rural areas (549, 550). While the South African government has acknowledged the 
need to address the rising burden of CVD risk factors with policies and guidelines 
related to the control of these risk factors being developed, translating them into 
effective programmes remains elusive and challenging (551).   
Currently, food marketing tends to promote less healthy foods (high in fat, sugar, and 
salt) which are more widely accessible and cheaper. Therefore, it is of little surprise 
that the epidemic of overweight/obesity has flourished without an appropriate public 
health response (442). The environment needs to be conducive to the uptake of 
healthier lifestyles in terms of easy access to cheaper healthier food options and safe 
convenient spaces for exercising. The current environment in South Africa makes it 
difficult to live healthier lifestyles, particularly for the poor majority, who are restricted 
in their choices by the lack of availability of healthy foods in the poorer sector of 
















the control of the healthcare sector and requires input from motivated stakeholders in 
other government departments.  
Comprehensive national and local interventions need to be developed that utilise 
every opportunity to encourage and promote active living, healthy eating, and energy 
balance (229). The DOH needs to drive the development of integrated, 
comprehensive and multi-sector policies for the prevention of CVD and other NCDs. 
The DOH in the South African Declaration on the Prevention of NCDs acknowledged 
that there needed to be a shift towards a ‘whole of government’ and a ‘whole of 
society’ approach with regards to NCDs, including CVDs, as these were caused or 
influenced by behavioural, environmental, social and economic factors (552).  
The draft South African Strategic Plan for NCDs, 2012-2016 suggests that 
consideration may be given to taxing undesirable processed foods while exempting 
healthier choices from taxation (539). Other recommendations include controlling 
meals served to the workforce (e.g. in the army), to children during school hours, and 
to banning junk food advertisements to children during key television programmes. 
Numerous studies have demonstrated the effectiveness of such interventions (553). 
The plan is to engage with relevant government departments including agriculture, 
trade and industry, and treasury to increase the accessibility and availability of 
healthy foods as well as to improve eating habits through public awareness 
campaigns. The aim is to decrease overweight/obesity by 3% by 2016 and by 10% 
by 2020 (539). This may be difficult to achieve in light of the high and rising levels of 
overweight/obesity prevalent in women in this study. 
Evidence from other countries such as Finland, the US and Poland have 
demonstrated the health benefits that accrue in populations following the 
implementation of population-based interventions; there are rapid wide-ranging 
improvements in diet and decreased calorie intake (51, 236, 311, 536). In accord with 
WHO recommendations to phase out industrially produced trans-fats (156), the 
South African government in February 2011 introduced legislation restricting the 
trans-fatty acid content to a maximum of 2 grams per 100 grams of oil or fat (554). 
Evidence from Denmark, which similarly banned the use of oils and fats containing 
more than 2% of industrially produced trans-fatty acids in foods, showed that this 
method was effective in reducing trans-fat intake. Furthermore, this intervention was 
cost saving as it required no consumer education (156, 536).  
Considering that trans-fats adversely affect lipid profiles and increase the risk for 
















positive impact on health. The Disease Control Priorities (DCP) project report 
indicated that substituting 2% energy from trans-fat with polyunsaturated fat led to a 
reduction of CVD risk ranging between 7-8% and 25-40%, without considering the 
additional beneficial effects on diabetes (156). 
A front-of-pack food labelling with respect to levels of salt, fat, saturated fat, sugar 
and other nutrients would enable consumers to make informed healthier choices as 
well as stimulate product reformulation. A recommended suggestion that is easy to 
understand is the ‘traffic light system’ where red indicates bad/unhealthy and green 
good/healthy choices (with amber between the two) (216, 222, 536). This type of 
labelling enables consumers to make choices easily and has already been found to 
dramatically influence the purchase of foods, particularly those in the red category 
(216). Additionally, the cheaper pricing of healthy compared to unhealthy alternatives 
requires attention in order to increase affordability and to encourage the uptake of the 
healthier option. 
Interventions also include reducing salt intake, which has been associated with a 
drop in BP and a lower risk of CVD event. Notably, Charlton and colleagues 
demonstrated the BP-lowering effect for systolic BP in a local hypertensive 
population on treatment following the dietary manipulation of seven commonly 
consumed processed foods. The BP lowering effect of this dietary intervention was 
estimated to contribute to a 20-% reduction in the number of deaths attributed to high 
BP (555). 
In South Africa, salt ingestion at approximately 8.1grams/day (556) exceeds the 
recommended maximum 4-6 grams/day with almost 50% of intake from non-
discretionary sources (536, 555, 556). In light of the high hypertension prevalence in 
this population, it is crucial that CVD prevention strategies in South Africa include a 
component that attempts to lower BP across the whole population. Even modest 
decreases in BP, if experienced across an entire population, have the potential to 
yield substantial reductions in CVD morbidity and mortality (216, 285, 293, 307, 309).  
In accord with WHO recommendations that governments implement policies 
regarding food labelling, legislation and product reformulation (217), South Africa has 
announced the need to legally control the salt content in most processed food (37) 
and has commenced discussions with the appropriate consumer and industry groups 
to initiate a process of voluntary reductions in food sodium levels (556). Such an 
initiative would have a significant impact on BP levels as the black population has 
















demonstrated that, for a given reduction in salt intake, the declines in BP were larger 
in individuals of African origin compared to whites (216, 285). Moderating salt intake 
would also correspond with international recommendations that advocate for salt 
reduction as a key cost-effective intervention to target the burden of NCDs (80). The 
aim is to reduce salt consumption in South Africa to 7 grams/day by 2016 and to <5 
grams/day by 2020 (539). 
In addition, measures to improve food labelling of products recognised as significant 
sources of salt intake need to be implemented (311). Government legislation to 
introduce effective cost-saving initiatives such as the New Zealand and Australian 
‘Tick’ programme locally, whereby the salt content of selected processed foods is 
decreased could greatly benefit population health, particularly in view of the high 
prevalence of hypertension (309, 536).  
Further, for effective salt reduction at the population level, it is important for policy 
development and implementation to target the main source of dietary sodium in the 
population (308). Worthy of investigation, therefore, are policies to reduce the salt 
content of bread, which comprises 25-40% of sodium intake, and is the single 
greatest contributor to non-discretionary salt intake in South Africa (536, 556, 557). In 
a milieu of rising hypertension prevalence and the known profound effect of salt 
intake, reducing salt intake to achieve the WHO recommended salt consumption 
target of <5 grams/day would be one of the most cost-effective strategies to combat 
the epidemic of hypertension and CVD, and to improve population health in South 
Africa (309, 556). Potentially, 8% of strokes, 6.5% of IHD and 11% of hypertensive 
heart disease could be prevented if recommended reductions in the salt content of 
bread and some other commonly consumed food products in South Africa were 
introduced (556). In addition to major beneficial effects on health, there will also be 
significant cost savings such as reduced healthcare costs (285). Direct healthcare 
cost savings from a decline in stroke incidence would amount to an estimated R300 
million (US$40 million) annually (556).   
Opposition from food manufacturers and their shareholders with vested interests is 
likely to be encountered because of the potential negative impact on lucrative sales 
from junk food and ready meals (often laden with cheaper sugar, salt and fat laden 
ingredients) (216, 536, 553). Furthermore, with regards to salt, it is also a major 
determinant of thirst and a reduction in intake will reduce fluid consumption with a 
subsequent reduction in caloric-laden soft drink. The other benefit of added salt in 
food products for manufacturers is that salt enhances cheap and unpalatable food 
















Such nutrition-related policies therefore require political will for implementation. 
Despite challenges South Africa urgently needs to develop and implement evidence-
based policies and strategies to effectively address the daunting CVD epidemic. 
About 40% of deaths from CVD and other NCDs have been reported to be caused by 
the consumption of foods high in saturated and industrially produced trans-fats, salt 
and sugar (80). Therefore, if South Africa is to seriously tackle the growing epidemic 
of these diseases, it is essential that such dietary measures be introduced.    
5.2.4. PROMOTING PHYSICAL ACTIVITY 
In addition to population-based strategies that encourage healthier food patterns 
(limiting tobacco and alcohol use, and reducing salt and trans-fat intake), 
interventions need to create an enabling environment for physical activity. In 
response to the WHO’s recommendations in its Global Strategy on Diet, Physical 
Activity and Health, various South African government departments promoted 
physical activity. The DOH introduced the ‘Vuka! South Africa – Move for Your 
Health’ campaign and the Department of Education and Department of Sport and 
Recreation developed a policy framework on physical activity, reflected in the White 
Paper ‘Getting the Nation to Play’, which supported the initiatives undertaken by the 
DOH (200). These initiatives have, however, not been met with any notable success. 
Even though individual behaviour determines physical activity levels, there are 
multiple influences on health-related behaviours and conditions, including individual, 
community and public policy factors (200). Therefore, physical activity is not simply a 
personal choice; it is influenced by the built environment, infrastructures for public 
transport, urbanisation patterns, safety issues, education on physical activity in 
childhood, and many other systemic factors that are not addressed in strategies 
focusing on individuals (29). Environmental factors that prevent South Africans from 
participating in optimal physical activity include a lack of safety and high crime rates, 
and a lack of green areas and recreation facilities. Cultural beliefs and attitudes 
towards thin people also seem to contribute to low levels of physical activity among 
South Africans (200, 238). Additionally, the poor have fewer opportunities for physical 
activity and recreation (539). 
The WHO Global Strategy stressed that inter-sectoral planning and collaboration is 
required across government departments to create safe and ‘walkable’ communities, 
schools and neighbourhoods, and to increase awareness of the importance of 
physical activity for health (200). In addition to the involvement of the government 
















departments to create safe and attractive opportunities for physical activity, 
particularly within urban environments. Evidence demonstrates that cities which 
encourage walking and cycling above car use have better health statistics (401). 
Developing and implementing policies to create enabling environments for physical 
activity are in accord with the WHO Action Plan endorsed by the World Health 
Assembly in 2008 (198).  
Currently, there are undertakings to develop a national strategy to increase 
population-wide physical activity in South Africa (Dr Kolbe-Alexander, personal 
communication). The government plans to encourage physical activity by improving 
awareness of the importance of regular physical activity, by promoting inter-sectoral 
collaboration to increase opportunities for activity and by implementing programmes 
and interventions to promote activity. The aim is a 10-% increase in moderate-
intensity physical activity per week by 2020 (539). 
A life-course approach that instils a culture of regular physical activity and other 
healthy lifestyle behaviours from childhood to older age is also needed (200). The 
complex interplay of personal, political, cultural and environmental factors reinforces 
the need for health to become an explicit objective in all policies if the prevention and 
control of CVD and other NCDs are to be achieved (29).  
5.3. INDIVIDUAL HIGH-RISK APPROACHES  
5.3.1. HEALTHCARE DELIVERY IN SOUTH AFRICA    
According to World Bank figures from World Development Indicators 2008, South 
Africa spends 8.7% of its gross domestic product (GDP) on health; more than any 
other African country and just slightly less than Sweden (8.9%) (544, 558). However, 
the largest proportion of healthcare spending occurs in the private sector; most of the 
population, who lack health insurance, receive care in the overburdened and 
underfunded public health system, which spends 3.5% of GDP on healthcare (558, 
559).  
The country’s healthcare services are struggling to cope with the quadruple burden of 
disease, comprising HIV/AIDS, CVD and other NCDs, poverty-related diseases, and 
violence and injuries (381, 549). The focus of care is currently on infectious diseases, 
particularly HIV/AIDS and TB, and overburdened healthcare services and health 
professionals in South Africa perceive diabetes, dyslipidaemia, hypertension and 
their associated consequences as less urgent (382). In stark contrast to the poor 
treatment illustrated by the data presented in the previous chapter, effective 
















significantly and life expectancy increasing to the extent that CVD-related deaths now 
represent a rising proportion of mortality in HIV-infected individuals (470). The risk of 
CVD has now emerged as an important consideration in HIV-infected individuals and 
is likely to increase as they live longer (560). 
Notwithstanding the growing burden of CVDs with their potential catastrophic costs, 
the health system response has been limited (536). These chronic conditions are 
marginalised and have received little priority from healthcare services and 
professionals alike (382). Therefore, it is not surprising that the management of 
diabetes and hypertension in South Africa is far from optimal, as demonstrated in this 
and other studies (465, 480, 498, 550, 558, 561, 562). Furthermore, studies 
conducted over a decade or more ago reported poor control of diabetes and 
hypertension and attest to the longstanding nature of this problem (465).  
The almost non-existent management of dyslipidaemia prevailing in this study is also 
inexcusable. Although statins have been available only since 2004 in the Western 
Cape public healthcare sector, there are now more cost-effective generics universally 
available. These have been included in the national Essential Drug List (389) albeit 
with a maximum dosage of only 10 mg of simvastatin. With the advent of generic 
medication to offset the high cost of treatment for dyslipidaemia, and the rising 
prevalence of IHD in the black population, it has become imperative to screen for and 
manage individuals with dyslipidaemia using the total cardiovascular risk assessment 
approach.  
Several reasons exist for the poor management of diabetes, hypertension and 
dyslipidaemia and include healthcare system, healthcare provider and individual 
barriers (53, 492). In South Africa, the lack of sufficient healthcare providers, facilities 
and resources including time, space, equipment and medication contribute to the 
scant attention paid to CVDs. Healthcare providers work under increasingly difficult 
circumstances with staff shortages a major barrier to effectively managing patients 
with diabetes and hypertension (465, 550, 563). This results in prolonged queuing for 
patients and a reduced quality of care provided (563). Resources to cater for the 
greater load of diabetic and hypertensive patients referred from secondary and 
tertiary healthcare facilities are inadequate with no provisions made for the larger 
patient volumes (465).  
5.3.2. REORIENTATION OF HEALTHCARE SERVICES  
For the successful management of these conditions, changes are required in the 
















emphasises that the treatment and control of CVD risk factors do not require massive 
resources. A well-organised and focused strategy by healthcare systems, in a 
supportive political milieu, can achieve acceptable control in a setting of modest 
resources (53).  
Healthcare systems can maximise their returns from scarce resources through 
innovative means by shifting services to incorporate care for chronic conditions (564). 
In many developing countries, resources are inappropriately directed to tertiary 
healthcare, while lower-level healthcare facilities are often not equipped with basic 
facilities (53). Similarly, in South Africa healthcare expenditure is currently dominated 
by tertiary-level hospitals, with 30% of total public health expenditure spent on super-
tertiary hospitals based in Johannesburg, Cape Town and Durban (565). In light of 
the expanding demand for chronic care of CVD and other NCDs this needs to be 
rectified with a redistribution of resources to PHC services. These services play a key 
role in the provision of preventive and care interventions and are usually the foremost 
access point for healthcare (53, 56). 
An optimally functioning PHC system is vital for the effective execution of prevention 
strategies and identification of individuals at high-risk for CVD (536), and needs to be 
reinforced to deliver better chronic disease care (564). The challenge in providing 
effective CVD risk management within PHC systems is that these services have 
been developed for treating acute, time-limited episodic conditions that cater for 
urgent patient needs. They are thus not geared to support the continuity of care 
required for patient follow-up in CVD risk management (53, 564). Nursing staff at 
PHC clinics in Cape Town rotate through different departments, in line with an acute 
care model but inappropriate for chronic care management, despite the fact that at 
least 50% of patients attending PHC clinics have chronic needs (550, 566).  
An evolution in PHC is necessary with improvements in the design and organisation 
of the healthcare system to optimise the care provided for CVD and other NCDs 
(563, 564, 566). On-going care provided by a well-functioning team is the basis for 
optimal control of chronic diseases (566). Continuity of care in the management of 
chronic diseases, in terms of specific healthcare providers as well as information 
flow, is vital and can also save time and money with the elimination of investigations 
that may be unnecessarily repeated by new healthcare providers (567, 568). 
Furthermore, the referral process from PHC facilities to more specialised centres is 
currently flawed (563, 566). There needs to be greater cohesion and better links 
















settings and healthcare providers (539, 564, 566). This will result in improved health, 
reduced waste, fewer inefficiencies and a less frustrating experience for the patient 
(564). 
5.3.3. TASK SHIFTING TO LOWER-LEVEL HEALTHCARE WORKERS 
The major challenges for the delivery of CVD care are the shortage of healthcare 
providers with the appropriate training and skills, and an already overburdened 
workforce (53), as evident in South Africa (465, 550). For efficient and effective 
chronic care delivery, specialised training in chronic care management and dedicated 
chronic care teams are required (550). However, with human resources already 
accounting for 50-70% of healthcare expenditure in South Africa (559), there is an 
urgent need to find feasible and cost-effective solutions for improving delivery of CVD 
care. 
One long-term strategy to address the issue of human resources is to train and allow 
less specialised healthcare providers, such as nurses and community healthcare 
workers (CHWs), to reliably and effectively assess and manage CVD in PHC settings 
(536). At the clinic level, CHWs could provide education, check BP and glucose 
levels, and administer basic urine tests while specifically trained nurses could 
prescribe medication and refer patients with complications or severe disease to 
physicians. The reallocation of such CVD risk-factor care, typically from a physician 
to a healthcare provider with a lower education and training level, or to an individual 
specifically trained to execute a limited task only, without having the formal health 
education, is referred to as task shifting (569).  
South Africa has developed extensive experience of task shifting with the successful 
treatment and care of HIV/AIDS patients. Assigning the care of uncomplicated 
HIV/AIDS to lower-level healthcare workers such as specially trained nurses and 
adherence counsellors in clinics has been demonstrated to improve the quality and 
access to care, and adherence to medication. Drawing on this expertise and 
success, and in view of budgetary constraints, a task shifting model for CVD 
management warrants consideration (536, 568).  
The introduction of CHWs as part of a PHC outreach programme has the potential to 
strengthen health system effectiveness and reduce the pressure experienced at PHC 
facilities. Furthermore, utilising trained CHWs to conduct support groups for 
individuals with chronic conditions could potentially improve the care for CVD risk 
















imparts an appropriate skill and knowledge base to CHWs with close monitoring and 
evaluation by managers at district and sub-district levels (53, 465).  
5.3.4. INTEGRATION OF HIV/AIDS AND CARDIOVASCULAR DISEASE CARE  
The key principles in the care of patients with chronic illnesses have been 
incorporated by the National DOH in the management of HIV/AIDS (567). Seeing that 
the requirements for effective decentralised provision of therapy for HIV/AIDS and for 
CVDs are closely aligned (570), the care of chronic conditions such as diabetes and 
hypertension in South Africa could be integrated with HIV/AIDS care. This may 
improve patient outcomes for CVD, seeing that adherence levels and patient 
management are usually better within the HIV clinics (346, 536, 559). The effort, 
services and resources which are directed at individuals and communities affected by 
HIV/AIDS can be harnessed to strengthen the delivery for CVD and other NCDs 
(570). Furthermore, positioning integrated chronic care for both infectious and NCDs 
at the heart of the PHC system is likely to garner a greater response for CVD risk-
factor management (536). Also, with the ageing of the HIV population and the 
reduction in premature mortality owing to ART, the same individuals will likely 
develop CVD risk factors and require simultaneous treatment for HIV and CVD. 
Nonetheless, the efficiency, quality and acceptability to users, and the effects on 
health status of integrating care for chronic infectious and NCDs will need to be 
determined (536, 568, 570).  
5.3.5. SCREENING FOR CARDIOVASCULAR DISEASE RISK FACTORS 
Together with the appropriate management of individuals with known CVD risk 
factors and the inclusion of those at high risk in dedicated CVD programmes, the 
ultimate goal should encompass the early identification of those with asymptomatic 
and previously undiagnosed CVD risk factors, such as diabetes and hypertension. 
Currently, there exists no clear policy for screening of CVD risk factors in South 
Africa. Besides, the country lacks the staff, facilities and funds to implement 
population-based screening programmes, especially in view of the HIV/AIDS 
pandemic (558).  
Targeted screening programmes to identify individuals with high-risk characteristics 
(such as older age, high BMI or WC, the presence of a known risk factor or a positive 
family history) (246) should ideally be undertaken to address the suboptimal 
detection of diabetes, hypertension and dyslipidaemia. To identify people at high risk 
for diabetes, the IDF and American Diabetes Association, among other 
















varying combinations of age, BMI, WC, first-degree relative with diabetes, self-
reported hypertension and physical activity. However, a screening questionnaire has 
not been validated for Africa. Once validated, screening programmes may be 
implemented by trained CHWs, who are closely monitored, at clinics, social 
development pay points or other government services.   
Screening programmes can also potentially be easily incorporated into the current 
HIV Counselling and Testing campaign, which has already tested over 13 million 
individuals for HIV, and offers an excellent opportunity for the screening of CVD and 
other NCDs. In addition to HIV and TB screening, healthcare providers conducting 
testing could routinely offer testing for diabetes, hypertension and other NCD risk 
factors (539). Early detection and effective treatment for diabetes, hypertension and 
other CVD risk factors will result in efficient and cost-effective management because 
of decreased complications and hospitalisations (249).  
After individuals at high-risk for diabetes are identified on the screening questions, 
the challenge remains regarding the appropriate biochemical test to use. This test 
needs to be reliable, high performance, convenient and low-cost (461). OGTT are 
cumbersome and inconvenient while HbA1C tests are expensive. Further, both 
require skilled healthcare personnel and laboratory facilities for sample analyses, a 
major challenge in resource constrained setting such as South Africa. The most 
practical alternative, as recommended by the WHO, is using a point-of-care capillary 
glucose test which is simple and reliable for identifying undiagnosed diabetes (461, 
573). 
5.3.6. PATIENT-CENTRED APPROACH TO CARDIOVASCULAR DISEASE 
MANAGEMENT 
Unlike acute illnesses where patients are treated usually without their active 
participation (465), comprehensive CVD care relies on individuals adhering to daily 
drug regimens, implementing lifestyle advice and returning for follow-up assessments 
(53). Therefore, the focus needs to be on patients’ central role in and responsibility 
for their own healthcare and constitutes an important shift in current clinical practice 
(564, 567). Patients need to be assisted in achieving their goals by healthcare 
providers as well as their families, support groups and community (539, 564, 567). 
For improved patient adherence to therapy and lifestyle recommendations, it is 
important for knowledge and advice to be imparted in a culturally relevant context. 
For example, when designing and implementing obesity treatment and prevention 
















of obesity. These range from perceptions of what constitutes an ideal body shape 
and size with the preferred form being overweight, to food availability and portion 
sizes (574). In African cultures, being overweight is acceptable and even desired, as 
it is perceived to be associated with dignity, respect, wealth, strength, attractiveness, 
happiness and health, and with being well-treated by their husbands (224, 229, 238, 
574, 575). Moreover, in the context of the high prevalence of the HIV/AIDS epidemic 
in South Africa, excess body weight is associated with a lack of this disease and 
stigmatisation (396, 447, 575). In the context of this positive attitude towards 
overweight/obesity, changing knowledge and awareness presents a challenge (576). 
Extensive education is required to alter perceptions of overweight/obesity considering 
the widespread ignorance of the link between obesity and increased CVD risk (442).  
5.4. THE NATIONAL DEPARTMENT OF HEALTH’S STRATEGY FOR 
CARDIOVASCULAR DISEASE IN SOUTH AFRICA 
In accordance with the recent UN resolution that seeks to halt the increasing trends 
in premature deaths from NCDs, the South African DOH has prioritised the 
management of NCDs, which is a significant step for the control of CVDs (552). The 
DOH stated that it was committed to developing a full and comprehensive NCD 
strategic plan with the aim of introducing multi-sectorial public policies that created 
sustainable health promoting environments (552).  
That the healthcare for individuals with NCDs, including CVD, needed to be fully 
integrated into the re-engineering of PHC in South Africa is also stated in the NCD 
strategic plan. In addition, population-based prevention, screening and better self-
management with increased adherence is needed to achieve good NCD care which 
is in line with the WHO innovative model for chronic care (552). As a result, 
healthcare in South Africa is undergoing a process of reformation. The strengthening 
of health systems is regarded as a prevention and control mechanism for reducing 
CVD and other NCDs. An essential component of the re-engineering of the PHC 
services will be the establishment of PHC outreach teams in all community wards in 
the country. The plan is for CHWs to visit households directly, and identify and refer 
those at high risk for assessment at local clinics, among other duties (539). The focus 
for improving health outcomes will be on health promotion and disease prevention 
(577). 
Goals for NCDs with targets to be achieved by 2020 were set at the South African 
Summit on the Prevention and Control of NCDs in 2011 and included the following 
















 Reduce the relative premature mortality (under age 60 years) from NCDs by 
at least 25% 
 Reduce tobacco use by 20% 
 Reduce the per capita consumption of alcohol by 20% 
 Reduce the mean population salt intake to <5 grams per day  
 Reduce the percentage overweight/obese by 10%  
 Reduce the prevalence of raised BP by 20%  
 Increase the prevalence of physical activity by 10% 
Realising the targets for tobacco use, alcohol consumption, diet and physical activity 
have been discussed under Section 5.2. with the South African strategy advocating 
the ‘best buys’ in terms of implementation costs, health impact and cost-
effectiveness. Additional aims, in conjunction with the population-based interventions 
and lifestyle measures, include reducing the prevalence of raised BP through 
medication and improving control of hypertension and diabetes by 30%, thereby 
contributing to a reduction in premature mortality (539). These are aligned with the 
global NCD targets which will be incorporated into the WHO global action plan for the 
prevention and control of NCDs covering the period 2013-2020 (579).  
These targets set by South Africa were among the first initiatives globally aimed at 
reducing the burden of NCDs and announced ahead of the UN High-Level Meeting in 
September 2011 (580). The foundation of the South African NCD strategic plan has 
been the numerous good legislative and policy initiatives as well as guidelines and 
standards for CVD and other NCDs that have been formulated by the DOH over the 
past two decades. These include the national programmes for the control and 
management of hypertension (1998) and diabetes (1998) at primary level, policy 
guidelines on primary prevention of chronic diseases of lifestyle (1999), national 
guideline on foot health at primary level (2000), national guideline on stroke and 
transient ischaemic attack management (2001), national guideline on the prevention 
and management of overweight and obesity (2003), and the updated national 
guidelines on the management of hypertension (2006), among other initiatives (539). 
However, there has been a lack of an equivalent emphasis on the implementation, 
monitoring and assessment of these policies throughout the healthcare system (581). 
In view of the re-engineering of PHC in the country and the current global focus on 


















5.5. CONCLUSION  
This thesis aimed to determine the prevalence of CVD risk factors in 2008/09, the 
changes in these between 1990 and 2008/09, and the association between 
psychosocial stress and the other CVD risk factors in a random sample of the 25-74-
year-old urban black population of Cape Town. A high prevalence with rising levels 
over time was reported for many CVD risk factors including diabetes, hypertension 
and dyslipidaemia in the studied population. The worsening profile of other risk 
factors, in particular overweight/obesity in women, can explain part of the observed 
changes. The association of psychosocial stress was found to be independently 
related to certain CVD risk factors, notably with diabetes in women.  
Moreover, not only are most of these risk factor rates higher now compared to two 
decades ago, but in view of the high rates of IGT (predictive of future diabetes), 
hypertension and dyslipidaemia, the extremely high levels of overweight/obesity, 
effective treatment of HIV/AIDS, and with continuing urbanisation and ageing 
populations the burden of CVD in this setting is likely to increase exponentially. This 
highlights the importance of, as well as the expanding demand for, cost-effective 
chronic care of CVDs, their risk factors and related conditions such as diabetes.  
Management of cardiovascular risk factors in South Africa is far from optimal, as 
demonstrated in this and other studies, and needs to be urgently prioritised in order 
to minimise CVD morbidity and mortality. The proposed re-engineering of PHC in 
South Africa and the strengthening of health systems with the prioritisation of NCD 
management will potentially improve CVD risk factor care.  
In addition to optimal care for high-risk individuals, identified using a total CVD risk 
approach, interventions that encompass population-based strategies for primordial 
prevention are also required. Apart from the implementation of a comprehensive 
tobacco control policy and the recent legislations regulating the trans-fatty acid and 
sodium contents of foods, South Africa has thus far failed to adequately address the 
burgeoning CVD epidemic. Seeing that exposure to risk factors begins in childhood, 
the WHO recommends legislative and regulatory measures to protect children from 
the adverse impacts of marketing. The aim is to prevent the uptake of risky 
behaviours that predispose to CVD (582).   
While the rates of diabetes, hypertension and dyslipidaemia were equally high in men 
and women, some lifestyle behaviours were gender-specific. Certain were prominent 
















intake). Programmes and policies attempting to curb the rates of these lifestyle 
factors need to take cognisance of the influences affecting their genesis.  
The positive attitudes towards overweight/obesity among women need to be explored 
with measures to overcome these developed in association with the communities 
affected. These will include realigning images of success and wealth with slimness 
and health, and overweight/obesity with the converse. 
Despite comprehensive tobacco control legislation in South Africa, the smoking 
prevalence remained unchanged in women and was the highest among the youngest 
men. Further research is required to identify measures to curb smoking in these 
vulnerable groups. These may include anti-smoking campaigns or patient-centred 
smoking cessation programmes targeted specifically at these groups. 
In conjunction with the introduction of comprehensive legislation to curb alcohol 
misuse, community-based research is required to investigate the culture of 
problematic alcohol use and encourage responsible drinking. This may include 
advertisements or promoting the establishment of predetermined community drivers 
or the use of taxi services when inebriated.   
Surveillance is crucial to provide information for the development of policies and 
programmes, to assessment initiatives implemented and to monitor progress (38).    
Furthermore, on-going surveillance, currently absent in South Africa, is needed to 
monitor and track the burden of CVD and its risk factors in the community. The lack 
of reliable data for CVD risk factors and cause-specific mortality leads to the inability 
to accurately assess the effects of policies and programmes. A national surveillance 
framework should include the key risk factors, the outcomes in terms of morbidity and 
mortality, and the health system response and capacity (38).  
The use of adult health indicators reflecting improvement, or otherwise, of healthcare 
provision is essential to monitor trends in the quality of care provided. The health 
system response regarding quality of care may be assessed, among other measures, 
by evaluating the implementation of clinical practice guidelines and a patient-centred 
style of communication which leads to greater patient satisfaction. Adequate capacity 
may be determined in terms of the proportion of well-trained medical and nursing 
staff and their effective interaction with CHWs. Logistical aspects such as drug 
availability/shortages or patient waiting-time at clinics also influence the quality of 
















The current healthcare response may be partly responsible for the differential care of 
hypertension demonstrated by age and gender in this study. This and other potential 
reasons such as time constraints or attitudes towards drug adherence need to be 
examined and addressed to achieve optimal hypertension management. 
Finally, the findings of this study are valuable in raising awareness about the 
increasing magnitude of the CVD risk-factor burden among policy makers and the 
public. This will place greater emphasis on these conditions in the required health 
policy agenda. Concerted prevention and control measures are urgently needed 
because, apart from unhealthy alterations in lifestyle behaviours, demographic shifts 
per se are estimated to contribute to a doubling of the number of CVD deaths in 
South Africa by 2040 (382). Failure to address this problem will otherwise impair 
socio-economic development and poverty alleviation in the country with 41% of CVD 
mortality predicted to occur in 35-64-year-olds, namely, the younger members of 
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ADDRESS OF PARTICIPANT………..………………………………..……………………            
            
…………………………………………………………………………………………………………………            
            
TELEPHONE 
……………………………………………………………………………………………….. 
           
            
2ND CONTACT PERSON’S DETAILS:            
            
NAME 
……………..………………………………..………………………….…………………..……… 
           
            
ADDRESS ………..………………………………..………………………………………….            
            
……………..………………………………..………………………..……………………………
…….… 
           
            
TELEPHONE ……………………………………………………………………………………            
            
DATE OF INTERVIEW:            
 D D M M Y Y Y Y  
          16 
            
GENDER:            
 Male 1 Female 2             
            
AGE AT LAST BIRTHDAY …………………..………………………………………………            
            
            
DATE OF BIRTH:            
 D D M M Y Y Y Y  
          27 
            
            
 
SECTION 2: MIGRATORY HISTORY (to calculate % life spent in urban setting)   Office use 
                   
2A. Place of birth (village/town): …………………………..………………………………………………………………..        29 
 
         
2B. Were you born in / on:         
          
 A rural village 1 A farm 2 A small town 3 A large city or town 4 Don’t know 9         
          
2C. Where did you spend most of your childhood (up to 10 years old)?         
          
 A rural village 1 A farm 2 A small town 3 A large city or town 4 Don’t know 9         
          2D. When was the first time you came to a big city? (If born in city give year of birth)         
 Y Y Y Y          
          
 If less than 12 months tick Yes for new arrival: Yes 1 No 2        36 
















SECTION 4: SELF-REPORTED MEDICAL HISTORY   Office use 
          
 STUDY NUMBER:        4 
          
4A. Would you say your health is poor, average, good, or very good/excellent?         
 Poor  1 Average  2 Good  3 Very good/excellent  4         
          
4B. Do you personally think that you are underweight, normal weight or overweight?         
 Underweight  1 Normal weight  2 Overweight  3 Don’t know  9         
          
4C. 
Has a doctor or nurse or health worker at a clinic or hospital told you that you have or have 
had 
        
 any of the following conditions?         
 1) High blood pressure Yes 1 No 2 Don’t know  9         
          
 2) Heart attack or angina (chest pains) Yes 1 No 2 Don’t know  9         
          
 3) Stroke Yes 1 No 2 Don’t know  9         
          
 4) High blood cholesterol or fats in the blood Yes 1 No 2 Don’t know  9         
          
 5) Diabetes or blood sugar Yes 1 No 2 Don’t know  9         
          
 6) Diabetes during pregnancy Yes 1 No 2 Don’t know  9        12 
          
4D. During the past 12 months have you been tested/checked for:         
 1) Hypertension/high blood pressure Yes 1 No 2          
 2) Diabetes Yes 1 No 2          
          
4E. During the past 12 months have you seen a traditional healer for:         
 1) Hypertension/high blood pressure Yes 1 No 2          
 2) Diabetes Yes 1 No 2          
          
4F. Are you currently taking any herbal or traditional remedy for:         
 1) Hypertension/high blood pressure Yes 1 No 2          
 2) Diabetes Yes 1 No 2         18 
          
SECTION 5: MEDICATION   Office use 
          
5A. Who pays for most of the medication, prescribed by a doctor or nurse, that you use?         
 READ THE ANSWER CATEGORIES TO THE RESPONDENT         
 Respondent 1          
 
 
        
 Family 2          
 
 
        
 Medical aid 3          
 
 
        
 Provided at clinic or public hospital 4          
 
 
        
 Employer 5          
 
 




6         19 
         
5B. Do you use any medicine regularly or daily that a doctor or nurse has prescribed?         
  Yes 1 No 2         
         
5C. How many different medicines do you use regularly or daily? 
No. of 
medicines: 
         22 


















SECTION 5: MEDICATION   Office use 
    
  STUDY NUMBER:          4 
5D. RECORD ALL THE DRUGS BROUGHT IN BY THE RESPONDENT:           
    
 1)           11 
    
 2)           18 
    
 3)           25 
    
 4)           32 
    
 5)           39 
    
 6)           46 
    
 7)           53 
    
 8)           60 
    
 9)           67 
    
 10)           74 
    
 11)          81 
    






SECTION 6: FAMILY MEDICAL HISTORY   Office use 
          
    STUDY NUMBER:        4 
          
6A. 
Do you have a close blood relative (father, mother, brother, sister / child) who has ever been 
diagnosed: 
        
 by a doctor or nurse with any of the following conditions?         
 1) High blood pressure Yes  1 No  2 Don’t know  9         
          
 
2) Heart attack/angina/chest pain when exerting 
himself/herself  
Yes  1 No  2 Don’t know  9         
          
 3) Stroke Yes  1 No  2 Don’t know  9         
          
 4) Diabetes  Yes  1 No  2 Don’t know  9         
          
6B.    Nowadays in South Africa far more young people die, or become very ill than before.         
 Has this happened in your family? Yes 1 No 2         
          
6C. Do you have to take care of a child whose parents are ill or have died? Yes 1 No 2         
          
6D. If YES, has this made it more difficult for you to care for your own health? Yes 1 No 2         
          
6E. Does anyone in your household have HIV/AIDS? Yes  1 No  2 Don’t know  9        12 
          




















SECTION 7: PSYCHOSOCIAL   Office use 
         
STUDY NUMBER:        4 
A) ORIENTATION TO LIFE QUESTIONNAIRE (SOC-13)         
 
Below are a series of questions relating to various aspects of our lives. For each question, you will first 
select the response which most closely resembles how you feel. Then, on a scale from 1 to 7, you will 
select the number closest to that response which best describes how you feel. You can choose any 
number between 1 and 7. Please give only one answer to each question. 
        
            




Very often          
  1 2 3 4 5 6 7         5 
            
 
2) Has it happened in the past that you were surprised by the behaviour of people whom you thought you 
knew well? 






         
  1 2 3 4 5 6 7          
            






         
  1 2 3 4 5 6 7          
            
 4) Until now your life has had:         
  
No clear  
direction or 
purpose at all 
Very clear  
direction  
and purpose 
         
  1 2 3 4 5 6 7         8 
            
 5) Do you have the feeling that you’re being treated unfairly?         
  Very often 
Very seldom 
or never  
         
  1 2 3 4 5 6 7          
            
 6) Do you have the feeling that you are in an unfamiliar situation and don’t know what to do?         
  Very often 
Very seldom 
or never  
         
  1 2 3 4 5 6 7          
            
 7) Doing the things you do every day is:         
  
A source of  
deep pleasure  
and satisfaction 
A source of 
 frustration  
and boredom 
         
  1 2 3 4 5 6 7          
            
 8) Do you feel confused or have very mixed-up feelings and ideas?         
  Very often  
Very seldom 
or never 
         
  1 2 3 4 5 6 7         12 
            
 9) Does it happen that you have feelings inside that you don’t like or would rather not feel?         
  Very often  
Very seldom 
or never 
         
  1 2 3 4 5 6 7          
            
 
10) Many people—even those who are confident and successful—sometimes feel like losers in certain 
situations.  How often have you felt this way in the past? 
        
  Never  Very often          
  1 2 3 4 5 6 7         14 



















SECTION 7: PSYCHOSOCIAL   Office use 
            





You saw things 
 in the right  
perspective? 
         
  1 2 3 4 5 6 7         15 
            
 12) How often do you have the feeling that there's little meaning in the things you do in your daily life?         
  Very often  
Very seldom 
or never 
         
  1 2 3 4 5 6 7          
            
 
13) Sometimes people have strong feelings that they cannot keep under control. How often do you have 
feelings that you're not sure you can keep under control? 
        
  Very often 
Very seldom 
or never  
         
  1 2 3 4 5 6 7          
          
B) LOCUS OF CONTROL         




Disagree Neutral  Agree  
Strongly 
agree  
        
     
     
1) In your general work, you feel you have control over what 
happens in most situations 
1 2 3 4 5        18 
     
     
2) You feel what happens in your life is often determined by 
factors beyond your control 
1 2 3 4 5         
     
     
3) Over the next 5-10 years, you expect to have more 
positive than negative experiences 
1 2 3 4 5         
     
     
4) You often have the feeling you are being treated unfairly 1 2 3 4 5         
     
     
5) In the past 10 years your life has been full of changes 
without you knowing what will happen next 
1 2 3 4 5         
     
     
6) You gave up trying to better your life a long time ago 1 2 3 4 5        23 
          
C) LIFE EVENTS QUESTIONNAIRE         
 
Have any of the following life events or problems happened to you during the last 6 months?  
What about more than  6 months ago? If so, please also rate the impact on you. 
        
 1) You yourself suffered a serious illness, injury or an assault Yes 1 No 2 
go to next question 
        
          
 1a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 1b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 
2) A serious illness, injury or assault happened to a close relative of 
yours 
Yes 1 No 2 
go to next question 
       29 
          
 2a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 2b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5        33 





















SECTION 7: PSYCHOSOCIAL   Office use 
          
 3) Your parent, child or spouse died Yes 1 No 2 
go to next question 
       34 
 
 
        
 3a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
 
 
        
 3b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 4) A close family friend or another relative (aunt, cousin, Grandparent) died Yes 1 No 2 
go to next question 
       39 
  
        
 4a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 4b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 5) You had a separation caused by marital difficulties Yes 1 No 2 
go to next question 
       44 
  
        
 5a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 5b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 6) You broke off a steady relationship Yes 1 No 2 
go to next question 
       49 
  
        
 6a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 6b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 
7) You had a serious problem with a close friend, neighbour or relative of 
yours 
Yes 1 No 2 
go to next question 
       54 
  
        
 7a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 7b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 
8) You became unemployed or you were seeking work unsuccessfully for 
more than one month  
Yes 1 No 2 
go to next question 
       59 
  
        
 8a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 8b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 9) You were fired from your job Yes 1 No 2 
go to next question 
       64 
  
        
 9a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 9b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5        68 

















SECTION 7: PSYCHOSOCIAL   Office use 
          
 10)  You had a major financial crisis Yes 1 
No 2 
go to next question 
       69 
  
        
 10a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 10b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 11)  You had problems with the police and a court appearance Yes 1 
No 2 
go to next question 
       74 
  
        
 11a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 11b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
          
 12)  Something you valued was lost or stolen Yes 1 
No 2 
go to next question 
       79 
 12a) Did this occur in the past 6 months? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5         
  
        
 12b) Did this occur more than 6 months ago? Yes 1 No 2         
 If yes, Impact: None 3 Some 4 Significant  5        83 
          
SECTION 8: ALCOHOL USE    Office use 
          
          
8A Do you consume drinks that contain alcohol such as beer, wine, spirits or sorghum          
 beer? Yes 1 No 2        5 
 If No, go to Section 9         
8B Have you ever felt that you should cut down on your drinking? Yes 1 No 2         
          
8C Have people annoyed you by criticizing your drinking? Yes 1 No 2         
          
8D Have you ever felt bad or guilty about your drinking? Yes 1 No 2         
          
8E Have you ever had a drink first thing in the morning to steady your nerves or get rid of a           
 hangover? Yes 1 No 2        9 
 
         
SECTION 9: TOBACCO USE   Office use 
          
9A Do you currently smoke any tobacco products, such as cigarettes, cigars, or pipes? Yes 1 No 2        10 
 If No, go to question 9F         
9B Do you currently smoke tobacco products daily? Yes 1 No 2         
 If No, go to question 9F         
9C How old were you when you first started smoking daily?   Years old           
 Don’t remember/not sure = 99         
9D If you do not remember how old you were, do you remember how long ago you started smoking          
 daily?                                                                                                    1 WEEKS AGO           
 2 MONTHS AGO           
 3 YEARS AGO          16 
9E  On average, how many of the following items do you smoke each day? [NONE = 00]         
 1 Manufactured cigarettes?           
 2 Hand-rolled cigarettes?           
 3 Pipes full of tobacco?           
 4 Cigars/Cheroots/Cigarillos?          24 
 

















SECTION 9: TOBACCO USE   Office use 
          
9F In the past, did you ever smoke daily? Yes 1 No 2        25 
 If No, go to question 9I         
 
 
        
9G How old were you when you first stopped smoking daily?  Years old           
 Don’t remember/not sure = 99         
 
 
        
9H If you do not remember how old you were, do you remember how long ago you stopped smoking          
 daily?       1 WEEKS AGO           




         30 
          
 ASSESSING USE OF SMOKELESS TOBACCO         
9I Do you currently use any smokeless tobacco, such as snuff or chewing tobacco? Yes 1 No 2         
 If No, go to question 9L         
 
 
        
9J Do you currently use smokeless tobacco daily? Yes 1 No 2         
 If No, go to question 9L         
 
 
        
9K  
On average, how many times do you use each of the following items per day? [ NONE = 
00] 
        
 1 Snuff (by mouth)?          34 
 2 Snuff (by nose)?           
 3 Chewing tobacco?           
                                                                                                                                    Go to Section 10         
          
9L In the past, did you ever use smokeless tobacco, such as snuff or chewing tobacco daily? Yes 1 No 2        40 
          
 
SECTION 10: PHYSICAL ACTIVITY – MODIFIED STEPS/GPAQ    Office use 
          
 STUDY NUMBER:        4 
10 
The next questions are about the time you spend doing different types of physical activities.  This includes 
activities you do at home, at work, travelling from place to place and during your spare time.  You are 
requested to answer the questions even if you don’t consider yourself to be an active person. 
        
 
Occupation-Related Physical Activity (paid or unpaid work):  When answering the following questions, 
think back over the past 12 months and consider (think of) a usual week. 
        
        
10A Does your work involve vigorous activities, (like heavy lifting, digging, or heavy construction)         
 for at least 10 minutes at a time?    Yes 1 No 2         
 If No, go to question 10D         
        
10B In a usual week, how many days do you do vigorous activities as part of your work?         
 DAYS:           
        
10C On a usual day on which you do vigorous activities, how much time do you spend doing such work?         
 1 HOURS:           
 2 MINUTES:            
        
10D Does your work involve moderate-intensity activities, (like brisk walking or carrying light loads)         
 for at least 10 minutes at a time? Yes 1 No 2        13 
 If No, go to question 10G         




















SECTION 10: PHYSICAL ACTIVITY – MODIFIED STEPS/GPAQ    Office use 
          
10E In a usual week, how many days do you do moderate-intensity activities as part of your work?         
 DAYS:          15 
        
10F On a usual day on which you do moderate-intensity activities, how much time do you spend doing such          
 work? 1 HOURS:           
 2 MINUTES:            
        
 
Travel-Related Physical Activity: Other than activities that you’ve already mentioned, I would like to ask 
you about the way you travel to and from places (to work, to shopping, to market, to church, etc.). 
        
        
10G Do you walk or use a bicycle (pedal cycle) for at least 10 minutes at a time to get to and from places?         
   Yes 1 No 2         
 If No, go to question 10J         
        
10H In a usual week, how many days do you walk or cycle for at least 10 minutes to get to and from places?         
 DAYS:           
        
10I On a usual day, how much time do you spend walking or cycling for travel?         
  1 HOURS:           
 2 MINUTES:            
        
 
Non-Work Related and Leisure Time Physical Activity:  The next questions ask about activities you do 
in your leisure or spare time, for recreation or fitness.  Do not include the physical activities you do at work 
or for travel already mentioned. 
        
        
10J In your leisure or spare time, do you do any vigorous activities (like running or strenuous          
 sports, weightlifting) for at least 10 minutes at a time? Yes 1 No 2         
 If No, go to question 10M         
        
10K In a usual week, how many days do you do vigorous activities as part of your leisure or spare time?         
 DAYS:           
        
10L How much time do you spend doing this on a usual day?         
  1 HOURS:           
 2 MINUTES:           38 
        
10M In your leisure or spare time, do you do any moderate-intensity activities (like brisk walking, cycling or         
 swimming) for at least 10 minutes at a time? Yes 1 No 2         
 If No, go to question 10P         
        
10N In a usual week, how many days do you do moderate-intensity activities as part of your leisure          
 
or spare time?           
DAYS: 
         42 
        
10O How much time do you spend doing this on a usual day?         
  1 HOURS:           
 2 MINUTES:            
        
 
Sitting / Resting Activity:  Now I would like to ask you about the time spent sitting or resting, not including 
sleeping, in the past 7 days.  This may include time sitting at a desk, visiting friends, reading, or sitting 
down to watch television during working hours and leisure or spare time. 
        
        
10P Over the past 7 days, how much time did you spend sitting or reclining (lying) on a usual day          
 (excluding sleeping)? 1 HOURS:           
 2 MINUTES:           52 


















SECTION 11: DIETARY HISTORY    Office use 
     
STUDY NUMBER:            4 
 
           
24-HOUR RECALL RECORDING SHEET             
INTERVIEWER’S NAME 
……………..……………………………………………………………….… 
           
            
DATE OF INTERVIEW:            
 D D M M Y Y Y Y  
           
            
            
Tick the day of the week you are recalling             
            
 
Sunday 1 Monday 2 Tuesday 3 Wednesday 4 Thursday 5 Friday 6 Saturday 7           16 
            
            
 
Steps for the Interviewer to follow when interviewing each participant  
  
 
Step 1:  You can start the dietary interview as follows: “I want you to think back to when you woke up yesterday morning. What time was it?  
Now I want you to try to remember what you ate and drank yesterday from the moment you woke up until you went to sleep again last night. Run 
through the whole day in your mind and try to remember everything you ate and drank.” 
 
  
 You must now give the participant time to remember - during this time you must not disturb them.   
  
 
Now you can carry on and ask the participant to tell you what he/she ate and drank yesterday, starting in the morning after you got up. . 
What was the first thing you ate after you woke up……what time was that? And then……what time was that? And then……what time was that? 
You don’t have to remember the exact time; tell me if it was for breakfast, lunch, supper, between breakfast and lunch, between lunch and supper 
or after supper.  
Intervals to chose from: B = breakfast;  S1 = midmorning snack; L = lunch, S2 = afternoon snack; D = dinner; AD = After dinner snack  




Step 2: To check whether the participant forgot anything, ask him / her the following questions:  
 Did you have any cold drinks or other drinks yesterday? 
 Did you have any sweets and or chocolate yesterday 
 Did you have any cake yesterday? 
 Did you have any biscuits yesterday? 
 Did you have any rusks yesterday? 
 Did you have any savoury snacks like chips / popcorn / salty biscuits yesterday? 
 Did you have any other fruit yesterday? 
 Did you have any other vegetables yesterday? 
 Did you have cheese yesterday? 
 Did you have any other bread or rolls yesterday? 






3a What you ate or drank yesterday was it …….? 
The same as usual More than usual Less than usual  
  
 
3b What type of milk is usually used in your home?   
  
 





3d What type of oil is usually used in your home?   
 
Step 4: Now I am going to ask you more about each food item that you ate yesterday.  
First, I want you to describe the food item and tell me how it was prepared. 





Step 5: Now I want to know how much of each food item you ate.  (portion sizes) 
You will then start using the food photo manual to obtain the relevant information 





















STEP 1: Time  STEP 1: Foods eaten  STEP 4: Description of the food item STEP 5: Description of the portion size 
    
    
    
    
    
    
    
    
    
    
    
    
    
STEP 2: Time STEP 2:Forgotten foods   
    
    
    


















 MEASUREMENTS  Official use: 
        STUDY NUMBER:          
4 
        Anthropometer’s name: …………………………………………………….       
 
        
Weight:   
    
kg 
      
10 
        
Height:  
    
cm 
       
        
Waist circumference:  
    
cm 
       
        
Hip circumference:  
    
cm 
      
22 
        
Discard 1st blood pressure reading  1st Systolic blood pressure :  
   
mmHg 
       
        
1st Diastolic blood pressure :  
   
mmHg           
       
        
1st Heart rate :  
   
 
       
        
2nd  Systolic blood pressure :  
   
mmHg 
      
25 
        
2nd  Diastolic blood pressure :  
   
mmHg           
       
        
2nd Heart rate :  
   
 
      
 
        
3rd Systolic blood pressure :  
   
mmHg 
      
34 
        
3rd Diastolic blood pressure :  
   
mmHg           
       
        
3rd Heart rate : 
          
40 

















CRIBSA: BLOOD RESULTS  Official use: 
        
Name:……………………………………………………………... 
Study number    
     
4 
               
Oral glucose tolerance test (OGGT) (mmol/ℓ) Fasting glucose 0 minutes  
     
 
        
75 g oral glucose: Blood glucose 30 minutes  
     
 
         
Blood glucose 120 minutes 
     
13 
        
Insulin (MIU/mℓ)  0 minutes  
     
 
        
Insulin (MIU/mℓ) 30 minutes  
     
 
        
Insulin (MIU/mℓ) 120 minutes 
     
22 
        
 
Total cholesterol (mmol/ℓ) 
     
 
         
HDL cholesterol (mmol/ℓ) 
     
28 
         
Triglycerides (mmol/ℓ) 
     
 
         
LDL cholesterol (mmol/ℓ) 
     
34 
         
 
      














































CONSENT TO PARTICIPATE IN RESEARCH STUDY 
 
Cardiovascular Risk in Black South Africans (CRIBSA) Study  
 
Investigators: Dr N Peer, Prof NS Levitt, Prof K Steyn, Dr N Steyn, Prof VE Lambert,  
Dr C Lombard 
 
 
STUDY NUMBER     
Dear Participant 
 
You are being asked to participate in a research study. 
 
You have heard and understood an explanation of the research project and 
have read a written explanation of what is required.  Confidentiality will be 
adhered to at all times. 
 
You are free to refuse to participate or can withdraw permission to take 
part at any time and you need not answer all the questions during the 
interview.  Any questions that you may have at any time will be answered.    
 
You may contact Dr Nasheeta Peer at telephone (021) 938 0811 any time 
you have questions about the research.   
 
Your participation in this research is voluntary, and you will not be penalised 
or lose benefits if you refuse to participate or decide to stop at any stage. 
 
If you agree to participate, you will be given a signed copy of this document 
and a written summary of the research. 
 
 




........................................................................   ……………….. 




To my knowledge, consent was given willingly and with full understanding.   
 
 
........................................................................   ……………….. 




........................................................................   ……………….. 


















DNA will be isolated and stored for future analyses of genes related to 
cardiovascular disease (CVD) and its risk factors. This is a new area of study 
and not all genetic aspects of CVD are currently known. These tests are done 
anonymously and will not be linked back to any specific person.  
 
 
2.) I also give permission that my DNA may be isolated and stored for 




........................................................................   ……………….. 









........................................................................   ……………….. 




........................................................................   ……………….. 
Signature of Witness    Date 
 
 
